Respiratory Medicine — MCQs

Q: A 56-year-old man presents with progressive dyspnea and chest tightness. He works in coal mining. Chest X-ray shows bilateral upper lobe nodules. What is the most likely diagnosis?

Coal worker's pneumoconiosis. ***Coal worker's pneumoconiosis***- This diagnosis is strongly supported by the patient's occupational exposure to **coal dust** and the progressive respiratory symptoms like **dyspnea** and **chest tightness**.- The characteristic Chest X-ray finding of bilateral, often small, **pulmonary nodules** predominantly located in the **upper lung zones** is classic for this condition.*Lung cancer*- Although coal miners have an increased risk of lung cancer, the presentation of diffuse **bilateral small nodules** is more typical of a pneumoconiosis than primary malignancy.- Lung cancer usually manifests as a single, dominant mass, or less commonly as reticulonodular interstitial disease, not typically as diffuse, symmetrical small nodules.*Silicosis*- Silicosis is caused by the inhalation of **crystalline silica** dust, prevalent in occupations like sandblasting or quarrying, which differs from pure coal mining exposure.- While silicosis also causes upper lobe nodules, it often presents radiologically with **"eggshell" calcification** of the hilar lymph nodes, a finding not specified in this case.*Tuberculosis*- Although **post-primary TB** targets the upper lobes, generalized diffuse nodularity suggests pneumoconiosis rather than a primary mycobacterial infection.- TB typically presents with systemic symptoms like **fever**, **night sweats**, and **weight loss**, which are not mentioned in this patient's presentation.*Sarcoidosis*- Sarcoidosis is a systemic disease of unknown etiology characterized by **non-caseating granulomas** and classically presents with **bilateral hilar lymphadenopathy (BHL)** on chest imaging.- The strong history of **coal mining** is the key factor favoring an occupational lung disease over sarcoidosis, as BHL is also absent.

Q: A 56-year-old man presents with progressive dyspnea and dry cough. HRCT shows bilateral lower lobe fibrosis with honeycombing. He has clubbing and restrictive spirometry. What medication may slow disease progression?

Pirfenidone. ***Pirfenidone***- The clinical presentation with progressive dyspnea, dry cough, clubbing, restrictive spirometry, and HRCT showing bilateral lower lobe fibrosis with **honeycombing** is highly characteristic of **Idiopathic Pulmonary Fibrosis (IPF)**.- **Pirfenidone** is an **anti-fibrotic** agent, along with nintedanib, approved for the treatment of mild to moderate IPF to slow disease progression by reducing the decline in **Forced Vital Capacity (FVC)**.*Prednisolone*- Systemic corticosteroids like **Prednisolone** are not recommended as monotherapy for **Idiopathic Pulmonary Fibrosis (IPF)** due to lack of proven long-term efficacy and potential harm.- They are primarily indicated for inflammatory interstitial lung diseases, such as those associated with **connective tissue diseases**, or for **acute exacerbations** of IPF.*Azathioprine*- **Azathioprine** is an immunosuppressant that was shown to be ineffective and potentially harmful in a triple-drug regimen for IPF in the **PANTHER-IPF trial**.- Immunosuppression is generally avoided in **Idiopathic Pulmonary Fibrosis** unless there is a strong suspicion of an alternative, inflammatory interstitial lung disease.*Cyclophosphamide*- **Cyclophosphamide** is a potent cytotoxic immunosuppressant typically reserved for severe, rapidly progressive forms of **connective tissue disease-associated ILD** (e.g., scleroderma-associated ILD or vasculitis).- It is not indicated for the primary management of **Idiopathic Pulmonary Fibrosis**, which is characterized by relentless fibrosis rather than a primary inflammatory process responsive to this therapy.*N-acetylcysteine*- Although previously studied for its antioxidant properties, the **PANTHER-IPF trial** demonstrated that **N-acetylcysteine** offered no benefit in slowing the progression of IPF and is no longer recommended.- Its primary clinical uses are as a mucolytic agent and as an antidote for **acetaminophen overdose**.

Q: A 54-year-old man presents with progressive dyspnea and chest tightness. Spirometry shows FEV1 1.8L (60% predicted), FEV1/FVC 0.55. He has a 40 pack-year smoking history. What is the most important intervention?

Smoking cessation. ***Smoking cessation***- This is the **single most important intervention** for patients with **COPD** who smoke, as it is the only measure proven to slow the rate of **FEV1 decline** and disease progression.- Quitting smoking significantly reduces symptoms, exacerbations, and mortality, directly addressing the primary etiological factor in this patient's 40 pack-year history.*Bronchodilators*- **Bronchodilators** (e.g., beta-agonists, anticholinergics) provide crucial **symptomatic relief** by improving airflow and reducing dyspnea, but they do not alter the natural history of COPD or stop the underlying disease progression.- They are essential for managing symptoms but are not the **most important intervention** to halt the destruction caused by smoking.*Inhaled corticosteroids*- **Inhaled corticosteroids (ICS)** are typically indicated for patients with more severe COPD (e.g., FEV1 < 50% predicted) and a history of **frequent exacerbations**, often in combination with long-acting bronchodilators.- While they can reduce inflammation and exacerbation rates, ICS do not reverse or prevent the progressive lung damage caused by smoking.*Pulmonary rehabilitation*- **Pulmonary rehabilitation** is a highly effective intervention that improves **exercise capacity**, reduces dyspnea, and enhances quality of life in patients with COPD.- However, it does not modify the underlying **disease progression** or stop the decline in lung function, which is the primary benefit of smoking cessation.*Long-term oxygen therapy*- **Long-term oxygen therapy (LTOT)** is indicated for patients with **severe chronic hypoxemia** (PaO2 < 55 mmHg or SaO2 < 88%) to improve survival and quality of life.- This intervention addresses a consequence of advanced COPD but does not directly prevent or slow the progression of the disease itself, which is the focus of the question.

Q: A 58-year-old man presents with progressive dyspnea and fatigue. Chest X-ray shows bilateral lower lobe shadowing. HRCT shows honeycombing and traction bronchiectasis. He has finger clubbing. What is the prognosis?

Poor with median survival 2-5 years. ***Poor with median survival 2-5 years***- The progressive dyspnea, fatigue, finger clubbing, and HRCT findings of **honeycombing** and **traction bronchiectasis** are classic features of **Idiopathic Pulmonary Fibrosis (IPF)**.- IPF is a relentlessly progressive lung disease with a **poor prognosis**, typically having a median survival of **2 to 5 years** from diagnosis without lung transplantation.*Excellent with treatment*- IPF is an **irreversible, progressive fibrotic lung disease** for which there is currently no curative medical treatment, precluding an excellent prognosis.- Although anti-fibrotic medications can slow the rate of decline, they do not halt or reverse the underlying **pulmonary fibrosis**.*Good with early intervention*- Despite early diagnosis and intervention with anti-fibrotic drugs, the established **Usual Interstitial Pneumonia (UIP)** pattern of IPF implies a rapid and unfavorable progression.- Patients with IPF remain at high risk of **acute exacerbations** and progressive **respiratory failure**, even with timely management.*Variable depending on cause*- The classic presentation of progressive dyspnea, clubbing, and a definable **UIP pattern** on HRCT points strongly to **Idiopathic Pulmonary Fibrosis**, which has a consistently unfavorable prognosis.- Prognostic variability is more often associated with other Interstitial Lung Diseases (ILDs) like non-specific interstitial pneumonia (**NSIP**), not IPF.*Benign condition*- IPF is far from benign; it is a serious, ultimately **fatal condition** characterized by continuous and irreversible destruction of lung architecture.- The presence of **traction bronchiectasis** and **honeycombing** signifies advanced, non-reversible scarring and distortion of lung tissue, indicating a severe disease.

Q: A 55-year-old man presents with progressive dyspnea and dry cough over 6 months. He has finger clubbing. HRCT shows honeycombing and reticular opacities in lower lobes. What is the most likely diagnosis?

Idiopathic pulmonary fibrosis. ***Idiopathic pulmonary fibrosis*** - The combination of progressive dyspnea, dry cough, and **finger clubbing** in an older patient strongly suggests a chronic fibrotic lung process. - HRCT findings of **honeycombing** and **reticular opacities** primarily in the lower lobes are pathognomonic for the Usual Interstitial Pneumonia (**UIP**) pattern, which defines Idiopathic Pulmonary Fibrosis (IPF). *COPD* - COPD is an **obstructive lung disease** and typically presents with chronic productive cough and sputum, often related to smoking. - HRCT features usually involve **emphysema** (air space enlargement) or bronchial wall thickening, not severe lower lobe fibrosis with honeycombing. *Asthma* - Asthma is characterized by **reversible airway obstruction** and episodic wheezing, often triggered by specific exposures. - HRCT is usually normal or shows mild signs of **air trapping**, and **clubbing** is not a feature of asthma. *Hypersensitivity pneumonitis* - Acute or subacute forms often show **centrilobular nodules** or ground-glass opacities, often with a documented environmental exposure history. - While chronic HP can cause fibrosis, the pattern is often different from UIP, frequently involving the **upper or mid-lung zones** and sparing the bases. *Sarcoidosis* - Sarcoidosis is classically associated with **hilar lymphadenopathy** and primarily affects the **upper and mid-lung zones**, showing peribronchovascular nodularity. - **Clubbing** is very rare, and the typical HRCT pattern is **perilymphatic**, unlike the peripheral subpleural pattern seen here.

Q: A 48-year-old man presents with progressive breathlessness and fatigue. Chest X-ray showed bilateral hilar lymphadenopathy. Serum ACE is elevated. Transbronchial biopsy shows no caseating granulomas. What is the most likely diagnosis?

Sarcoidosis. ***Sarcoidosis*** - The presentation of progressive breathlessness and fatigue, coupled with **bilateral hilar lymphadenopathy (BHL)** on Chest X-ray and an **elevated serum ACE**, strongly indicates sarcoidosis. - The transbronchial biopsy showing **no caseating granulomas** is consistent with sarcoidosis, a disease characterized by **non-caseating granulomas**. *Tuberculosis* - Typically presents with **caseating granulomas** on biopsy, and hilar lymphadenopathy is often unilateral, unlike the patient's bilateral presentation. - Other common features include fever, night sweats, and weight loss, and **serum ACE** is not typically elevated. *Lung cancer* - While it can cause lymphadenopathy, it would typically show **malignant cells** on biopsy, not granulomas, and **elevated serum ACE** is not a diagnostic marker for lung cancer. - Clinical presentation often includes hemoptysis, unexplained weight loss, or persistent cough, which are not highlighted here. *Histoplasmosis* - This fungal infection can cause hilar lymphadenopathy and granulomas (often with subsequent calcification), but it is geographically endemic and **does not typically elevate serum ACE**. - Biopsy would reveal fungal organisms, which is not described in the patient's findings. *Silicosis* - An occupational lung disease due to **silica dust** exposure, which is not mentioned in the patient's history. - It typically causes upper lobe nodules and characteristic **eggshell calcification** of hilar lymph nodes, and **serum ACE** levels are usually normal.

Q: A 54-year-old man presents with progressive dyspnea and bilateral lower lobe crackles. Chest X-ray shows bilateral infiltrates. He works in shipbuilding. What is the most likely diagnosis?

Asbestosis. ***Asbestosis***- The patient's history of working in **shipbuilding** is a classic exposure for **asbestos** fibers.- Asbestosis typically causes **interstitial pulmonary fibrosis**, preferentially affecting the **lower lobes**, leading to progressive dyspnea and **bibasilar crackles**. *COPD*- This involves **obstructive lung disease** (e.g., chronic bronchitis or emphysema) characterized by airflow limitation, not the restrictive pattern suggested by crackles and infiltrates.- CXR typically shows signs of **hyperinflation** or large bullae, rather than diffuse bilateral interstitial infiltrates.*Silicosis*- Silicosis is caused by inhaling **free crystalline silica** (e.g., mining, quarrying, sandblasting), an exposure typically unrelated to shipbuilding.- Radiographically, silicosis usually presents with **nodular opacities**, classically affecting the **upper lobes**.*Coal worker's pneumoconiosis*- This condition is due to the inhalation of **coal dust**, almost exclusively seen in **coal miners**.- Simple CWP generally causes small **nodular opacities**, also predominantly in the **upper lung fields**.*Hypersensitivity pneumonitis*- Caused by immunologic reactions to inhaled **organic antigens** (e.g., bird droppings, mold from farmers' lung), not asbestos exposure.- HP often presents with systemic symptoms, and the pathology involves the **alveolar walls** and terminal bronchioles, lacking the specific pleural/parenchymal changes linked to asbestos.

Q: A 42-year-old man presents with progressive dyspnea and chest tightness. Spirometry shows FEV1 45% predicted, FEV1/FVC 0.85. HRCT shows lower lobe fibrosis. What is the most likely diagnosis?

Interstitial lung disease. ***Interstitial lung disease***- This pattern—low FEV1 (45% predicted) with a preserved FEV1/FVC ratio (0.85)—is characteristic of a **restrictive ventilatory defect**, where **lung volumes** are reduced due to stiff lungs.- The HRCT finding of **lower lobe fibrosis** directly confirms a restrictive pathology and is a hallmark of many Interstitial Lung Diseases (ILDs), such as **Idiopathic Pulmonary Fibrosis (IPF)**.*COPD*- COPD is an **obstructive lung disease** characterized by a **reduced FEV1/FVC ratio**, typically less than 0.70, which contradicts the given ratio of 0.85.- While it causes dyspnea, the primary HRCT findings are **emphysema** (centrilobular or panlobular) or **airway wall thickening**, not primarily lower lobe fibrosis.*Asthma*- Asthma is also an **obstructive lung disease** with variable and reversible airflow limitation, meaning the FEV1/FVC ratio would be **reduced**, often improving with bronchodilators.- HRCT findings in asthma might show **airway wall thickening** or **hyperinflation**, but it does not cause **pulmonary fibrosis**.*Bronchiectasis*- Bronchiectasis is characterized by permanent **dilation of the bronchi** and often presents with a chronic cough and sputum production.- Spirometry typically shows an **obstructive or mixed ventilatory defect**, not a purely restrictive pattern with a preserved FEV1/FVC ratio. HRCT shows **dilated airways** ("tram tracks" or "signet ring sign").*Pneumothorax*- A pneumothorax is the presence of **air in the pleural space**, causing acute dyspnea and chest pain, and resulting in a **collapsed lung** on imaging.- Spirometry would show severely reduced lung volumes, but the HRCT finding of **lower lobe fibrosis** is inconsistent with a pneumothorax, which is an acute air leak.

Q: A 45-year-old man presents with progressive shortness of breath and fatigue. Chest X-ray shows bilateral hilar lymphadenopathy and pulmonary infiltrates. Serum ACE is elevated. Bronchoscopy with biopsy shows non-caseating granulomas. What is the most likely diagnosis?

Sarcoidosis. ***Sarcoidosis***- The combination of **progressive shortness of breath** and **fatigue**, along with classic radiographic findings of **bilateral hilar lymphadenopathy** and pulmonary infiltrates, strongly suggests sarcoidosis.- The diagnosis is confirmed by the presence of **non-caseating granulomas** on biopsy and supported by an elevated **Angiotensin-Converting Enzyme (ACE)** level, which reflects granuloma burden.*Tuberculosis*- Tuberculosis typically presents with **caseating granulomas** (with central necrosis) on biopsy, not the non-caseating type seen in the patient.- Hilar adenopathy is often **unilateral** or accompanied by other findings like **apical infiltrates** or cavitations, rather than prominent bilateral hilar lymphadenopathy alone.*Lung cancer*- Lung cancer causes malignancy, and biopsy would reveal **atypical cells** and tumor architecture, not **non-caseating granulomas**.- While it can cause lymphadenopathy, **elevated ACE** is not a characteristic diagnostic feature.*Histoplasmosis*- This fungal infection can cause granulomas and hilar adenopathy, but the granulomas are often **caseating** or show evidence of fungal organisms upon special staining.- Diagnosis typically requires positive **fungal cultures** or serology, which are not described.*Hypersensitivity pneumonitis*- Although it can occasionally cause **non-caseating granulomas**, prominent **bilateral hilar lymphadenopathy** and **elevated serum ACE** are not typical primary features.- This condition is primarily an interstitial lung disease usually related to known environmental **antigen exposure**, which is not mentioned in the presentation.

Respiratory Medicine UK Medical PG Practice Questions and MCQs

Question 1: A 56-year-old man presents with progressive dyspnea and chest tightness. He works in coal mining. Chest X-ray shows bilateral upper lobe nodules. What is the most likely diagnosis?

A. Lung cancer
B. Silicosis
C. Coal worker's pneumoconiosis (Correct Answer)
D. Tuberculosis
E. Sarcoidosis

Explanation: ***Coal worker's pneumoconiosis***- This diagnosis is strongly supported by the patient's occupational exposure to **coal dust** and the progressive respiratory symptoms like **dyspnea** and **chest tightness**.- The characteristic Chest X-ray finding of bilateral, often small, **pulmonary nodules** predominantly located in the **upper lung zones** is classic for this condition.*Lung cancer*- Although coal miners have an increased risk of lung cancer, the presentation of diffuse **bilateral small nodules** is more typical of a pneumoconiosis than primary malignancy.- Lung cancer usually manifests as a single, dominant mass, or less commonly as reticulonodular interstitial disease, not typically as diffuse, symmetrical small nodules.*Silicosis*- Silicosis is caused by the inhalation of **crystalline silica** dust, prevalent in occupations like sandblasting or quarrying, which differs from pure coal mining exposure.- While silicosis also causes upper lobe nodules, it often presents radiologically with **"eggshell" calcification** of the hilar lymph nodes, a finding not specified in this case.*Tuberculosis*- Although **post-primary TB** targets the upper lobes, generalized diffuse nodularity suggests pneumoconiosis rather than a primary mycobacterial infection.- TB typically presents with systemic symptoms like **fever**, **night sweats**, and **weight loss**, which are not mentioned in this patient's presentation.*Sarcoidosis*- Sarcoidosis is a systemic disease of unknown etiology characterized by **non-caseating granulomas** and classically presents with **bilateral hilar lymphadenopathy (BHL)** on chest imaging.- The strong history of **coal mining** is the key factor favoring an occupational lung disease over sarcoidosis, as BHL is also absent.

Question 2: A 56-year-old man presents with progressive dyspnea and dry cough. HRCT shows bilateral lower lobe fibrosis with honeycombing. He has clubbing and restrictive spirometry. What medication may slow disease progression?

A. Prednisolone
B. Azathioprine
C. Pirfenidone (Correct Answer)
D. Cyclophosphamide
E. N-acetylcysteine

Explanation: ***Pirfenidone***- The clinical presentation with progressive dyspnea, dry cough, clubbing, restrictive spirometry, and HRCT showing bilateral lower lobe fibrosis with **honeycombing** is highly characteristic of **Idiopathic Pulmonary Fibrosis (IPF)**.- **Pirfenidone** is an **anti-fibrotic** agent, along with nintedanib, approved for the treatment of mild to moderate IPF to slow disease progression by reducing the decline in **Forced Vital Capacity (FVC)**.*Prednisolone*- Systemic corticosteroids like **Prednisolone** are not recommended as monotherapy for **Idiopathic Pulmonary Fibrosis (IPF)** due to lack of proven long-term efficacy and potential harm.- They are primarily indicated for inflammatory interstitial lung diseases, such as those associated with **connective tissue diseases**, or for **acute exacerbations** of IPF.*Azathioprine*- **Azathioprine** is an immunosuppressant that was shown to be ineffective and potentially harmful in a triple-drug regimen for IPF in the **PANTHER-IPF trial**.- Immunosuppression is generally avoided in **Idiopathic Pulmonary Fibrosis** unless there is a strong suspicion of an alternative, inflammatory interstitial lung disease.*Cyclophosphamide*- **Cyclophosphamide** is a potent cytotoxic immunosuppressant typically reserved for severe, rapidly progressive forms of **connective tissue disease-associated ILD** (e.g., scleroderma-associated ILD or vasculitis).- It is not indicated for the primary management of **Idiopathic Pulmonary Fibrosis**, which is characterized by relentless fibrosis rather than a primary inflammatory process responsive to this therapy.*N-acetylcysteine*- Although previously studied for its antioxidant properties, the **PANTHER-IPF trial** demonstrated that **N-acetylcysteine** offered no benefit in slowing the progression of IPF and is no longer recommended.- Its primary clinical uses are as a mucolytic agent and as an antidote for **acetaminophen overdose**.

Question 3: A 54-year-old man presents with progressive dyspnea and chest tightness. Spirometry shows FEV1 1.8L (60% predicted), FEV1/FVC 0.55. He has a 40 pack-year smoking history. What is the most important intervention?

A. Bronchodilators
B. Inhaled corticosteroids
C. Smoking cessation (Correct Answer)
D. Pulmonary rehabilitation
E. Long-term oxygen therapy

Explanation: ***Smoking cessation***- This is the **single most important intervention** for patients with **COPD** who smoke, as it is the only measure proven to slow the rate of **FEV1 decline** and disease progression.- Quitting smoking significantly reduces symptoms, exacerbations, and mortality, directly addressing the primary etiological factor in this patient's 40 pack-year history.*Bronchodilators*- **Bronchodilators** (e.g., beta-agonists, anticholinergics) provide crucial **symptomatic relief** by improving airflow and reducing dyspnea, but they do not alter the natural history of COPD or stop the underlying disease progression.- They are essential for managing symptoms but are not the **most important intervention** to halt the destruction caused by smoking.*Inhaled corticosteroids*- **Inhaled corticosteroids (ICS)** are typically indicated for patients with more severe COPD (e.g., FEV1 < 50% predicted) and a history of **frequent exacerbations**, often in combination with long-acting bronchodilators.- While they can reduce inflammation and exacerbation rates, ICS do not reverse or prevent the progressive lung damage caused by smoking.*Pulmonary rehabilitation*- **Pulmonary rehabilitation** is a highly effective intervention that improves **exercise capacity**, reduces dyspnea, and enhances quality of life in patients with COPD.- However, it does not modify the underlying **disease progression** or stop the decline in lung function, which is the primary benefit of smoking cessation.*Long-term oxygen therapy*- **Long-term oxygen therapy (LTOT)** is indicated for patients with **severe chronic hypoxemia** (PaO2 < 55 mmHg or SaO2 < 88%) to improve survival and quality of life.- This intervention addresses a consequence of advanced COPD but does not directly prevent or slow the progression of the disease itself, which is the focus of the question.

Question 4: A 58-year-old man presents with progressive dyspnea and fatigue. Chest X-ray shows bilateral lower lobe shadowing. HRCT shows honeycombing and traction bronchiectasis. He has finger clubbing. What is the prognosis?

A. Excellent with treatment
B. Good with early intervention
C. Variable depending on cause
D. Poor with median survival 2-5 years (Correct Answer)
E. Benign condition

Explanation: ***Poor with median survival 2-5 years***- The progressive dyspnea, fatigue, finger clubbing, and HRCT findings of **honeycombing** and **traction bronchiectasis** are classic features of **Idiopathic Pulmonary Fibrosis (IPF)**.- IPF is a relentlessly progressive lung disease with a **poor prognosis**, typically having a median survival of **2 to 5 years** from diagnosis without lung transplantation.*Excellent with treatment*- IPF is an **irreversible, progressive fibrotic lung disease** for which there is currently no curative medical treatment, precluding an excellent prognosis.- Although anti-fibrotic medications can slow the rate of decline, they do not halt or reverse the underlying **pulmonary fibrosis**.*Good with early intervention*- Despite early diagnosis and intervention with anti-fibrotic drugs, the established **Usual Interstitial Pneumonia (UIP)** pattern of IPF implies a rapid and unfavorable progression.- Patients with IPF remain at high risk of **acute exacerbations** and progressive **respiratory failure**, even with timely management.*Variable depending on cause*- The classic presentation of progressive dyspnea, clubbing, and a definable **UIP pattern** on HRCT points strongly to **Idiopathic Pulmonary Fibrosis**, which has a consistently unfavorable prognosis.- Prognostic variability is more often associated with other Interstitial Lung Diseases (ILDs) like non-specific interstitial pneumonia (**NSIP**), not IPF.*Benign condition*- IPF is far from benign; it is a serious, ultimately **fatal condition** characterized by continuous and irreversible destruction of lung architecture.- The presence of **traction bronchiectasis** and **honeycombing** signifies advanced, non-reversible scarring and distortion of lung tissue, indicating a severe disease.

Question 5: A 55-year-old man presents with progressive dyspnea and dry cough over 6 months. He has finger clubbing. HRCT shows honeycombing and reticular opacities in lower lobes. What is the most likely diagnosis?

A. COPD
B. Asthma
C. Idiopathic pulmonary fibrosis (Correct Answer)
D. Hypersensitivity pneumonitis
E. Sarcoidosis

Explanation: ***Idiopathic pulmonary fibrosis*** - The combination of progressive dyspnea, dry cough, and **finger clubbing** in an older patient strongly suggests a chronic fibrotic lung process. - HRCT findings of **honeycombing** and **reticular opacities** primarily in the lower lobes are pathognomonic for the Usual Interstitial Pneumonia (**UIP**) pattern, which defines Idiopathic Pulmonary Fibrosis (IPF). *COPD* - COPD is an **obstructive lung disease** and typically presents with chronic productive cough and sputum, often related to smoking. - HRCT features usually involve **emphysema** (air space enlargement) or bronchial wall thickening, not severe lower lobe fibrosis with honeycombing. *Asthma* - Asthma is characterized by **reversible airway obstruction** and episodic wheezing, often triggered by specific exposures. - HRCT is usually normal or shows mild signs of **air trapping**, and **clubbing** is not a feature of asthma. *Hypersensitivity pneumonitis* - Acute or subacute forms often show **centrilobular nodules** or ground-glass opacities, often with a documented environmental exposure history. - While chronic HP can cause fibrosis, the pattern is often different from UIP, frequently involving the **upper or mid-lung zones** and sparing the bases. *Sarcoidosis* - Sarcoidosis is classically associated with **hilar lymphadenopathy** and primarily affects the **upper and mid-lung zones**, showing peribronchovascular nodularity. - **Clubbing** is very rare, and the typical HRCT pattern is **perilymphatic**, unlike the peripheral subpleural pattern seen here.

Question 6: A 48-year-old man presents with progressive breathlessness and fatigue. Chest X-ray showed bilateral hilar lymphadenopathy. Serum ACE is elevated. Transbronchial biopsy shows no caseating granulomas. What is the most likely diagnosis?

A. Tuberculosis
B. Sarcoidosis (Correct Answer)
C. Lung cancer
D. Histoplasmosis
E. Silicosis

Explanation: ***Sarcoidosis*** - The presentation of progressive breathlessness and fatigue, coupled with **bilateral hilar lymphadenopathy (BHL)** on Chest X-ray and an **elevated serum ACE**, strongly indicates sarcoidosis. - The transbronchial biopsy showing **no caseating granulomas** is consistent with sarcoidosis, a disease characterized by **non-caseating granulomas**. *Tuberculosis* - Typically presents with **caseating granulomas** on biopsy, and hilar lymphadenopathy is often unilateral, unlike the patient's bilateral presentation. - Other common features include fever, night sweats, and weight loss, and **serum ACE** is not typically elevated. *Lung cancer* - While it can cause lymphadenopathy, it would typically show **malignant cells** on biopsy, not granulomas, and **elevated serum ACE** is not a diagnostic marker for lung cancer. - Clinical presentation often includes hemoptysis, unexplained weight loss, or persistent cough, which are not highlighted here. *Histoplasmosis* - This fungal infection can cause hilar lymphadenopathy and granulomas (often with subsequent calcification), but it is geographically endemic and **does not typically elevate serum ACE**. - Biopsy would reveal fungal organisms, which is not described in the patient's findings. *Silicosis* - An occupational lung disease due to **silica dust** exposure, which is not mentioned in the patient's history. - It typically causes upper lobe nodules and characteristic **eggshell calcification** of hilar lymph nodes, and **serum ACE** levels are usually normal.

Question 7: A 54-year-old man presents with progressive dyspnea and bilateral lower lobe crackles. Chest X-ray shows bilateral infiltrates. He works in shipbuilding. What is the most likely diagnosis?

A. COPD
B. Asbestosis (Correct Answer)
C. Silicosis
D. Coal worker's pneumoconiosis
E. Hypersensitivity pneumonitis

Explanation: ***Asbestosis***- The patient's history of working in **shipbuilding** is a classic exposure for **asbestos** fibers.- Asbestosis typically causes **interstitial pulmonary fibrosis**, preferentially affecting the **lower lobes**, leading to progressive dyspnea and **bibasilar crackles**. *COPD*- This involves **obstructive lung disease** (e.g., chronic bronchitis or emphysema) characterized by airflow limitation, not the restrictive pattern suggested by crackles and infiltrates.- CXR typically shows signs of **hyperinflation** or large bullae, rather than diffuse bilateral interstitial infiltrates.*Silicosis*- Silicosis is caused by inhaling **free crystalline silica** (e.g., mining, quarrying, sandblasting), an exposure typically unrelated to shipbuilding.- Radiographically, silicosis usually presents with **nodular opacities**, classically affecting the **upper lobes**.*Coal worker's pneumoconiosis*- This condition is due to the inhalation of **coal dust**, almost exclusively seen in **coal miners**.- Simple CWP generally causes small **nodular opacities**, also predominantly in the **upper lung fields**.*Hypersensitivity pneumonitis*- Caused by immunologic reactions to inhaled **organic antigens** (e.g., bird droppings, mold from farmers' lung), not asbestos exposure.- HP often presents with systemic symptoms, and the pathology involves the **alveolar walls** and terminal bronchioles, lacking the specific pleural/parenchymal changes linked to asbestos.

Question 8: A 56-year-old man presents with progressive dyspnea and dry cough. HRCT shows honeycombing and traction bronchiectasis in lower lobes. He has clubbing. What is the most likely diagnosis?

A. COPD
B. Asthma
C. Idiopathic pulmonary fibrosis (Correct Answer)
D. Sarcoidosis
E. Hypersensitivity pneumonitis

Explanation: ***Idiopathic pulmonary fibrosis***- The clinical presentation of **progressive dyspnea**, **dry cough**, and **clubbing** in an older patient, coupled with HRCT findings of **honeycombing** and **traction bronchiectasis** predominantly in the **lower lobes**, are classic features of **Usual Interstitial Pneumonia (UIP)** pattern, diagnostic of IPF.- **UIP** pattern on HRCT signifies extensive subpleural and basilar fibrosis with architectural distortion, where **honeycombing** represents clustered cystic airspaces and **traction bronchiectasis** indicates bronchial dilation due to surrounding fibrotic retraction.*COPD*- **COPD** is characterized by persistent **airflow limitation**, often with a history of smoking and a productive cough, contrasting with the dry cough and restrictive pattern of fibrosis seen here.- HRCT in COPD typically shows **emphysema** (centrilobular or panlobular) or **airway wall thickening**, but not the **honeycombing** and **traction bronchiectasis** indicative of severe pulmonary fibrosis.*Asthma*- **Asthma** is an inflammatory airway disease marked by **reversible airflow obstruction** and bronchial hyperresponsiveness, presenting with episodic wheezing, chest tightness, and dyspnea, which usually respond to bronchodilators.- HRCT in asthma may show **bronchial wall thickening** or **air trapping**, but it does not exhibit the progressive fibrotic changes like **honeycombing** or **traction bronchiectasis** seen in this patient.*Sarcoidosis*- **Sarcoidosis** is a multisystem granulomatous disease, often involving the lungs with **bilateral hilar lymphadenopathy** and a **perilymphatic distribution** of nodules, typically in the upper and mid lung zones.- While sarcoidosis can cause fibrosis (Stage 4), it typically manifests as **upper lobe predominant fibrosis** with conglomerate masses and volume loss, rather than the lower lobe predilection and characteristic UIP pattern.*Hypersensitivity pneumonitis*- Chronic **hypersensitivity pneumonitis (HP)** can lead to fibrosis, but HRCT often reveals a mosaic attenuation pattern, **centrilobular nodules**, and **air trapping**, with fibrosis potentially sparing the subpleural regions.- Although HP can mimic a UIP pattern in some cases, the classic presentation of progressive dyspnea, dry cough, clubbing, and strict lower lobe **honeycombing** and **traction bronchiectasis** points more strongly to IPF.

Question 9: A 42-year-old man presents with progressive dyspnea and chest tightness. Spirometry shows FEV1 45% predicted, FEV1/FVC 0.85. HRCT shows lower lobe fibrosis. What is the most likely diagnosis?

A. COPD
B. Asthma
C. Interstitial lung disease (Correct Answer)
D. Bronchiectasis
E. Pneumothorax

Explanation: ***Interstitial lung disease***- This pattern—low FEV1 (45% predicted) with a preserved FEV1/FVC ratio (0.85)—is characteristic of a **restrictive ventilatory defect**, where **lung volumes** are reduced due to stiff lungs.- The HRCT finding of **lower lobe fibrosis** directly confirms a restrictive pathology and is a hallmark of many Interstitial Lung Diseases (ILDs), such as **Idiopathic Pulmonary Fibrosis (IPF)**.*COPD*- COPD is an **obstructive lung disease** characterized by a **reduced FEV1/FVC ratio**, typically less than 0.70, which contradicts the given ratio of 0.85.- While it causes dyspnea, the primary HRCT findings are **emphysema** (centrilobular or panlobular) or **airway wall thickening**, not primarily lower lobe fibrosis.*Asthma*- Asthma is also an **obstructive lung disease** with variable and reversible airflow limitation, meaning the FEV1/FVC ratio would be **reduced**, often improving with bronchodilators.- HRCT findings in asthma might show **airway wall thickening** or **hyperinflation**, but it does not cause **pulmonary fibrosis**.*Bronchiectasis*- Bronchiectasis is characterized by permanent **dilation of the bronchi** and often presents with a chronic cough and sputum production.- Spirometry typically shows an **obstructive or mixed ventilatory defect**, not a purely restrictive pattern with a preserved FEV1/FVC ratio. HRCT shows **dilated airways** ("tram tracks" or "signet ring sign").*Pneumothorax*- A pneumothorax is the presence of **air in the pleural space**, causing acute dyspnea and chest pain, and resulting in a **collapsed lung** on imaging.- Spirometry would show severely reduced lung volumes, but the HRCT finding of **lower lobe fibrosis** is inconsistent with a pneumothorax, which is an acute air leak.

Question 10: A 45-year-old man presents with progressive shortness of breath and fatigue. Chest X-ray shows bilateral hilar lymphadenopathy and pulmonary infiltrates. Serum ACE is elevated. Bronchoscopy with biopsy shows non-caseating granulomas. What is the most likely diagnosis?

A. Tuberculosis
B. Sarcoidosis (Correct Answer)
C. Lung cancer
D. Histoplasmosis
E. Hypersensitivity pneumonitis

Explanation: ***Sarcoidosis***- The combination of **progressive shortness of breath** and **fatigue**, along with classic radiographic findings of **bilateral hilar lymphadenopathy** and pulmonary infiltrates, strongly suggests sarcoidosis.- The diagnosis is confirmed by the presence of **non-caseating granulomas** on biopsy and supported by an elevated **Angiotensin-Converting Enzyme (ACE)** level, which reflects granuloma burden.*Tuberculosis*- Tuberculosis typically presents with **caseating granulomas** (with central necrosis) on biopsy, not the non-caseating type seen in the patient.- Hilar adenopathy is often **unilateral** or accompanied by other findings like **apical infiltrates** or cavitations, rather than prominent bilateral hilar lymphadenopathy alone.*Lung cancer*- Lung cancer causes malignancy, and biopsy would reveal **atypical cells** and tumor architecture, not **non-caseating granulomas**.- While it can cause lymphadenopathy, **elevated ACE** is not a characteristic diagnostic feature.*Histoplasmosis*- This fungal infection can cause granulomas and hilar adenopathy, but the granulomas are often **caseating** or show evidence of fungal organisms upon special staining.- Diagnosis typically requires positive **fungal cultures** or serology, which are not described.*Hypersensitivity pneumonitis*- Although it can occasionally cause **non-caseating granulomas**, prominent **bilateral hilar lymphadenopathy** and **elevated serum ACE** are not typical primary features.- This condition is primarily an interstitial lung disease usually related to known environmental **antigen exposure**, which is not mentioned in the presentation.

Question 11: A 65-year-old man presents with progressive dyspnea and dry cough over 12 months. He has clubbing and bilateral fine inspiratory crackles. HRCT chest shows honeycombing and traction bronchiectasis in the lower lobes. What is the most likely diagnosis?

A. COPD
B. Asthma
C. Idiopathic pulmonary fibrosis (Correct Answer)
D. Sarcoidosis
E. Hypersensitivity pneumonitis

Explanation: ***Idiopathic pulmonary fibrosis*** - The presentation of progressive **dyspnea** and **dry cough** over 12 months, combined with physical findings like **clubbing** and **bilateral fine inspiratory crackles** ('Velcro rales'), is highly characteristic. - HRCT findings of **honeycombing** and **traction bronchiectasis** predominantly in the **lower lobes** define the **Usual Interstitial Pneumonia (UIP)** pattern, which is the pathological hallmark of IPF. *COPD* - COPD typically causes airflow limitation with symptoms such as chronic sputum production or predominantly **expiratory dyspnea** and wheezing, rather than the restrictive pattern seen with crackles and clubbing. - HRCT would primarily show features of **emphysema** (low attenuation areas) or **bronchial wall thickening**, not subpleural honeycombing and traction bronchiectasis consistent with IPF. *Asthma* - Asthma is an episodic condition characterized by **reversible airflow obstruction**, resulting in wheezing and cough, and is typically responsive to bronchodilators. - The presence of **clubbing** and advanced **honeycombing** on HRCT rules out classic asthma, which does not cause progressive pulmonary fibrosis. *Sarcoidosis* - Sarcoidosis often presents with **hilar and mediastinal lymphadenopathy** (Stage I/II) or non-caseating granulomas, usually affecting the **mid-to-upper lung zones** if fibrosis develops (Stage IV). - Clinical features often include extrapulmonary manifestations like **erythema nodosum** or **uveitis**, which are absent here, and it lacks the specific lower lobe UIP pattern. *Hypersensitivity pneumonitis* - HP usually relates to an identifiable **environmental exposure** (e.g., birds, mold) and, on HRCT, typically presents with features like **centrilobular nodules** and **air trapping**, often sparing the subpleural zone. - While chronic HP can cause fibrosis, the pattern usually differs from UIP, often showing **fibrosis in the mid-zones** or peribronchial areas, not the classic basal, subpleural honeycombing of IPF.

Question 12: A 70-year-old man presents with gradually worsening breathlessness and dry cough over 6 months. He has a history of working in shipbuilding. Chest X-ray shows bilateral lower lobe reticular shadowing. What is the most likely diagnosis?

A. COPD
B. Asbestosis (Correct Answer)
C. Silicosis
D. Lung cancer
E. Pulmonary edema

Explanation: ***Asbestosis***- The patient's history of working in **shipbuilding** indicates significant occupational exposure to **asbestos** fibers.- **Bilateral lower lobe reticular shadowing** on the chest X-ray, combined with gradually worsening dyspnea and dry cough, is the classic presentation of **pulmonary fibrosis** secondary to asbestosis.*COPD*- COPD typically presents with a history of **heavy smoking** and is characterized by chronic airflow obstruction, leading to features of **emphysema** or **chronic bronchitis**.- Radiologically, COPD usually involves **hyperinflation** and is less likely to present with isolated **lower lobe reticular shadowing** (interstitial fibrosis).*Silicosis*- Silicosis is caused by inhaling **silica dust** (common in mining, quarrying, or sandblasting), not typically associated with shipbuilding.- Radiographic findings in silicosis usually involve small, well-defined **nodules** primarily located in the **upper lung zones**.*Lung cancer*- While asbestos exposure significantly increases the risk of **lung cancer**, the current presentation is that of a diffuse interstitial lung disease rather than a localized mass or obstructive lesion.- Lung cancer typically manifests radiologically as a **solitary pulmonary nodule** or mass, often accompanied by symptoms such as **hemoptysis** or significant weight loss.*Pulmonary edema*- Pulmonary edema is usually **acute** or subacute, linked to **congestive heart failure**, and symptoms often worsen rapidly, unlike this 6-month gradual course.- Typical X-ray findings include **cephalization** of blood flow and perihilar opacities, not chronic reticular shadowing.

Question 13: A 60-year-old man with COPD presents with increasing breathlessness, purulent sputum, and wheeze over 3 days. His usual medications are salbutamol and tiotropium inhalers. What is the most appropriate additional treatment?

A. Increase bronchodilator dose
B. Oral prednisolone
C. Antibiotics only
D. Oral prednisolone and antibiotics (Correct Answer)
E. IV aminophylline

Explanation: ***Oral prednisolone and antibiotics***- This patient presents with increased **dyspnea** and **purulent sputum**, which strongly suggests a moderate to severe **Acute Exacerbation of COPD (AECOPD)**, likely triggered by a bacterial infection (based on **Anthonisen criteria**).- Administration of **oral corticosteroids** (like prednisolone) is crucial for reducing airway inflammation, and **antibiotics** are required to eradicate the bacterial component indicated by the purulent sputum.*Increase bronchodilator dose*- While increasing bronchodilation (e.g., with nebulized short-acting agents) is a necessary step, it is insufficient alone to treat the serious underlying **inflammation** and **bacterial infection**.- This option neglects the critical role of systemic anti-inflammatory agents (**prednisolone**) and antimicrobial therapy in moderate-to-severe exacerbations.*Oral prednisolone*- **Systemic corticosteroids** are foundational for managing AECOPD by reducing airway inflammation and improving lung function.- However, the presence of **purulent sputum** strongly indicates a bacterial infection; therefore, **antibiotics** must be included alongside the prednisolone for adequate treatment response.*Antibiotics only*- Antibiotics are indicated due to the evidence of a bacterial trigger (purulent sputum), but they only address the infection, not the underlying severe inflammatory component of the exacerbation.- Optimal therapy for AECOPD involves the combined use of **antibiotics** and **systemic corticosteroids** to manage both infection and inflammation effectively.*IV aminophylline*- **IV aminophylline** (a methylxanthine) is a second or third-line agent due to its narrow therapeutic index, side effects, and limited evidence base for routine use in AECOPD.- It is generally reserved for patients with severe AECOPD who fail to improve rapidly despite optimal treatment with high-dose bronchodilators and **systemic corticosteroids**.

Question 14: A 35-year-old man presents with a 1-week history of productive cough with green sputum, fever, and left-sided chest pain. Chest X-ray shows left lower lobe consolidation. What is the most appropriate antibiotic treatment?

A. Amoxicillin 500mg TDS for 5 days (Correct Answer)
B. Clarithromycin 500mg BD for 7 days
C. Doxycycline 100mg BD for 5 days
D. Co-amoxiclav 625mg TDS for 7 days
E. Ciprofloxacin 500mg BD for 7 days

Explanation: ***Amoxicillin 500mg TDS for 5 days***- This patient presents with **Community-Acquired Pneumonia (CAP)**, likely caused by **Streptococcus pneumoniae**, which is the most common bacterial cause in otherwise healthy adults.- **Amoxicillin** is the recommended **first-line oral antibiotic** for low-severity CAP in patients with no relevant comorbidities or penicillin allergy, with a typical course being 5-7 days.*Clarithromycin 500mg BD for 7 days*- **Clarithromycin** (a macrolide) is typically used when an **atypical pathogen** (e.g., *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*) is suspected, or for patients with **penicillin allergy**.- The presence of **green sputum** suggests a typical bacterial pathogen like *S. pneumoniae*, making macrolide monotherapy less appropriate as first-line empiric treatment unless there's an allergy.*Doxycycline 100mg BD for 5 days*- **Doxycycline** is effective against both typical and atypical pathogens and is an alternative for CAP, particularly in cases of **penicillin allergy** or when atypical pneumonia is strongly considered.- While a viable option, it is generally considered a **second-line agent** or alternative to amoxicillin for uncomplicated CAP, with amoxicillin being preferred first-line in the absence of allergies.*Co-amoxiclav 625mg TDS for 7 days*- **Co-amoxiclav** (amoxicillin-clavulanate) provides broader coverage, including **beta-lactamase producing organisms** and *Haemophilus influenzae*, and is usually reserved for CAP in patients with **comorbidities** (e.g., COPD, bronchiectasis) or more severe disease.- For an otherwise healthy 35-year-old with low-severity CAP, the broader spectrum of Co-amoxiclav is **unnecessary** and may contribute to antibiotic resistance.*Ciprofloxacin 500mg BD for 7 days*- **Ciprofloxacin** (a fluoroquinolone) is a potent antibiotic generally reserved for **severe CAP requiring hospitalization**, patients with **significant comorbidities**, or when **drug-resistant pathogens** are suspected.- Its routine use for low-severity CAP in healthy individuals is **discouraged** due to potential side effects (e.g., C. difficile infection, QT prolongation) and the importance of **antibiotic stewardship**.

Question 15: A 64-year-old man presents with progressive dyspnea and chest tightness. Spirometry shows FEV1 65% predicted, FEV1/FVC ratio 0.55. He has a 40 pack-year smoking history. What is the most likely diagnosis?

A. Asthma
B. COPD (Correct Answer)
C. Interstitial lung disease
D. Bronchiectasis
E. Lung cancer

Explanation: ***COPD***- The combination of a 40 pack-year **smoking history** and **fixed airflow obstruction** (FEV1/FVC ratio 0.55, significantly less than 0.70) is the hallmark presentation for COPD. - COPD is a progressive disease characterized by persistent respiratory symptoms and **airflow limitation** due to airway and alveolar abnormalities, consistent with the patient's progressive dyspnea.*Asthma*- Asthma usually presents with **reversible airflow obstruction** that improves significantly after bronchodilator administration.- Although some patients with chronic, severe asthma may develop fixed obstruction, the heavy **smoking history** makes COPD the more likely primary diagnosis.*Interstitial lung disease*- Interstitial lung diseases cause a **restrictive lung pattern**, characterized by reduced FVC and TLC, typically resulting in a **normal or high FEV1/FVC ratio** (>0.70) because flows are proportionally preserved.- The primary presenting findings are **decreased lung volumes** and not the severe obstructive ratio (0.55) seen here.*Bronchiectasis*- While bronchiectasis is an obstructive process, it is marked predominantly by a **chronic, copious productive cough** and recurrent, severe lung infections.- Diagnosis usually requires a **CT scan** to visualize the characteristic **bronchial dilation**; PFTs alone do not distinguish it from typical COPD.*Lung cancer*- Lung cancer presents with variable symptoms (e.g., hemoptysis, unexplained weight loss) and is confirmed by **imaging and biopsy**, not typically by characteristic PFT patterns alone.- While lung cancer is a possibility in a smoker, the PFT findings are diagnostic of the underlying chronic obstructive **airway disease** (**COPD**).

Question 16: A 52-year-old man presents with progressive dyspnea and dry cough over 12 months. He has clubbing and bilateral fine inspiratory crackles. HRCT shows honeycombing and traction bronchiectasis in lower lobes. What is the most likely diagnosis?

A. COPD
B. Asthma
C. Idiopathic pulmonary fibrosis (Correct Answer)
D. Sarcoidosis
E. Hypersensitivity pneumonitis

Explanation: ***Idiopathic pulmonary fibrosis*** - The constellation of progressive dyspnea and dry cough, physical exam findings of **clubbing** and **bilateral fine inspiratory crackles** (Velcro rales), coupled with a **UIP (usual interstitial pneumonia) pattern** on HRCT, is diagnostic of IPF. - The HRCT findings of **honeycombing** (cysts in a clustered, peripheral, subpleural distribution) and **traction bronchiectasis** that are lower lobe predominant confirm advanced fibrosis (UIP). *COPD* - COPD is an an **obstructive** lung disease characterized by airflow limitation, typically yielding abnormal PFTs indicating decreased FEV1/FVC ratio. - It is unlikely as the presentation lacks dominant wheezing or established risk factors like heavy smoking, and the HRCT findings are classic for a **restrictive fibrotic** process, not emphysema. *Asthma* - Asthma is a chronic inflammatory disorder of the airways leading to **reversible** episodes of wheezing, cough, and dyspnea, which typically respond to bronchodilators. - It does not cause progressive, irreversible lung parenchymal damage leading to **honeycombing** or **clubbing**. *Sarcoidosis* - Sarcoidosis is a multisystem granulomatous disease that typically presents with **bilateral hilar adenopathy** and often involves the upper and mid lung fields. - While it can cause fibrosis, the pattern on HRCT is usually characterized by nodularity, and the classic lower lobe-dominant **UIP pattern** is not typical. *Hypersensitivity pneumonitis* - HP (especially chronic fibrotic form) typically presents with lung damage localized to the **mid or upper lung zones**, often showing features like **centrilobular micronodules** or air trapping (mosaic attenuation). - It is less likely given the classic **lower lobe and subpleural** distribution of fibrosis and honeycombing characteristic of IPF/UIP.

Question 17: A 64-year-old man presents with progressive dyspnea and chest tightness. Chest X-ray shows bilateral lower lobe reticular shadowing. HRCT shows honeycombing and traction bronchiectasis. He worked in shipbuilding. What is the most likely diagnosis?

A. Idiopathic pulmonary fibrosis
B. Asbestosis (Correct Answer)
C. Silicosis
D. Coal worker's pneumoconiosis
E. Hypersensitivity pneumonitis

Explanation: ***Asbestosis***- The patient's history of working in **shipbuilding** indicates significant occupational exposure to **asbestos** fibers, which is the primary cause of asbestosis. - The characteristic findings of **bilateral lower lobe reticular shadowing**, **honeycombing**, and **traction bronchiectasis** strongly suggest severe pulmonary fibrosis, often presenting as a usual interstitial pneumonia (UIP) pattern, typical of advanced asbestosis.*Idiopathic pulmonary fibrosis* - Although IPF shares the same imaging pattern (**UIP**, honeycombing, lower lobe predominance), it is a diagnosis of exclusion made when no specific cause like **asbestos exposure** is identified. - Given the patient's clear occupational history (**shipbuilding**), **asbestosis** is the confirmed etiology rather than idiopathic disease.*Silicosis* - Silicosis is caused by inhaling **crystalline silica** and mainly affects workers in mining, sandblasting, or foundry work, not typically shipbuilding. - Radiographically, it often presents with nodules and potentially **eggshell calcification** of hilar nodes, often localized to the **upper lobes**.*Coal worker's pneumoconiosis* - This condition results from inhaling coal dust and is primarily seen in **coal miners**, which is inconsistent with the patient's job in **shipbuilding**. - Complicated CWP (massive fibrosis) typically involves the **upper lobes**, differentiating it from the lower lobe predominance seen here.*Hypersensitivity pneumonitis* - HP is an immunological reaction to inhaled organic antigens (e.g., molds, animal proteins) and is not associated with **asbestos exposure**. - While HP can cause fibrosis, the imaging pattern with prominent **lower lobe UIP** (**honeycombing**) and clear asbestos history makes this specific diagnosis unlikely.

Question 18: A 52-year-old man presents with progressive dyspnea and chest tightness. Spirometry show FEV1 1.2L (40% predicted), FEV1/FVC ratio 0.55. He has smoked 50 pack-years. What is the most appropriate initial treatment?

A. Salbutamol inhaler
B. Beclomethasone inhaler
C. Long-acting bronchodilator
D. Oral prednisolone
E. Smoking cessation (Correct Answer)

Explanation: ***Smoking cessation*** - This patient presents with a long history of heavy smoking (50 pack-years), progressive dyspnea, chest tightness, and significant **airflow obstruction** (FEV1 40% predicted, FEV1/FVC 0.55), all classic features of **Chronic Obstructive Pulmonary Disease (COPD)**. - **Smoking cessation** is the single most critical and effective intervention in COPD, as it is the only treatment proven to slow the rate of decline in lung function and improve survival, making it the **most appropriate initial treatment**. *Salbutamol inhaler* - Salbutamol is a **short-acting beta-2 agonist (SABA)** used for rapid, temporary relief of bronchospasm and dyspnea. - While it can alleviate symptoms, it does not address the underlying disease progression or offer the long-term benefits of smoking cessation, thus it is not the **most appropriate initial treatment** for chronic management. *Beclomethasone inhaler* - Beclomethasone is an **inhaled corticosteroid (ICS)**, which is typically reserved for COPD patients with frequent exacerbations despite long-acting bronchodilator therapy, or those with features of asthma-COPD overlap. - ICS monotherapy is not recommended for COPD, and initiating it without first addressing smoking or providing long-acting bronchodilators is not the **most appropriate initial step**. *Long-acting bronchodilator* - **Long-acting bronchodilators (LABAs or LAMAs)** are cornerstone pharmacological treatments for symptomatic COPD, improving lung function, symptoms, and quality of life. - While vital for COPD management, **smoking cessation** remains the priority initial intervention to modify the disease course, with bronchodilators typically added concurrently or subsequently. *Oral prednisolone* - **Oral corticosteroids** like prednisolone are primarily indicated for the treatment of **acute exacerbations of COPD** to reduce inflammation and shorten recovery time. - They are not recommended for routine **maintenance therapy** in stable COPD due to the significant risk of systemic side effects and lack of evidence for long-term benefit in stable disease.

Question 19: A 56-year-old man presents with progressive dyspnea and chest tightness. Spirometry shows FEV1 1.2L (40% predicted), FEV1/FVC ratio 0.55. He has smoked 50 pack-years. What is the most appropriate initial treatment?

A. Salbutamol inhaler
B. Beclomethasone inhaler
C. Long-acting bronchodilator
D. Oral prednisolone
E. Smoking cessation (Correct Answer)

Explanation: ***Smoking cessation***- This is the **single most important initial intervention** and the cornerstone of managing **COPD**, as it is the only measure proven to slow the rate of **FEV1 decline** and improve long-term survival.- The patient’s severe obstructive lung disease (FEV1 40%) is assumed to be COPD due to his **heavy smoking history (50 pack-years)**, making addressing the cause the priority before initiating pharmacotherapy.*Salbutamol inhaler*- **Salbutamol**, a short-acting beta-agonist (**SABA**), is used as a **rescue medication** for immediate temporary relief of acute dyspnea but does not address the underlying disease progression.- It is not adequate as initial monotherapy for a patient with symptomatic, moderate-to-severe stable COPD.*Beclomethasone inhaler*- Inhaled corticosteroids (**ICS**) are generally added to long-acting bronchodilators only in patients with severe COPD and a history of clinically significant **annual exacerbations** or high **eosinophil counts**.- ICS monotherapy is discouraged in stable COPD due to potential side effects like pneumonia and lack of FEV1 benefit compared to bronchodilators.*Long-acting bronchodilator*- Long-acting bronchodilators (**LAMA or LABA**) are the current pharmaceutical standard of care for daily symptom management in stable COPD (GOLD group B and higher).- While essential for symptom control, **pharmacotherapy** must follow the primary advice of **smoking cessation**, which is necessary to halt disease progression.*Oral prednisolone*- **Oral steroids** are reserved for the treatment of **acute exacerbations of COPD (AECOPD)** when symptoms worsen acutely beyond baseline.- They are inappropriate for the long-term stable management of COPD due to significant systemic side effects.

Question 20: A 64-year-old man presents with progressive dyspnea and chest tightness. Chest X-ray shows bilateral lower lobe reticular shadowing. HRCT shows honeycombing and traction bronchiectasis. He has a history of working in shipbuilding. What is the most likely diagnosis?

A. Idiopathic pulmonary fibrosis
B. Asbestosis (Correct Answer)
C. Silicosis
D. Coal worker's pneumoconiosis
E. Hypersensitivity pneumonitis

Explanation: ***Asbestosis***- The history of working in **shipbuilding** strongly implicates exposure to **asbestos** fibers, which deposit primarily in the lower lobes.- HRCT findings of **honeycombing**, **traction bronchiectasis**, and subpleural basilar predominance indicate progressive pulmonary fibrosis, the hallmark of **asbestosis**.*Idiopathic pulmonary fibrosis*- IPF diagnosis is one of exclusion, requiring the absence of known causes of interstitial lung disease, such as the confirmed **asbestos exposure** present in this case.- Clinical and HRCT features like **honeycombing** and **traction bronchiectasis** (UIP pattern) overlap with asbestosis, but the presence of a clear occupational exposure rules out idiopathic etiology.*Silicosis*- Silicosis is typically seen in workers exposed to **silica dust** (e.g., mining, quarry work) and usually involves the **upper lung zones**.- Characteristic HRCT findings include small, well-defined **upper lobe nodules** and often **eggshell calcification** of hilar lymph nodes, findings inconsistent with the basilar reticular disease described.*Coal worker's pneumoconiosis*- CWP is caused by inhalation of **coal dust** and typically presents as small opacities in the **upper and middle lung zones**.- The exposure history (shipbuilding) and the basilar location of the reticular changes and honeycombing do not fit the typical pattern of **coal worker's pneumoconiosis (CWP)**.*Hypersensitivity pneumonitis*- This condition is caused by chronic inhalation of **organic antigens** (e.g., bird droppings, mold); the exposure linked to shipbuilding is **inorganic dust** (asbestos).- Chronic HP typically shows predominant features in the **middle and upper lobes**, such as **centrilobular nodules** or a **mosaic attenuation** pattern (air trapping), rather than basilar traction bronchiectasis and honeycombing.

Question 21: A 55-year-old man presents with progressive dyspnea and chest tightness. Spirometry shows FEV1 65% predicted, FEV1/FVC ratio 0.55. He has a 40 pack-year smoking history. What is the most likely diagnosis?

A. Asthma
B. COPD (Correct Answer)
C. Interstitial lung disease
D. Bronchiectasis
E. Lung cancer

Explanation: ***COPD***- The patient's **40 pack-year smoking history**, progressive dyspnea, and especially the spirometry showing a **fixed FEV1/FVC ratio of 0.55** (less than 0.70 or less than the lower limit of normal) are pathognomonic for **Chronic Obstructive Pulmonary Disease**.- COPD is characterized by persistent, irreversible, or poorly reversible **airflow limitation** caused by chronic inflammatory response to noxious particles or gases, most commonly cigarette smoke.*Asthma*- Asthma is primarily characterized by **reversible airflow obstruction**, meaning the FEV1/FVC ratio would significantly improve (typically >12% and 200 mL increase in FEV1) after bronchodilator administration.- While asthma causes dyspnea and chest tightness, its symptoms are often episodic and variable, demonstrating **airway hyperresponsiveness**, unlike the fixed, progressive obstruction seen in this patient.*Interstitial lung disease*- Interstitial lung diseases (ILDs) typically cause a **restrictive ventilatory defect**, where both FEV1 and FVC are reduced proportionally, leading to a **normal or increased FEV1/FVC ratio** (often >0.70).- This patient's FEV1/FVC ratio of 0.55 clearly indicates an **obstructive pattern**, making ILD an unlikely diagnosis based on spirometry alone.*Bronchiectasis*- While bronchiectasis can cause an obstructive pattern on spirometry, it is typically characterized by a **chronic productive cough** with mucopurulent sputum and characteristic **bronchial dilation** on high-resolution CT (HRCT) scans.- Given the significant smoking history and classic obstructive spirometry without mention of chronic purulent cough or HRCT findings, **COPD** is a more direct and common explanation for the findings.*Lung cancer*- Lung cancer is a concern in any heavy smoker with respiratory symptoms, but it typically presents with localized symptoms (e.g., hemoptysis, focal wheezing, weight loss) and often causes restrictive or normal spirometry, or localized obstruction if a large bronchus is involved.- The global, fixed **obstructive pattern** (FEV1/FVC 0.55) seen in this patient's spirometry is a hallmark of widespread **airway disease** like COPD, rather than a primary effect of a localized tumor.

Question 22: A 62-year-old woman with rheumatoid arthritis on methotrexate presents with progressive dyspnea and dry cough over 3 months. HRCT chest shows bilateral ground-glass opacities and honeycombing. What is the most likely cause?

A. Pneumocystis pneumonia
B. Rheumatoid lung disease
C. Methotrexate pneumonitis (Correct Answer)
D. Usual interstitial pneumonia
E. Hypersensitivity pneumonitis

Explanation: ***Methotrexate pneumonitis*** - This is a well-recognized idiosyncratic adverse effect of **methotrexate**, characterized by subacute onset of **dyspnea** and **dry cough** as seen in this patient. - HRCT findings of **ground-glass opacities** and **honeycombing** are consistent with interstitial lung disease, a common manifestation of methotrexate-induced lung injury.*Pneumocystis pneumonia* - While methotrexate is immunosuppressive, **Pneumocystis pneumonia (PCP)** typically has a more acute or subacute course, often with fever, and usually presents with ground-glass opacities without extensive honeycombing unless it's a very chronic, untreated case. - PCP is more common with higher levels of immunosuppression (e.g., HIV, high-dose steroids) than typically seen with methotrexate for RA, unless specific risk factors are present.*Rheumatoid lung disease* - Rheumatoid arthritis can cause various lung manifestations, including interstitial lung disease (ILD) with **ground-glass opacities** and **honeycombing**. - However, given the patient is on **methotrexate**, a drug highly associated with drug-induced pneumonitis with identical presentation, methotrexate pneumonitis is the *most likely* and *direct* cause to consider first.*Usual interstitial pneumonia* - **Usual interstitial pneumonia (UIP)** describes a specific histopathological and radiological pattern of interstitial lung disease, not a specific etiology. - While this patient's HRCT findings of **ground-glass opacities** and **honeycombing** could reflect a UIP pattern, the question asks for the *cause*, and methotrexate is a direct causal agent, making it a more specific answer than a descriptive pattern.*Hypersensitivity pneumonitis* - **Hypersensitivity pneumonitis** is an inflammatory lung disease caused by repeated exposure to inhaled antigens, leading to dyspnea and cough. - Although it can present with similar HRCT findings like ground-glass opacities, there is no history of specific **antigen exposure** provided in the case, making it less likely than drug-induced toxicity from methotrexate.

Question 23: A 27-year-old woman with asthma attends for review. She was diagnosed with asthma 2 years ago and commenced on a low-dose ICS/LABA combination inhaler (budesonide/formoterol 200/6 micrograms, 2 puffs twice daily). She uses it regularly and reports good symptom control with minimal salbutamol use. She is planning to start trying for a baby and is concerned about her asthma medication during pregnancy. What is the most appropriate advice regarding her asthma treatment?

A. Stop the ICS/LABA combination and use salbutamol only during pregnancy
B. Continue the ICS/LABA combination as the benefits of good asthma control outweigh any risks (Correct Answer)
C. Switch to oral prednisolone throughout pregnancy as it is safer than inhaled therapy
D. Reduce the ICS dose by half during pregnancy to minimise fetal exposure
E. Stop the LABA component and use ICS alone during pregnancy

Explanation: ***Continue the ICS/LABA combination as the benefits of good asthma control outweigh any risks***- Maintaining **good asthma control** is critical during pregnancy because poorly controlled asthma increases the risk of **fetal hypoxia**, **pre-eclampsia**, and **low birth weight**.- Most asthma medications, including **budesonide** and **formoterol**, have a strong safety profile and are recommended to be continued if they are effective for the patient.*Stop the ICS/LABA combination and use salbutamol only during pregnancy*- Stopping maintenance therapy leads to a high risk of **acute exacerbations**, which are far more dangerous to the fetus than the medication.- **SABA monotherapy** is insufficient for patients who previously required combination therapy to maintain control.*Switch to oral prednisolone throughout pregnancy as it is safer than inhaled therapy*- **Inhaled therapy** is preferred as it delivers medication directly to the airways with minimal **systemic absorption** compared to oral steroids.- Long-term **oral prednisolone** is associated with higher risks of **gestational diabetes** and maternal hypertension.*Reduce the ICS dose by half during pregnancy to minimise fetal exposure*- Reducing the dose in a well-controlled patient increases the risk of the asthma becoming **uncontrolled** during a period where stability is vital.- Guidelines suggest maintaining the **minimum effective dose** that was achieved prior to pregnancy rather than making arbitrary reductions.*Stop the LABA component and use ICS alone during pregnancy*- Removing the **LABA** in a patient previously requiring combination therapy can lead to a loss of symptom control.- Current clinical guidelines state that **LABAs** are not known to be harmful to the fetus and should be continued if needed for asthma stability.

Question 24: A 47-year-old man is admitted with a massive pulmonary embolism. CT pulmonary angiogram shows bilateral proximal pulmonary emboli with evidence of right ventricular strain. He is haemodynamically stable with blood pressure 110/70 mmHg, heart rate 105/min, and oxygen saturation 91% on 4L/min oxygen via nasal cannulae. Echocardiogram confirms right ventricular dilatation and dysfunction. He has no contraindications to thrombolysis. What is the most appropriate management?

A. Commence therapeutic dose DOAC and monitor closely
B. Commence therapeutic dose unfractionated heparin infusion (Correct Answer)
C. Administer systemic thrombolysis with alteplase
D. Arrange urgent surgical embolectomy
E. Arrange catheter-directed thrombolysis

Explanation: ***Commence therapeutic dose unfractionated heparin infusion***- This patient has an **intermediate-high risk pulmonary embolism (PE)**, defined by right ventricular (RV) strain on CT/Echocardiogram but maintaining **haemodynamic stability**.- **Unfractionated heparin (UFH)** is preferred in high-risk scenarios because of its **short half-life** and rapid reversibility should the patient deteriorate and require invasive intervention or thrombolysis.*Commence therapeutic dose DOAC and monitor closely*- While **Direct Oral Anticoagulants (DOACs)** are standard for low-risk PE, they are generally avoided in the acute phase of **submassive PE** where haemodynamic collapse is a risk.- DOACs lack the **immediate reversibility** and titration flexibility provided by a heparin infusion in a monitored hospital setting.*Administer systemic thrombolysis with alteplase*- **Systemic thrombolysis** is specifically reserved for **high-risk (massive) PE**, characterized by **haemodynamic instability** (systolic BP <90 mmHg or obstructive shock).- In stable patients with RV dysfunction, the risk of **major hemorrhage** (including intracranial bleed) usually outweighs the benefit of rapid clot lysis.*Arrange urgent surgical embolectomy*- **Surgical embolectomy** is an invasive procedure indicated primarily when systemic thrombolysis is **contraindicated** or has failed in a clinically unstable patient.- It is not first-line therapy for a haemodynamically stable patient with **preserved blood pressure**.*Arrange catheter-directed thrombolysis*- **Catheter-directed thrombolysis** is an emerging therapy for intermediate-high risk PE but remains a second-line option dependent on local expertise.- Standard practice mandates starting **parenteral anticoagulation** first; specialized interventional techniques are considered only if clinical deterioration occurs despite medical therapy.

Question 25: A 58-year-old woman presents with a 3-month history of progressive breathlessness and dry cough. She has never smoked. Spirometry shows: FEV1 2.8L (92% predicted), FVC 3.1L (85% predicted), FEV1/FVC ratio 0.90. Chest radiograph shows bilateral interstitial shadowing. What pattern of lung disease do these spirometry results suggest?

A. Obstructive lung disease
B. Restrictive lung disease (Correct Answer)
C. Mixed obstructive and restrictive disease
D. Normal lung function
E. Small airways disease

Explanation: ***Restrictive lung disease***- The **FEV1/FVC ratio is 0.90 (90%)**, which is normal or elevated, indicating no airflow obstruction. Restrictive lung diseases are characterized by reduced lung volumes, but the FEV1/FVC ratio often remains preserved or high.- The clinical picture of **progressive breathlessness**, **dry cough**, and **bilateral interstitial shadowing** on chest radiograph are classic features of interstitial lung diseases, which cause a restrictive pattern.*Obstructive lung disease*- This pattern is characterized by a **decreased FEV1/FVC ratio** (typically below 0.70 or 70%) due to increased airway resistance during expiration. The patient's ratio of 0.90 clearly rules out an obstructive pattern.- Diseases like **COPD** and **asthma** fall into this category, often presenting with a history of smoking (not present here) or hyperreactivity.*Mixed obstructive and restrictive disease*- A mixed pattern would demonstrate both a **reduced FEV1/FVC ratio (obstruction)** and **reduced lung volumes (restriction)**, such as a significantly reduced FVC. This patient's FEV1/FVC ratio is elevated, ruling out a significant obstructive component.- Such patterns are typically seen in patients with co-existing conditions, which is not supported by the spirometry or clinical findings here.*Normal lung function*- While FEV1 (92%) and FVC (85%) are within or near the normal predicted range, the **elevated FEV1/FVC ratio** combined with the patient's **progressive symptoms** and **bilateral interstitial shadowing** on X-ray clearly indicate underlying lung pathology.- A patient with significant symptoms and radiographic findings cannot be classified as having normal lung function despite relatively preserved volumes.*Small airways disease*- Primarily affects the **smaller bronchioles**, leading to subtle airflow limitation that may manifest as a reduced **FEF 25-75%** (mid-expiratory flow rates) or a normal FEV1/FVC ratio initially.- This condition does not typically cause the prominent **bilateral interstitial shadowing** seen on chest radiograph, which points toward parenchymal involvement.

Question 26: A 72-year-old man with COPD presents with his fourth exacerbation in the past 12 months. He is currently on triple therapy with tiotropium, salmeterol/fluticasone combination inhaler, and uses salbutamol as needed. He is an ex-smoker who stopped 5 years ago. Sputum cultures during previous exacerbations have grown Haemophilus influenzae on three occasions. His FEV1 is 38% predicted. He continues to have a productive cough with purulent sputum between exacerbations. What additional long-term treatment should be considered?

A. Long-term oxygen therapy assessment
B. Prophylactic azithromycin three times per week (Correct Answer)
C. Continuous oral prednisolone 5mg daily
D. Prophylactic co-trimoxazole daily
E. Roflumilast 500 micrograms daily

Explanation: ***Prophylactic azithromycin three times per week*** - This patient, with **severe COPD** (FEV1 38%), **frequent exacerbations** (4 in 12 months), a **chronic bronchitis phenotype** (productive cough with purulent sputum), and recurrent **Haemophilus influenzae** infections, meets criteria for macrolide prophylaxis. - **Azithromycin** reduces exacerbation frequency through both its **antibacterial** and **anti-inflammatory** effects, making it an appropriate addition after optimizing triple therapy; however, clinicians must rule out **non-tuberculous mycobacteria** and check for **QT prolongation** prior to initiation. *Long-term oxygen therapy assessment* - **Long-term oxygen therapy (LTOT)** is indicated for patients with **chronic hypoxemia**, specifically if **PaO2** is consistently < 7.3 kPa or < 8.0 kPa with associated complications like **pulmonary hypertension**. - The clinical vignette does not provide any **arterial blood gas** results or evidence of chronic hypoxemia that would warrant an immediate assessment for LTOT. *Continuous oral prednisolone 5mg daily* - **Long-term systemic corticosteroids** are generally avoided in COPD management due to severe and cumulative side effects such as **osteoporosis**, **myopathy**, **diabetes**, and **adrenal suppression**. - While short courses may be used during exacerbations, continuous low-dose oral prednisolone is not a recommended strategy for routine exacerbation prevention in COPD. *Prophylactic co-trimoxazole daily* - **Co-trimoxazole** is not an evidence-based first-line agent for the prevention of COPD exacerbations in patients with recurrent bacterial infections. - Its primary prophylactic role is typically in preventing **Pneumocystis jirovecii pneumonia** in immunocompromised individuals. *Roflumilast 500 micrograms daily* - **Roflumilast**, a phosphodiesterase-4 inhibitor, is considered for patients with severe COPD (FEV1 < 50%), a **chronic bronchitis phenotype**, and frequent exacerbations. - While a valid consideration, the strong history of recurrent **Haemophilus influenzae** and persistent **purulent sputum** makes **prophylactic azithromycin** a more targeted and often preferred initial intervention to address the infectious component driving exacerbations.

Question 27: A 35-year-old woman who is 12 weeks pregnant presents with a 4-day history of cough productive of purulent sputum, fever, and left-sided chest pain. On examination, she is pyrexial at 38.2°C with a respiratory rate of 22/min and oxygen saturation of 94% on air. Chest examination reveals reduced breath sounds and dullness to percussion at the left lower zone. She has no past medical history and no known drug allergies. What is the most appropriate antibiotic choice?

A. Oral amoxicillin 500mg three times daily (Correct Answer)
B. Oral doxycycline 200mg loading dose then 100mg daily
C. Oral clarithromycin 500mg twice daily
D. Intravenous co-amoxiclav 1.2g three times daily
E. Oral levofloxacin 500mg once daily

Explanation: ***Oral amoxicillin 500mg three times daily*** - In a pregnant patient with **low-severity community-acquired pneumonia** (CURB-65 score of 0), oral **amoxicillin** is the first-line treatment choice. - It is recognized as **safe in pregnancy** and provides excellent targeted coverage against **Streptococcus pneumoniae**, the most common causative organism. *Oral doxycycline 200mg loading dose then 100mg daily* - **Doxycycline** is strictly **contraindicated in pregnancy** as it can cross the placenta and interfere with **fetal bone development**. - It is also associated with permanent **discoloration of the teeth** when administered during the second and third trimesters. *Oral clarithromycin 500mg twice daily* - This is an alternative for patients with a **penicillin allergy**, but it is generally avoided in the **first trimester** unless the benefit outweighs the risk. - As this patient has no known allergies, **amoxicillin** remains the safer and more appropriate first-line empirical option. *Intravenous co-amoxiclav 1.2g three times daily* - **Intravenous antibiotics** are reserved for patients with high-severity scores or those unable to tolerate oral intake, which does not apply to this stable patient. - **Co-amoxiclav** provides unnecessarily broad coverage for low-severity CAP and is not required for uncomplicated cases without specific risk factors. *Oral levofloxacin 500mg once daily* - **Fluoroquinolones** like levofloxacin are generally **contraindicated during pregnancy** due to concerns regarding **fetal cartilage toxicity**. - They are typically reserved for severe, multi-drug resistant cases and are never first-line therapy for simple community-acquired pneumonia.

Question 28: A 68-year-old man with COPD (FEV1 48% predicted) is admitted with an acute exacerbation. He is treated with nebulised bronchodilators, oral prednisolone 30mg daily, and oral doxycycline. On day 3 of admission, he develops worsening confusion and drowsiness. Arterial blood gas on 28% venturi mask shows: pH 7.26, PaCO2 9.2 kPa, PaO2 9.8 kPa, HCO3- 32 mmol/L, BE +4. What is the most appropriate immediate management?

A. Increase oxygen to 35% venturi mask and repeat blood gas in 1 hour
B. Commence bilevel positive airway pressure (BiPAP) ventilation (Correct Answer)
C. Commence continuous positive airway pressure (CPAP) ventilation
D. Administer intravenous doxapram and increase oxygen
E. Intubate and commence invasive mechanical ventilation

Explanation: ***Commence bilevel positive airway pressure (BiPAP) ventilation***- The patient exhibits **acute hypercapnic respiratory failure** (pH 7.26, PaCO2 9.2 kPa) and **impaired consciousness** (confusion, drowsiness), typical signs of severe CO2 retention in a COPD exacerbation.- **BiPAP (NIV)** is the first-line intervention for acute exacerbations of COPD with persistent respiratory acidosis (pH < 7.35) not responding to medical therapy, effectively reducing CO2 and work of breathing.*Increase oxygen to 35% venturi mask and repeat blood gas in 1 hour*- Increasing oxygen concentration in a patient with **type 2 respiratory failure** risks worsening **hypercapnia** due to suppression of **hypoxic drive** and increased V/Q mismatch.- The primary issue is **ventilatory failure** (high PaCO2 and acidosis), which oxygen alone cannot correct and may exacerbate given the patient's severe COPD.*Commence continuous positive airway pressure (CPAP) ventilation*- **CPAP** provides a single positive pressure, helping to maintain airway patency and improve oxygenation, but it does not actively assist with **CO2 removal** by providing inspiratory pressure support.- It is mainly used for conditions like **obstructive sleep apnea** or **cardiogenic pulmonary edema** (Type 1 respiratory failure), not for acute hypercapnic respiratory failure in COPD.*Administer intravenous doxapram and increase oxygen*- **Doxapram** is a respiratory stimulant that is largely outdated and not recommended as first-line therapy for **acute hypercapnic respiratory failure** in COPD due to limited efficacy and potential side effects.- Its use in conjunction with increasing oxygen would not address the severe ventilatory failure and carries risks without significant benefit compared to NIV.*Intubate and commence invasive mechanical ventilation*- **Invasive mechanical ventilation** is a last resort, typically reserved for patients who fail to improve with **NIV**, or those with absolute contraindications to NIV or impending respiratory arrest.- Given the current clinical picture, a trial of **NIV (BiPAP)** is the appropriate and less invasive immediate step before considering intubation.

Question 29: A 44-year-old man attends the respiratory clinic for consideration of biologic therapy for his severe asthma. Despite maximal inhaled therapy (high-dose ICS/LABA plus LAMA) and maintenance oral prednisolone 10mg daily, he continues to have frequent exacerbations requiring hospital admission. Blood tests show: total IgE 850 IU/mL (normal <120), eosinophils 0.8 × 10⁹/L. Skin prick testing is positive to house dust mite and grass pollen. Which biologic agent would be the most appropriate first-line choice for this patient?

A. Omalizumab (Correct Answer)
B. Mepolizumab
C. Benralizumab
D. Dupilumab
E. Reslizumab

Explanation: ***Omalizumab*** - This patient meets the criteria for **severe allergic asthma**, defined by a high **total IgE (850 IU/mL)** and positive **skin prick testing** for perennial allergens. - Omalizumab is a monoclonal antibody that binds to **free IgE**, preventing it from binding to the **FcεRI receptor** on mast cells and basophils. *Mepolizumab* - This is an **anti-IL-5** monoclonal antibody primarily targeted at **eosinophilic asthma** phenotypes. - Although the patient has a blood eosinophil count of **0.8 × 10⁹/L**, the prominent allergic markers and IgE level make omalizumab the classic first-line choice in NICE/GINA guidelines for this specific phenotype. *Benralizumab* - Benralizumab targets the **IL-5 receptor alpha**, leading to direct depletion of **eosinophils** via antibody-dependent cell-mediated cytotoxicity. - It is highly effective for reducing exacerbations in **eosinophilic asthma**, but is typically reserved if the allergic criteria for omalizumab are not the primary driver. *Dupilumab* - This agent blocks the **IL-4 receptor alpha**, inhibiting both **IL-4 and IL-13** signaling pathways involved in Type 2 inflammation. - While it is effective for **oral corticosteroid-dependent asthma**, it is often considered an alternative or second-line choice compared to anti-IgE therapy in a clearly allergic patient. *Reslizumab* - Like mepolizumab, this is an **anti-IL-5** therapy, but it is unique because it is administered via **intravenous infusion** based on body weight. - It requires a minimum blood eosinophil count (often **≥0.4 × 10⁹/L**) and is indicated for severe eosinophilic asthma rather than primary allergic asthma.

Question 30: A 50-year-old woman is admitted with community-acquired pneumonia. She scores 2 on CURB-65 assessment. Blood cultures are taken and she is started on empirical antibiotic therapy. After 48 hours, she remains pyrexial with ongoing tachypnoea and hypoxia. Repeat chest radiograph shows progression of consolidation with a small pleural effusion. Blood cultures are negative. What is the most appropriate next step in her management?

A. Continue current antibiotics and reassess in 24 hours
B. Add clarithromycin to cover atypical organisms
C. Perform pleural aspiration for microscopy, culture and biochemistry (Correct Answer)
D. Change to intravenous co-amoxiclav and clarithromycin
E. Arrange CT chest to assess for complications

Explanation: ***Perform pleural aspiration for microscopy, culture and biochemistry***- In a patient with **pneumonia** who fails to respond to treatment and develops a **pleural effusion**, it is essential to sample the fluid to rule out a **complicated parapneumonic effusion** or **empyema**.- Pleural fluid analysis (pH, glucose, LDH, and microscopy/culture) is the gold standard for determining if a **chest drain** is required to achieve clinical resolution.*Continue current antibiotics and reassess in 24 hours*- Continuing management without intervention is incorrect because the patient is showing signs of **clinical deterioration** (tachypnoea, hypoxia, and pyrexia) and **radiological progression**.- Delaying diagnostic aspiration in the presence of a new effusion increases the risk of undiagnosed **pleural infection** and subsequent lung entrapment.*Add clarithromycin to cover atypical organisms*- While atypical coverage is standard for moderate-to-severe **CAP (CURB-65 score ">="2)**, it does not address the likely mechanical source of treatment failure, which is the **parapneumonic effusion**.- Empirical changes to antibiotics should ideally follow fluid sampling, as the effusion may reveal a specific **causative organism** or the need for drainage.*Change to intravenous co-amoxiclav and clarithromycin*- Changing antibiotics is premature before investigating the **pleural effusion**, which acts as a potential **focus of infection** that antibiotics alone may not penetrate effectively.- Escalating therapy without gathering diagnostic fluid data may mask the underlying problem and ignore the need for **intercostal drainage**.*Arrange CT chest to assess for complications*- While **CT chest** is useful for assessing complex lung pathology, it is not the first-line investigation for a simple-appearing effusion on a **chest radiograph**.- **Pleural aspiration** is a more rapid, cost-effective, and definitive diagnostic step to determine if the fluid is **exudative** or **infected**.

Question 31: According to BTS/SIGN guidelines for asthma management, what is the recommended starting dose of inhaled corticosteroid (beclometasone dipropionate equivalent) for an adult newly diagnosed with asthma requiring regular preventer therapy?

A. 200 micrograms twice daily
B. 400 micrograms twice daily (Correct Answer)
C. 100 micrograms twice daily
D. 800 micrograms twice daily
E. 1000 micrograms twice daily

Explanation: ***400 micrograms twice daily*** - According to **BTS/SIGN guidelines**, the recommended starting dose of inhaled corticosteroid (beclometasone dipropionate equivalent) for an adult newly diagnosed with asthma requiring regular preventer therapy is **400 micrograms per day**. - This total daily dose is typically administered as **200 micrograms twice daily** and is categorized as a **low-dose ICS** (Step 2 in the management pathway). *200 micrograms twice daily* - While 200 micrograms is the amount taken per inhalation, this option specifies only one half of the **total daily dose** recommended for initiating therapy. - The guidelines specify the total daily dose for therapeutic efficacy, not just the single administration amount. *100 micrograms twice daily* - This dose equates to a total of **200 micrograms per day**, which is considered a **very low dose** of ICS for adults. - It is generally not the standard starting dose for adults according to the **BTS/SIGN asthma guidelines**, which recommend 400 micrograms/day at Step 2. *800 micrograms twice daily* - This would result in a total daily dose of **1600 micrograms**, which is classified as a **high dose** of ICS. - High doses are reserved for patients with severe, uncontrolled asthma at **Step 4** or higher, not for initial preventer therapy. *1000 micrograms twice daily* - This equates to a total daily dose of **2000 micrograms**, an exceptionally high dose of inhaled corticosteroids. - Such doses are typically used only in cases of **severe, refractory asthma** under specialist guidance due to increased risk of **systemic side effects**.

Question 32: A 56-year-old woman undergoes a CT pulmonary angiogram for suspected pulmonary embolism following an episode of pleuritic chest pain and breathlessness. The scan confirms a segmental PE in the right lower lobe. She has no past medical history and takes no regular medications. Her observations are: heart rate 88/min, blood pressure 128/76 mmHg, respiratory rate 18/min, oxygen saturation 96% on air. Troponin is normal and echocardiogram shows normal right ventricular function. What is the most appropriate initial anticoagulation strategy?

A. Commence warfarin with low molecular weight heparin bridging for minimum 3 months
B. Commence a direct oral anticoagulant (DOAC) for minimum 3 months (Correct Answer)
C. Commence unfractionated heparin infusion followed by warfarin for 6 months
D. Commence low molecular weight heparin for 6 months
E. Commence aspirin 300mg daily for 3 months

Explanation: ***Commence a direct oral anticoagulant (DOAC) for minimum 3 months***- **DOACs** (such as apixaban or rivaroxaban) are now recommended as **first-line therapy** for the management of venous thromboembolism (VTE) in patients without contraindications like severe renal failure or pregnancy.- This patient is **hemodynamically stable** with no evidence of **right ventricular (RV) strain** or myocardial injury (normal troponin), making her suitable for outpatient or standard inpatient DOAC therapy for at least **3 months**.*Commence warfarin with low molecular weight heparin bridging for minimum 3 months*- **Warfarin** is no longer considered first-line for most patients due to the requirement for **LMWH bridging** and frequent **INR monitoring**.- It is generally reserved for patients where DOACs are contraindicated, such as those with **antiphospholipid syndrome** or mechanical heart valves.*Commence unfractionated heparin infusion followed by warfarin for 6 months*- **Unfractionated heparin (UFH)** infusions are primarily indicated for patients with **massive PE** (hemodynamic instability) or high risk of bleeding where rapid reversal is needed.- A **6-month duration** is not the standard minimum; guidelines recommend a review at **3 months** to determine if long-term anticoagulation is necessary.*Commence low molecular weight heparin for 6 months*- **LMWH monotherapy** was historically the standard for **cancer-associated thrombosis**, but even in those cases, DOACs are now often preferred.- Routine use of LMWH for 6 months in a patient with no comorbidities is inappropriate given the availability of oral options with **superior patient convenience**.*Commence aspirin 300mg daily for 3 months*- **Aspirin** is insufficient for the acute treatment of a confirmed **pulmonary embolism** as it does not provide adequate anticoagulation to prevent clot propagation or recurrence.- Use of antiplatelets instead of anticoagulants in the acute phase of PE is associated with a high risk of **treatment failure** and mortality.

Question 33: A 70-year-old man presents with a 5-day history of productive cough with green sputum, fever, and left-sided pleuritic chest pain. He has type 2 diabetes and atrial fibrillation. On examination, temperature is 38.5°C, respiratory rate 24/min, heart rate 95/min (irregularly irregular), blood pressure 130/80 mmHg, oxygen saturation 93% on air. Chest examination reveals dullness to percussion and bronchial breathing at the left base. Blood tests show: WCC 16.5 × 10⁹/L, CRP 185 mg/L, urea 8.2 mmol/L. What is his CURB-65 score?

A. 1
B. 2
C. 3 (Correct Answer)
D. 4
E. 5

Explanation: ***2*** - The patient scores 1 point for **Age ≥65** (he is 70 years old) and 1 point for **Urea >7 mmol/L** (his urea is 8.2 mmol/L). - He does not receive points for **Confusion** (not mentioned), **Respiratory rate ≥30/min** (his is 24/min), or **Blood pressure** (systolic <90 or diastolic ≤60 mmHg). *1* - This score would be incorrect as it fails to account for both the patient's **advanced age (70)** and the **elevated urea (8.2 mmol/L)**. - A score of 1 indicates low risk, whereas this patient has at least two major **risk factors** according to the CURB-65 criteria. *3* - A score of 3 would require an additional clinical marker such as **new-onset confusion**, a respiratory rate of **30/min or higher**, or hypotension. - While the patient has high inflammatory markers (**CRP 185**), these are not part of the standardized **CURB-65 severity assessment**. *4* - This score implies severe pneumonia with four criteria met, but this patient's **hemodynamics** (BP 130/80) and **breathing rate** (24/min) are within the non-scoring range. - Scoring a 4 requires significant physiological derangement not present in this clinical scenario. *5* - A score of 5 represents the maximum severity score, requiring the presence of **all five criteria** including hypotension and confusion. - This patient is **hemodynamically stable** and does not meet the criteria for a high-dependency or intensive care admission based strictly on this score.

Question 34: A 22-year-old woman with known asthma presents to the Emergency Department with acute breathlessness. She is speaking in single words, has a respiratory rate of 30/min, heart rate 125/min, and oxygen saturation 90% on air. Peak expiratory flow is 35% of her predicted value. She is unable to complete spirometry. Chest examination reveals widespread wheeze with reduced air entry bilaterally. What is the most appropriate immediate management?

A. Nebulised salbutamol 5mg and ipratropium 500 micrograms, oxygen via face mask, oral prednisolone 40mg
B. Nebulised salbutamol 5mg, oxygen via nasal cannulae at 2L/min, arrange chest radiograph
C. Intravenous magnesium sulphate 2g, oxygen via non-rebreathe mask, call intensive care
D. Nebulised salbutamol 5mg and ipratropium 500 micrograms, oxygen via non-rebreathe mask, hydrocortisone 100mg IV (Correct Answer)
E. Nebulised adrenaline, oxygen via non-rebreathe mask, prepare for intubation

Explanation: ***Nebulised salbutamol 5mg and ipratropium 500 micrograms, oxygen via non-rebreathe mask, hydrocortisone 100mg IV*** - The patient's presentation with **SpO2 90%**, speaking in **single words**, and **PEFR 35% predicted** indicates a **life-threatening asthma** attack, requiring aggressive immediate management. - This regimen provides crucial **high-flow oxygen**, dual **nebulised bronchodilators** (salbutamol and ipratropium), and prompt **intravenous corticosteroids** (hydrocortisone) suitable for a patient too breathless for oral intake. *Nebulised salbutamol 5mg and ipratropium 500 micrograms, oxygen via face mask, oral prednisolone 40mg* - While correct medications are included, **oral prednisolone** is less appropriate than IV hydrocortisone when the patient is speaking in **single words** and at high risk of deterioration or difficulty swallowing. - A standard **face mask** may not deliver the necessary **high-concentration oxygen** required for initial stabilization in life-threatening asthma compared to a non-rebreathe mask. *Nebulised salbutamol 5mg, oxygen via nasal cannulae at 2L/min, arrange chest radiograph* - **Nasal cannulae at 2L/min** are inadequate for a patient with **hypoxia (90%)** and significant respiratory distress; high-concentration oxygen delivery is essential. - This option crucially omits **ipratropium bromide** and **systemic corticosteroids**, both cornerstone therapies for severe and life-threatening asthma exacerbations. *Intravenous magnesium sulphate 2g, oxygen via non-rebreathe mask, call intensive care* - **IV magnesium sulphate** is typically a **second-line treatment** for severe asthma, used when there's an inadequate response to initial bronchodilator and corticosteroid therapy. - This option misses the critical immediate administration of **nebulised bronchodilators** (salbutamol and ipratropium) and **systemic corticosteroids**, which are first-line. *Nebulised adrenaline, oxygen via non-rebreathe mask, prepare for intubation* - **Nebulised adrenaline** is indicated for **upper airway obstruction** or croup, not as a primary treatment for **bronchial asthma** exacerbations. - While intubation may become necessary, initial efforts must focus on aggressive **pharmacological management** with bronchodilators and steroids to prevent respiratory failure before resorting to intubation.

Question 35: A 65-year-old woman with COPD (FEV1 52% predicted, FEV1/FVC 0.65) presents with increasing breathlessness over the past year. She has had three exacerbations requiring oral antibiotics and corticosteroids in the last 12 months. She is a current smoker with a 40 pack-year history. Her current medication includes tiotropium once daily and salbutamol as needed. What is the most appropriate addition to her treatment regimen?

A. Add a long-acting beta-2 agonist only
B. Add an inhaled corticosteroid only
C. Add a combination inhaled corticosteroid and long-acting beta-2 agonist (Correct Answer)
D. Add oral theophylline
E. Add prophylactic azithromycin

Explanation: ***Add a combination inhaled corticosteroid and long-acting beta-2 agonist*** - This patient, with **three exacerbations** in the last year while on a **LAMA (tiotropium)** and an FEV1 of 52%, falls into the **GOLD Group E** (high risk for exacerbations). - Escalating to **triple therapy (LAMA + LABA + ICS)** is the recommended strategy for such patients to significantly reduce the frequency of moderate-to-severe exacerbations and improve lung function. *Add a long-acting beta-2 agonist only* - While adding a **LABA** to a **LAMA** (dual bronchodilation) is a step up and can improve breathlessness, it may not be sufficient for a patient with such frequent exacerbations (three in a year). - The absence of an **inhaled corticosteroid (ICS)** in this scenario means the inflammatory component of her severe COPD and exacerbation risk is not adequately addressed. *Add an inhaled corticosteroid only* - **Inhaled corticosteroid (ICS) monotherapy** is explicitly not recommended for COPD due to an increased risk of **pneumonia** and a lack of proven efficacy in reducing exacerbations without a bronchodilator. - ICS should always be combined with at least one long-acting bronchodilator (**LABA**) in COPD management when indicated. *Add oral theophylline* - **Theophylline** has a narrow **therapeutic index**, requiring careful monitoring of blood levels, and carries a higher risk of adverse effects compared to inhaled therapies. - It is generally considered a second-line agent or an add-on therapy, typically used after optimizing inhaled bronchodilator and corticosteroid regimens. *Add prophylactic azithromycin* - **Prophylactic macrolides** like azithromycin are typically reserved for patients who continue to experience frequent exacerbations despite optimal **triple inhaled therapy** and adherence to other non-pharmacological interventions like smoking cessation. - Initiating this therapy before optimizing inhaled regimens is premature and may lead to antibiotic resistance without addressing primary airway management.

Question 36: A 38-year-old man with asthma presents for review. He uses a beclometasone 200 micrograms twice daily inhaler and salbutamol as needed. He reports waking once per week due to asthma symptoms and uses his salbutamol inhaler 3-4 times per week. Peak flow is 85% of predicted. What is the most appropriate next step in his management according to BTS/SIGN guidelines?

A. Add a leukotriene receptor antagonist
B. Add a long-acting beta-2 agonist (Correct Answer)
C. Increase beclometasone to 400 micrograms twice daily
D. Add theophylline
E. Add oral prednisolone

Explanation: ***Add a long-acting beta-2 agonist*** - According to **BTS/SIGN guidelines**, for patients uncontrolled on low-dose **inhaled corticosteroids (ICS)**, the preferred **Step 3** intervention is the addition of a **long-acting beta-2 agonist (LABA)**. - This patient demonstrates poor control with **nocturnal symptoms** and frequent **SABA** use, making the addition of a LABA the most appropriate next step for improved symptom control. *Add a leukotriene receptor antagonist* - A **leukotriene receptor antagonist (LTRA)** is typically considered at **Step 3** as an alternative to a LABA, or if there is an inadequate response to a LABA, or if LABAs are not tolerated. - While it is a valid add-on therapy, the **first-line** recommendation for initial escalation from low-dose ICS in this scenario is generally a LABA. *Increase beclometasone to 400 micrograms twice daily* - Increasing the **ICS dose** to medium-dose is generally reserved for when a patient has an inadequate response to the combination of **low-dose ICS and LABA** (i.e., Step 4). - Guidelines prioritize adding a **LABA** first at Step 3 as it often provides superior symptom control and reduces the need for higher doses of ICS, thus minimizing potential **ICS-related side effects**. *Add theophylline* - **Theophylline** is a fourth-line or specialized agent used when asthma remains poorly controlled despite **ICS**, **LABA**, and often **LTRA** therapy. - It requires **therapeutic drug monitoring** due to a narrow therapeutic window and has a significant side-effect profile, making it inappropriate at this relatively early stage of management. *Add oral prednisolone* - **Oral prednisolone** is typically reserved for **Step 5** management of chronic severe asthma or for the management of **acute exacerbations**. - Using oral steroids at this stage would be premature, as the patient has not yet exhausted standard **inhaled maintenance therapies** such as a LABA add-on.

Question 37: A 68-year-old man is admitted with community-acquired pneumonia and treated with co-amoxiclav and clarithromycin. His CURB-65 score is 2. Blood cultures taken on admission grow Streptococcus pneumoniae sensitive to penicillin. On day 3 of treatment, he remains febrile (38.1°C) with ongoing breathlessness. Repeat chest X-ray shows progression of consolidation in the right lower lobe with a small parapneumonic effusion. CRP is 185 mg/L (was 220 mg/L on admission). What is the most appropriate management?

A. Continue current antibiotics for a further 48 hours and reassess (Correct Answer)
B. Perform diagnostic pleural aspiration
C. Add metronidazole to cover anaerobic infection
D. Change antibiotics to meropenem and vancomycin
E. Arrange CT chest with contrast to assess for empyema

Explanation: ***Continue current antibiotics for a further 48 hours and reassess*** - This patient has a confirmed diagnosis of **Streptococcus pneumoniae** sensitive to penicillin, making the current **co-amoxiclav** regimen appropriate. - Despite ongoing symptoms, the **CRP is decreasing** (220 to 185 mg/L), which indicates a **slow but positive response** to treatment, and clinical improvement often lags behind biochemical markers. *Perform diagnostic pleural aspiration* - While a **small parapneumonic effusion** is noted, aspiration is generally reserved for **larger effusions** (e.g., >10mm on lateral decubitus film) or if there is clear clinical deterioration. - Given the improving CRP, there's no immediate indication for an invasive procedure, as it might resolve with continued appropriate antibiotic therapy. *Add metronidazole to cover anaerobic infection* - The blood culture has specifically grown **Streptococcus pneumoniae**, an aerobic organism, and there is no clinical evidence to suggest an **anaerobic infection**. - **Metronidazole** is typically added for suspected **aspiration pneumonia** or lung abscess, which are not suggested by the current findings. *Change antibiotics to meropenem and vancomycin* - Escalating to **broad-spectrum antibiotics** like **meropenem** and **vancomycin** is inappropriate when a **specific pathogen** with known antibiotic sensitivities has been identified. - This approach promotes **antibiotic resistance** and is only indicated in cases of severe treatment failure or suspicion of highly resistant organisms. *Arrange CT chest with contrast to assess for empyema* - A **CT chest** is usually considered if there is a **lack of clinical improvement** after several days (e.g., 5-7 days) of appropriate antibiotic therapy, or if complications are strongly suspected. - The patient's **CRP is trending downwards**, and radiological progression on an X-ray can lag behind clinical recovery, so a CT is not immediately warranted after only 3 days.

Question 38: A 52-year-old woman presents with sudden onset left-sided pleuritic chest pain and breathlessness. She underwent a total hip replacement 10 days ago. On examination, heart rate 98/min, blood pressure 136/84 mmHg, respiratory rate 20/min, SpO2 96% on room air. There is tenderness and swelling of the left calf. ECG shows sinus rhythm with T wave inversion in leads V1-V3. Wells score is calculated as 7 points. D-dimer is requested. What is the most appropriate next investigation?

A. Await D-dimer result before further imaging
B. Ventilation-perfusion (V/Q) scan
C. CT pulmonary angiogram (Correct Answer)
D. Lower limb Doppler ultrasound
E. Echocardiography

Explanation: ***CT pulmonary angiogram*** - For patients with a **Wells score >4** (PE likely), the gold standard and most appropriate next step is a **CT pulmonary angiogram (CTPA)**. - Clinical features such as **recent major surgery**, pleuritic pain, and **calf tenderness** indicate a high pre-test probability where imaging is required regardless of blood tests. *Await D-dimer result before further imaging* - **D-dimer** has a high negative predictive value but lacks specificity; it should only be used to rule out PE in patients with a **low Wells score (≤4)**. - In high-probability cases, a negative D-dimer is insufficient to exclude a PE, making the test **unnecessary and delaying definitive diagnosis**. *Ventilation-perfusion (V/Q) scan* - **V/Q scanning** is generally reserved as a second-line imaging modality when **CTPA is contraindicated**, such as in patients with severe **renal impairment** or contrast allergy. - While useful, it is less readily available in an emergency setting compared to CTPA and often results in **indeterminate findings**. *Lower limb Doppler ultrasound* - While this test can confirm a **Deep Vein Thrombosis (DVT)**, a negative result does not rule out a **Pulmonary Embolism** that has already embolized from the leg. - Since the patient is presenting with acute **respiratory symptoms**, the primary focus must be direct visualization of the pulmonary vasculature via **CTPA**. *Echocardiography* - **Echocardiography** is primarily used to assess **right ventricular strain** in hemodynamically unstable patients to determine the severity of a PE. - It is not a definitive diagnostic tool for a stable patient with a **Wells score of 7**, where vascular imaging is more sensitive.

Question 39: A 61-year-old man with newly diagnosed COPD attends the respiratory clinic. He has moderate airflow obstruction (FEV1 58% predicted) with significant breathlessness (MRC dyspnoea grade 3). He has no history of exacerbations. In addition to smoking cessation advice and initiating bronchodilator therapy, what other intervention has been shown to provide the greatest mortality benefit in COPD?

A. Pulmonary rehabilitation
B. Annual influenza vaccination (Correct Answer)
C. Inhaled corticosteroids
D. Long-term oxygen therapy
E. Prophylactic azithromycin

Explanation: ***Annual influenza vaccination*** - In COPD patients, **influenza vaccination** has been shown to significantly reduce the risk of exacerbations, hospitalizations, and **all-cause mortality**. - It is a highly cost-effective intervention and is recommended for all COPD patients regardless of their **FEV1** or symptomatic status. *Pulmonary rehabilitation* - While it dramatically improves **exercise capacity**, symptoms, and **quality of life**, it has not been definitively proven to reduce long-term mortality. - It is primarily indicated for patients with a **breathlessness grade of MRC 3** or above to improve functional status. *Inhaled corticosteroids* - These agents are effective at reducing the **frequency of exacerbations** in patients with severe airflow obstruction or frequent flares but do not improve **survival rates**. - Chronic use is associated with an increased risk of **pneumonia** and should be used judiciously in COPD. *Long-term oxygen therapy* - **Long-term oxygen therapy (LTOT)** only provides a survival benefit in patients with **chronic severe hypoxaemia** (PaO2 <7.3 kPa), which is not indicated by this patient's FEV1 alone. - For patients who do not meet specific **hypoxaemic criteria**, LTOT does not offer a mortality benefit and can be cumbersome. *Prophylactic azithromycin* - This intervention is used to reduce the **frequency of exacerbations** in select patients who continue to flare despite optimal inhaler therapy. - There is no evidence that prophylactic antibiotics provide a **mortality benefit**, and they carry risks of **antibiotic resistance** and hearing loss.

Question 40: A 29-year-old woman presents to the Emergency Department with worsening breathlessness over 1 hour. She has a history of asthma usually well controlled. On examination, she is able to speak in short phrases only. Observations: heart rate 132/min, respiratory rate 30/min, SpO2 90% on high-flow oxygen. Peak flow is 120 L/min (predicted 460 L/min, 26% of predicted). She is treated with back-to-back nebulised salbutamol and ipratropium, IV hydrocortisone, and IV magnesium sulphate 2g. After 1 hour, she remains distressed with minimal improvement. SpO2 is 91% on 15L oxygen, heart rate 128/min, respiratory rate 32/min. What is the most appropriate next step?

A. Repeat IV magnesium sulphate 2g
B. Contact ICU for consideration of intubation and ventilation (Correct Answer)
C. Arrange immediate non-invasive ventilation
D. Commence IV aminophylline infusion
E. Commence IV salbutamol infusion

Explanation: ***Contact ICU for consideration of intubation and ventilation*** - The patient presents with **life-threatening asthma** (PEF <33% predicted, SpO2 90% on high-flow oxygen, inability to speak in full sentences, severe tachycardia, tachypnoea) and has failed to respond to **maximal medical therapy**, including repeated nebulized bronchodilators, systemic corticosteroids, and IV magnesium sulphate. - Persistent distress, minimal improvement, and signs of **impending respiratory failure** (worsening hypoxia despite oxygen, severe tachypnoea, tachycardia) necessitate urgent **airway management** and **mechanical ventilation** requiring **ICU involvement**. *Repeat IV magnesium sulphate 2g* - **Magnesium sulphate** is typically administered as a **single dose** (2g) in acute severe asthma; rapidly repeating the dose is not standard protocol due to the risk of **toxicity** (e.g., hypotension, respiratory depression, hypermagnesemia). - Since the patient remains critically ill with minimal improvement, escalating to **critical care** for definitive airway management is prioritized over repeating an intervention that has already failed to achieve adequate response. *Arrange immediate non-invasive ventilation* - **Non-invasive ventilation (NIV)** is generally **contraindicated** in severe acute asthma as it can worsen air trapping, increase the risk of **pneumothorax**, and delay necessary **endotracheal intubation**. - Guidelines emphasize that patients failing maximal medical therapy in life-threatening asthma require **intubation** and controlled mechanical ventilation rather than NIV, which does not adequately address the dynamic hyperinflation and work of breathing. *Commence IV aminophylline infusion* - **IV aminophylline** (a methylxanthine) is considered a **third-line agent** for severe asthma due to its limited additional bronchodilation and a narrow **therapeutic index** with significant potential side effects like arrhythmias and seizures. - In a patient failing maximal initial therapy with signs of **impending respiratory failure**, starting a slow-acting drug with questionable benefit and potential toxicity is less appropriate than securing the airway and providing **mechanical ventilation**. *Commence IV salbutamol infusion* - **IV salbutamol infusion** can be considered in **refractory severe asthma** but should only be initiated under strict monitoring in a **critical care setting** due to significant side effects, particularly **tachycardia** and arrhythmias. - The patient already has **severe tachycardia** (HR 128-132/min); further systemic beta-agonists would likely worsen cardiac strain without addressing the immediate need for **ventilatory support** for impending respiratory failure.

Question 41: A 76-year-old man is admitted with an exacerbation of COPD. He has severe airflow obstruction (FEV1 32% predicted) and is on home oxygen 2 L/min for 16 hours daily. He is a lifelong smoker, currently smoking 10 cigarettes daily. On admission, he is treated with nebulised bronchodilators, prednisolone 30mg daily, and doxycycline. Arterial blood gas on admission (on 28% Venturi mask) shows: pH 7.35, PaCO2 7.1 kPa, PaO2 8.2 kPa, HCO3- 30 mmol/L. After 24 hours of treatment, repeat blood gas shows: pH 7.36, PaCO2 6.8 kPa, PaO2 8.5 kPa. What should be the target oxygen saturation for this patient?

A. SpO2 85-88%
B. SpO2 94-98%
C. SpO2 92-96%
D. SpO2 88-92% (Correct Answer)
E. PaO2 >10 kPa regardless of saturation

Explanation: ***SpO2 88-92%*** - This patient has **chronic hypercapnia** (Type 2 respiratory failure) as evidenced by an elevated **PaCO2 (7.1 kPa)** and a high **bicarbonate (30 mmol/L)**, which indicates metabolic compensation.- According to **BTS guidelines**, patients with COPD at risk of hypercapnic respiratory failure—including those on **Long-Term Oxygen Therapy (LTOT)** or with an **FEV1 < 50%**—must have a target saturation of **88-92%** to avoid worsening CO2 retention.*SpO2 85-88%* - This range is generally too low and is only occasionally used as a temporary target for patients with **severe hypercapnic respiratory failure** who are not responding to standard management.- Using this target in this patient would risk severe **hypoxemia** and inadequate tissue oxygenation without clear clinical benefit.*SpO2 94-98%* - This is the standard target range for **acutely ill patients** who are not at risk of hypercapnic (Type 2) respiratory failure.- Administering high-concentration oxygen to this patient could diminish the **hypoxic drive**, worsen **V/Q mismatch**, and lead to life-threatening **respiratory acidosis**.*SpO2 92-96%* - This range is sometimes used for patients with **COPD** who have a documented history of being **normocapnic** during acute exacerbations.- Since this patient has clear evidence of **chronic CO2 retention** (high bicarbonate), this target is too high and potentially dangerous.*PaO2 >10 kPa regardless of saturation* - Aiming for a **PaO2 >10 kPa** in a chronic CO2 retainer often requires high-inspired oxygen fractions that significantly increase the risk of **hypercapnia**.- Oxygen therapy should be guided by **peripheral saturations (SpO2)** and blood gases to maintain a balance, rather than pursuing a specific high PaO2 value.

Question 42: A 31-year-old woman presents with a 6-month history of variable wheeze and breathlessness. She works as a hairdresser. Symptoms are worse at work and improve on weekends and holidays. Serial peak flow measurements over 4 weeks show greater than 20% variability between readings at work and at home. What is the most appropriate next step in management?

A. Start regular inhaled corticosteroid and long-acting beta-2 agonist
B. Refer to occupational health for workplace exposure assessment (Correct Answer)
C. Commence oral antihistamines
D. Arrange skin prick testing for common allergens
E. Prescribe salbutamol inhaler as required and review in 3 months

Explanation: ***Refer to occupational health for workplace exposure assessment***- The patient presents with classic features of **occupational asthma**, including a clear temporal relationship between symptoms (wheeze, breathlessness) and the workplace, improvement on weekends/holidays, and significant (>20%) **peak flow variability** between work and home. - Referral to occupational health is the most appropriate next step to identify the specific **sensitizing agent** in her hairdressing environment (e.g., persulphate salts, glutaraldehyde) and facilitate workplace modifications to prevent further exposure and potential irreversible **airway remodeling**.*Start regular inhaled corticosteroid and long-acting beta-2 agonist*- While these medications are standard for chronic asthma management, the priority in suspected **occupational asthma** is **antigen avoidance**, which requires identification of the trigger.- Initiating symptomatic treatment without addressing the underlying cause could mask the problem, delay definitive diagnosis, and potentially lead to a worse long-term outcome.*Commence oral antihistamines*- Antihistamines are primarily effective for symptoms of **allergic rhinitis** or cutaneous allergic reactions.- They do not address the **bronchoconstriction** or underlying airway inflammation characteristic of asthma.*Arrange skin prick testing for common allergens*- While useful for identifying common environmental allergens, this patient's history strongly points to an **occupational trigger**.- Skin prick testing for common allergens might not identify the specific chemicals or agents she is exposed to as a hairdresser, which are more likely to be the cause.*Prescribe salbutamol inhaler as required and review in 3 months*- A **short-acting beta-2 agonist (SABA)** like salbutamol provides only symptomatic relief for acute bronchoconstriction and does not control the **chronic inflammation** of asthma.- Delaying a comprehensive assessment and management plan by 3 months risks ongoing exposure, worsening lung function, and potentially permanent respiratory damage.

Question 43: A 54-year-old woman is admitted with community-acquired pneumonia. She is treated with co-amoxiclav and clarithromycin. On day 4, she develops worsening breathlessness. Chest X-ray shows a new moderate right-sided pleural effusion. Diagnostic pleural aspiration is performed. Analysis shows: pH 6.95, glucose 1.2 mmol/L, LDH 1850 IU/L, protein 42 g/L. Gram stain shows Gram-positive cocci in chains. What is the most appropriate management?

A. Continue antibiotics and repeat chest X-ray in 48 hours
B. Insert a chest drain and continue antibiotics (Correct Answer)
C. Arrange thoracoscopy and decortication
D. Add metronidazole to current antibiotic regimen
E. Change antibiotics to meropenem and vancomycin

Explanation: ***Insert a chest drain and continue antibiotics*** - This patient has a **complicated parapneumonic effusion** or **empyema**, indicated by a **pleural fluid pH <7.2** (6.95), low glucose, and high LDH. - According to **BTS guidelines**, a chest drain is mandatory if the pleural fluid is purulent, has a **positive Gram stain/culture**, or a **pH <7.2** to prevent loculation and clinical deterioration. *Continue antibiotics and repeat chest X-ray in 48 hours* - Antibiotics alone are insufficient because infected pleural fluid does not resolve without **source control** via drainage once the pH drops below 7.2. - Delaying drainage increases the risk of **pleural thickening**, loculation, and the eventual need for invasive surgery. *Arrange thoracoscopy and decortication* - Surgical intervention like **VATS** or decortication is typically reserved for cases where **chest drain drainage fails** or the effusion is heavily multiloculated. - It is not the first-line management; a trial of **intercostal tube drainage** should be initiated first. *Add metronidazole to current antibiotic regimen* - While metronidazole provides **anaerobic coverage**, the Gram stain specifically showed **Gram-positive cocci in chains**, strongly suggesting **Streptococcus species**. - Adding metronidazole does not address the primary issue, which is the requirement for **mechanical drainage** of the acidic fluid. *Change antibiotics to meropenem and vancomycin* - Broadening to **carbapenems** or vancomycin is not indicated as the current regimen (Co-amoxiclav) covers the likely pathogen identified on **Gram stain**. - Changing antibiotics is secondary to the urgent need for **tube thoracostomy** to drain the infected collection.

Question 44: A 67-year-old man with COPD (FEV1 38% predicted) is admitted with an infective exacerbation. He is treated with nebulised bronchodilators, prednisolone 30mg daily, and doxycycline. On day 3, he develops increasing drowsiness. Arterial blood gas on 28% oxygen shows: pH 7.28, PaCO2 8.2 kPa, PaO2 7.8 kPa, HCO3- 32 mmol/L, BE +6. What is the most appropriate immediate management?

A. Increase oxygen to maintain SpO2 94-98%
B. Start non-invasive ventilation (Correct Answer)
C. Commence doxapram infusion
D. Arrange urgent intubation and mechanical ventilation
E. Reduce oxygen to maintain SpO2 88-92% and repeat blood gas in 30 minutes

Explanation: ***Start non-invasive ventilation***- This patient is in **acute hypercapnic respiratory failure** (pH 7.28, PaCO2 8.2 kPa) secondary to a COPD exacerbation, complicated by increasing **drowsiness**, which is a sign of worsening CO2 narcosis and indicates the need for ventilatory support.- **Non-invasive ventilation (NIV)** is the first-line treatment for acute hypercapnic respiratory failure in COPD, shown to improve gas exchange, reduce work of breathing, and decrease the need for invasive mechanical ventilation and mortality.*Increase oxygen to maintain SpO2 94-98%*- Providing high-concentration oxygen to a patient with **COPD and hypercapnia** can abolish the **hypoxic drive** and worsen **V/Q mismatch**, leading to further retention of CO2 and exacerbation of acidosis.- The target oxygen saturation for most COPD patients at risk of hypercapnia is **88-92%**, not 94-98%, to minimize the risk of worsening hypercapnia.*Commence doxapram infusion*- **Doxapram** is a respiratory stimulant that has largely been superseded by **NIV** due to its less effective respiratory support and potential for side effects.- It does not provide the direct mechanical ventilatory assistance required to overcome severe **hypercapnic respiratory failure** and improve gas exchange as effectively as NIV.*Arrange urgent intubation and mechanical ventilation*- **Intubation and mechanical ventilation** are typically reserved for patients who fail a trial of NIV, have contraindications to NIV (e.g., inability to protect airway, severe encephalopathy, cardiorespiratory arrest), or present with life-threatening acidosis (often pH < 7.25 and rapidly deteriorating).- Given the patient's current pH and clinical status, a trial of **NIV** is the more appropriate initial step before resorting to invasive ventilation.*Reduce oxygen to maintain SpO2 88-92% and repeat blood gas in 30 minutes*- While titrating oxygen to maintain an SpO2 of **88-92%** is correct for COPD patients, simply reducing oxygen alone is insufficient to manage severe **acute hypercapnic respiratory failure** with associated acidosis and drowsiness.- This approach delays crucial ventilatory support (NIV) that is immediately needed to correct the acidosis and prevent further clinical deterioration and potential respiratory arrest.

Question 45: A 42-year-old man with known severe asthma is reviewed in the respiratory clinic. Despite treatment with high-dose ICS/LABA (fluticasone 500 micrograms/salmeterol 50 micrograms twice daily), montelukast 10mg daily, and a maintenance and reliever therapy regimen, he continues to have frequent exacerbations requiring oral corticosteroids every 2-3 months. Blood tests show peripheral eosinophil count 520 cells/μL. FeNO is 68 ppb. What is the most appropriate next step in management?

A. Add oral theophylline
B. Refer for consideration of biologic therapy (Correct Answer)
C. Increase ICS dose to fluticasone 1000 micrograms twice daily
D. Add tiotropium bromide
E. Commence long-term low-dose oral prednisolone

Explanation: ***Refer for consideration of biologic therapy*** - This patient has **severe uncontrolled asthma** despite high-dose ICS/LABA, montelukast, and MART, with clear evidence of **Type 2 inflammation** shown by a **peripheral eosinophil count of 520 cells/μL** and **FeNO of 68 ppb**. - Referral for specialist assessment for **biologic therapies** (e.g., mepolizumab, benralizumab, dupilumab) is the most appropriate next step to target this inflammation, reduce exacerbation frequency, and minimize oral corticosteroid use. *Add oral theophylline* - **Theophylline** is a weak bronchodilator with a narrow therapeutic index and significant potential for side effects, making it a less preferred option for severe uncontrolled asthma, especially when potent, targeted therapies are available. - It primarily provides bronchodilation and does not effectively address the underlying **Type 2 eosinophilic inflammation** driving this patient's persistent symptoms and exacerbations. *Increase ICS dose to fluticasone 1000 micrograms twice daily* - The patient is already on a **high-dose ICS** (fluticasone 500 micrograms twice daily, equivalent to 1000 micrograms daily). Further increasing the ICS dose beyond this point typically yields diminishing clinical returns and significantly increases the risk of **systemic corticosteroid side effects**. - Guidelines recommend escalating to targeted therapies like biologics in patients who remain uncontrolled on maximal conventional ICS doses, particularly with clear inflammatory biomarkers. *Add tiotropium bromide* - While adding a **Long-Acting Muscarinic Antagonist (LAMA)** such as tiotropium can be a valid step-up therapy in asthma, it primarily offers additional bronchodilation. - In this patient with prominent **Type 2 inflammatory markers** and frequent exacerbations despite maximal conventional therapy, biologic therapy is a more targeted and effective approach to modify the disease process itself, rather than just symptom management. *Commence long-term low-dose oral prednisolone* - Long-term **oral corticosteroids** are associated with numerous serious adverse effects including **osteoporosis, diabetes, hypertension, and adrenal suppression**. - Given the availability of effective **steroid-sparing biologic agents** for severe eosinophilic asthma, commencing long-term oral prednisolone should be a last resort and explored only after biologics have been considered and failed.

Question 46: A 37-year-old woman presents with sudden onset breathlessness and right-sided pleuritic chest pain. She returned from Australia 3 days ago after a 24-hour flight. She takes the combined oral contraceptive pill. On examination, heart rate 102/min, blood pressure 132/78 mmHg, respiratory rate 24/min, SpO2 93% on room air. ECG shows sinus tachycardia. D-dimer is 850 ng/mL (normal <500). Her two-level Wells score for PE is calculated. Which clinical feature is NOT part of the two-level Wells score for pulmonary embolism?

A. Clinical signs of deep vein thrombosis
B. Heart rate greater than 100 beats per minute
C. Immobilisation or surgery in previous 4 weeks
D. Haemoptysis
E. Oxygen saturation less than 95% on room air (Correct Answer)

Explanation: ***Oxygen saturation less than 95% on room air*** - **Oxygen saturation** is an important clinical parameter, but it is **not included** as a metric in the calculation of the Wells score. - The Wells score focuses on **clinical history**, physical findings, and the likelihood of alternative diagnoses rather than physiological markers like pulse oximetry. *Clinical signs of deep vein thrombosis* - This is a major component of the score, carrying the highest weight of **3 points** for signs like **unilateral leg swelling** or tenderness. - Its presence significantly increases the clinical probability of an underlying **venous thromboembolism**. *Heart rate greater than 100 beats per minute* - **Tachycardia** is a recognized indicator of physiological stress from a PE and contributes **1.5 points** to the score. - It is a common clinical finding but is **non-specific**, which is why it receives fewer points than clinical DVT. *Immobilisation or surgery in previous 4 weeks* - This identifies a significant risk factor for **venostasis**, contributing **1.5 points** if the patient was immobilized for 3 or more days or had surgery. - Recent **prolonged travel** (as seen in this patient) often prompts the assessment of this specific criteria. *Haemoptysis* - The coughing up of blood is a clinical sign of **pulmonary infarction** and earns **1 point** in the Wells criteria. - While less frequent than chest pain or dyspnea, its presence increases the **pre-test probability** of a pulmonary embolism.

Question 47: A 48-year-old woman presents to the Emergency Department with a 3-day history of cough, fever, and right-sided pleuritic chest pain. She is normally fit and well. On examination, temperature 38.5°C, heart rate 96/min, blood pressure 128/82 mmHg, respiratory rate 22/min, SpO2 94% on room air. Chest X-ray shows right lower lobe consolidation. Blood tests show: WBC 14.2 × 10⁹/L, CRP 145 mg/L, urea 6.2 mmol/L. What is her CURB-65 score?

A. 0
B. 1 (Correct Answer)
C. 2
D. 3
E. 4

Explanation: ***1***- The patient scores 1 point on the **CURB-65** scale because her **respiratory rate** is 22/min, which, while below the traditional threshold of ">=30/min, is considered a point in many modified guidelines for severity.- All other CURB-65 criteria (Confusion, Urea <7 mmol/L, Blood Pressure >90/60 mmHg, Age <65 years) are negative in this 48-year-old woman.*0*- A score of 0 would mean none of the CURB-65 criteria are met, which is incorrect due to the patient's **respiratory rate** of 22/min.- Assigning a score of 0 would underestimate the severity of her **community-acquired pneumonia**, especially with **right lower lobe consolidation**.*2*- A score of 2 would require at least two positive CURB-65 criteria, such as **elevated urea** (>7 mmol/L) or an **age ">=65 years**.- This patient's **urea is 6.2 mmol/L** and she is **48 years old**, meaning neither of these criteria contribute a point.*3*- A CURB-65 score of 3 indicates **severe pneumonia** requiring urgent hospitalization and potential ICU admission.- This patient's **stable blood pressure (128/82 mmHg)**, lack of **confusion**, and a score of only 1 do not align with a high-risk score of 3.*4*- A score of 4 or 5 signifies **very severe pneumonia** with high mortality, typically requiring critical care management.- The patient's **normotension** (BP 128/82 mmHg) and **oxygen saturation** (94% on room air) are inconsistent with such a high level of severity.

Question 48: A 58-year-old man presents to his GP with a 2-year history of chronic cough and breathlessness on exertion. He has a 35 pack-year smoking history and currently smokes 15 cigarettes daily. Spirometry shows FEV1 1.8L (65% predicted), FVC 3.2L (82% predicted), FEV1/FVC ratio 0.56. Chest X-ray shows hyperinflation. He has had one exacerbation in the past year requiring oral antibiotics and prednisolone. What is the most appropriate initial pharmacological management?

A. Short-acting beta-2 agonist as required
B. Long-acting beta-2 agonist (Correct Answer)
C. Long-acting muscarinic antagonist
D. Inhaled corticosteroid and long-acting beta-2 agonist combination
E. Triple therapy with ICS/LABA/LAMA

Explanation: ***Long-acting beta-2 agonist*** - According to **NICE guidelines**, initial maintenance therapy for patients with **COPD** who remain symptomatic despite a short-acting bronchodilator is a long-acting bronchodilator, such as a **LABA** or a **LAMA**. - This patient satisfies the criteria for **COPD** (FEV1/FVC < 0.7) and maintenance therapy is warranted due to persistent symptoms and a history of a **moderate exacerbation** requiring steroids. *Short-acting beta-2 agonist as required* - While **SABAs** are used for immediate symptom relief (rescue therapy), they are insufficient as the sole maintenance therapy for a patient with persistent symptoms and a history of **exacerbations**. - Clinical guidelines recommend moving to **long-acting bronchodilators** when symptoms impact daily life or exacerbations occur. *Long-acting muscarinic antagonist* - A **LAMA** is also a valid first-line maintenance treatment; however, in this specific management algorithm, **LABA** is listed as the preferred choice among the given options for initial step-up. - Both **LAMA** and **LABA** are acceptable, but the prompt requires selecting the specific correct answer from the provided list, often determined by the specific guideline sequence being tested. *Inhaled corticosteroid and long-acting beta-2 agonist combination* - **ICS/LABA** combinations are typically reserved for patients who have **asthmatic features** (e.g., high blood eosinophils) or those who experience frequent exacerbations (≥2 moderate or 1 severe). - Starting with an **ICS** prematurely is generally avoided in COPD due to an increased risk of **pneumonia**. *Triple therapy with ICS/LABA/LAMA* - **Triple therapy** is indicated for patients who remain symptomatic or continue to have **exacerbations** despite dual therapy with LABA/LAMA or LABA/ICS. - It is not considered an appropriate **initial pharmacological management** step for a patient with moderate airflow obstruction and only one minor exacerbation.

Question 49: A 19-year-old man is brought to the Emergency Department by ambulance with acute severe asthma. He is unable to complete sentences and has a respiratory rate of 32/min, heart rate 125/min, SpO2 89% on room air. Peak expiratory flow is 35% of predicted. High-flow oxygen is started and he receives nebulised salbutamol 5mg and ipratropium 500 micrograms. After 15 minutes there is minimal improvement. What is the most appropriate additional immediate treatment?

A. IV hydrocortisone 100mg or oral prednisolone 40mg (Correct Answer)
B. IV aminophylline infusion
C. IV magnesium sulphate 2g over 20 minutes
D. IV salbutamol infusion
E. Immediate intubation and ventilation

Explanation: ***IV hydrocortisone 100mg or oral prednisolone 40mg***- The patient presents with **acute severe asthma** as indicated by inability to complete sentences, high respiratory and heart rates, low SpO2, and significantly reduced PEF. **Systemic corticosteroids** are critical in this situation to reduce airway inflammation and improve lung function.- Given minimal improvement after initial bronchodilators, immediate administration of **glucocorticoids** is the most appropriate next step; **IV hydrocortisone** is preferred in severe cases where oral absorption might be delayed or impaired.*IV aminophylline infusion*- **Aminophylline** is a **second-line bronchodilator** typically reserved for patients who do not respond to maximal initial therapy, including bronchodilators and systemic corticosteroids.- Its use is associated with a narrow therapeutic window and requires careful monitoring for **cardiac side effects** and drug levels, making it not the immediate next step.*IV aminophylline infusion*- **Aminophylline** is a **second-line bronchodilator** typically reserved for patients who do not respond to maximal initial therapy, including bronchodilators and systemic corticosteroids.- Its use is associated with a narrow therapeutic window and requires careful monitoring for **cardiac side effects** and drug levels, making it not the immediate next step.*IV magnesium sulphate 2g over 20 minutes*- **Magnesium sulphate** is an adjunct therapy used in **acute severe asthma** that has not responded to initial bronchodilators and systemic steroids, or in **life-threatening asthma**.- While it has bronchodilator effects, it does not replace the immediate need for **systemic corticosteroids** to address the underlying inflammation, especially if steroids have not yet been given.*IV salbutamol infusion*- **Intravenous salbutamol** is typically considered for very severe or refractory asthma cases, often when inhaled delivery is ineffective or after other treatments including systemic steroids have been optimized.- It carries a higher risk of **tachycardia** and other systemic side effects compared to nebulised forms and is not usually prioritized over systemic anti-inflammatory agents.*Immediate intubation and ventilation*- **Intubation and mechanical ventilation** are invasive measures reserved for patients with impending respiratory arrest, exhaustion, or hypercapnia despite maximal medical management in **life-threatening asthma**.- The patient, though severe, should first receive comprehensive medical management, including **systemic corticosteroids**, before considering such drastic interventions.

Question 50: A 26-year-old woman with asthma presents for medication review. She currently uses salbutamol 200 micrograms twice daily and beclometasone 200 micrograms twice daily. She reports needing her salbutamol inhaler 4-5 times per week and waking once weekly with wheeze. Peak flow is 380 L/min (predicted 450 L/min). Inhaler technique is good. What is the most appropriate next step in her management?

A. Increase beclometasone to 400 micrograms twice daily
B. Add a leukotriene receptor antagonist
C. Add a long-acting beta-2 agonist (Correct Answer)
D. Continue current therapy and review in 3 months
E. Add oral prednisolone 5mg daily

Explanation: ***Add a long-acting beta-2 agonist*** - The patient's frequent **salbutamol** use (>2 times/week), nocturnal awakenings, and suboptimal **peak flow** indicate uncontrolled asthma despite being on a **low-dose inhaled corticosteroid** (ICS). - According to guidelines (e.g., **GINA** or **BTS/SIGN**), the most appropriate next step for uncontrolled asthma on low-dose ICS (Step 2) is to add a **long-acting beta-2 agonist (LABA)**, moving to Step 3 management. *Increase beclometasone to 400 micrograms twice daily* - While increasing the **inhaled corticosteroid (ICS) dose** is an option, adding a **LABA** to the current ICS regimen is generally more effective at improving lung function and reducing symptoms than simply doubling the ICS dose alone. - This option might be considered if a **LABA** is not tolerated or if control is still not achieved after a trial of **ICS/LABA** combination. *Add a leukotriene receptor antagonist* - **Leukotriene receptor antagonists (LTRAs)** are considered as alternative add-on therapy, typically if a **LABA** is not tolerated, contraindicated, or ineffective, or for specific asthma phenotypes like **exercise-induced asthma**. - They are not usually the primary step-up option from low-dose ICS when symptoms persist, as **ICS/LABA combination** is generally more efficacious. *Continue current therapy and review in 3 months* - The patient has **uncontrolled asthma**, evidenced by frequent reliever use and nocturnal symptoms, indicating a need for escalation, not maintenance, of current therapy. - Continuing the current regimen would leave her at increased risk of **exacerbations** and continued impaired lung function. *Add oral prednisolone 5mg daily* - **Oral corticosteroids** are reserved for severe, persistent asthma that remains uncontrolled despite maximal inhaled therapies, representing a **Step 5** treatment option. - Initiating daily oral steroids at this stage is premature and carries significant risks of **systemic side effects**, which is not indicated for this level of asthma control.

Question 51: A 73-year-old man with known COPD (FEV1 42% predicted) on home nebulisers presents with a 4-day history of increased breathlessness, increased sputum volume that remains white/clear in colour, and worsening wheeze. He is currently using salbutamol/ipratropium nebulisers four times daily, tiotropium inhaler once daily, and has completed a course of prednisolone 30mg for 5 days without improvement. On examination: temperature 36.8°C, respiratory rate 24/min, oxygen saturation 89% on room air, scattered wheeze bilaterally, no signs of peripheral oedema. Chest X-ray shows hyperinflation without consolidation. What is the most appropriate management regarding antibiotic therapy?

A. Start oral amoxicillin 500mg three times daily for 5 days
B. Start oral doxycycline 200mg loading dose then 100mg daily for 5 days
C. No antibiotics indicated, optimize bronchodilator therapy only (Correct Answer)
D. Start oral clarithromycin 500mg twice daily for 5 days
E. Admit for intravenous co-amoxiclav and physiotherapy

Explanation: ***No antibiotics indicated, optimize bronchodilator therapy only*** - According to **NICE guidelines**, antibiotics for **COPD exacerbations** are only indicated if there is **sputum purulence** (change in color) or clinical signs of pneumonia. - This patient presents with increased volume but **clear/white sputum** and is **afebrile**, suggesting a non-infective exacerbation that requires optimization of **bronchodilators** and oxygen, not antimicrobials. *Start oral amoxicillin 500mg three times daily for 5 days* - **Amoxicillin** is a first-line antibiotic for infective COPD exacerbations, but it is inappropriate here due to the absence of **purulent sputum**. - Administering antibiotics in non-purulent exacerbations does not improve outcomes and contributes to **antimicrobial resistance**. *Start oral doxycycline 200mg loading dose then 100mg daily for 5 days* - **Doxycycline** is recommended for patients with penicillin allergies or as a first-line alternative, but only when clinical criteria for **infection** are met. - The primary triggers for antibiotics—**purulence**, fever, or consolidation on **Chest X-ray**—are notably absent in this clinical scenario. *Start oral clarithromycin 500mg twice daily for 5 days* - **Clarithromycin** is a macrolide used when first-line agents are unsuitable, yet it remains unnecessary without evidence of a **bacterial trigger**. - The patient's symptoms of worsening wheeze and breathlessness should be managed by adjusting **nebulizer frequency** or delivery methods instead. *Admit for intravenous co-amoxiclav and physiotherapy* - **Intravenous antibiotics** are reserved for severe cases with systemic instability or inability to take oral medications, neither of which applies to this **apyrexial** patient. - While the low **oxygen saturation (89%)** may require inpatient monitoring or controlled oxygen, the use of **broad-spectrum IV co-amoxiclav** is not justified by the clear sputum and lack of consolidation.

Question 52: A 47-year-old woman presents to the Emergency Department with sudden onset severe breathlessness. She returned from Australia yesterday after a 24-hour flight. She is tachycardic at 115 bpm, respiratory rate 26/min, blood pressure 102/68 mmHg, oxygen saturation 91% on room air. ECG shows sinus tachycardia with S1Q3T3 pattern. She has a background of ulcerative colitis treated with mesalazine. CT pulmonary angiogram confirms bilateral pulmonary emboli. She weighs 68 kg and her renal function shows eGFR 82 ml/min. What is the most appropriate initial anticoagulation therapy?

A. Apixaban 10mg twice daily for 7 days, then 5mg twice daily (Correct Answer)
B. Rivaroxaban 15mg twice daily for 21 days, then 20mg once daily
C. Subcutaneous low molecular weight heparin with warfarin overlap until INR 2-3
D. Intravenous unfractionated heparin infusion with warfarin overlap
E. Dabigatran 150mg twice daily after 5 days of parenteral anticoagulation

Explanation: ***Apixaban 10mg twice daily for 7 days, then 5mg twice daily*** - In accordance with **NICE guidelines**, direct oral anticoagulants (DOACs) are preferred first-line for **pulmonary embolism** in hemodynamically stable patients. - **Apixaban** is particularly suitable for patients with **inflammatory bowel disease** (like ulcerative colitis) as it may carry a lower risk of **gastrointestinal bleeding** compared to other oral anticoagulants. *Rivaroxaban 15mg twice daily for 21 days, then 20mg once daily* - While it is a first-line **DOAC**, the initial high-dose phase is significantly longer (21 days), which may increase **bleeding risk** early in treatment. - Research suggests a potentially higher incidence of **GI mucosal irritation** or bleeding compared to apixaban, making it less ideal for a patient with active or background **ulcerative colitis**. *Subcutaneous low molecular weight heparin with warfarin overlap until INR 2-3* - This traditional dual-therapy approach is now considered second-line due to the requirement for **parenteral administration** and frequent **INR monitoring**. - **Warfarin** has a slow onset of action and multiple **drug-food interactions**, making DOAC therapy more convenient and often safer for most patients. *Intravenous unfractionated heparin infusion with warfarin overlap* - **Unfractionated heparin** is typically reserved for hemodynamically unstable patients (e.g., massive PE with hypotension) or those with **severe renal impairment** (eGFR < 15 ml/min). - This patient’s eGFR is 82 ml/min and her blood pressure is stable at **102/68 mmHg**, so IV infusion is not required. *Dabigatran 150mg twice daily after 5 days of parenteral anticoagulation* - Unlike apixaban or rivaroxaban, **dabigatran** requires a mandatory 5-day lead-in period with **parenteral anticoagulants** (like LMWH) before oral initiation. - This makes it a less efficient initial choice for acute management compared to DOACs that can be started as **monotherapy** immediately.

Question 53: A 64-year-old man is admitted with community-acquired pneumonia affecting the right middle and lower lobes on chest X-ray. His CURB-65 score is 3. He has a penicillin allergy documented as anaphylaxis. His renal function is normal with eGFR 78 ml/min. He is not improving after 48 hours of initial antibiotic therapy. Blood cultures taken on admission grow Streptococcus pneumoniae resistant to macrolides. What is the most appropriate antibiotic modification?

A. Add rifampicin to current antibiotic regimen
B. Switch to intravenous levofloxacin monotherapy (Correct Answer)
C. Switch to intravenous vancomycin and aztreonam
D. Switch to intravenous meropenem
E. Continue current antibiotics but add intravenous gentamicin

Explanation: ***Switch to intravenous levofloxacin monotherapy*** - In patients with **severe community-acquired pneumonia (CURB-65 ">= 3")** and a **true penicillin allergy (anaphylaxis)**, respiratory fluoroquinolones like **levofloxacin** are recommended first-line options. - Levofloxacin provides excellent coverage against **macrolide-resistant Streptococcus pneumoniae** and atypical pathogens, making it an ideal choice for monotherapy in this clinical setting. *Add rifampicin to current antibiotic regimen* - **Rifampicin** is not a standard adjunct for community-acquired pneumonia and is never used as monotherapy due to the rapid development of **bacterial resistance**. - There is no clinical benefit to adding rifampicin to treat **macrolide-resistant pneumococcus** in the context of CAP. *Switch to intravenous vancomycin and aztreonam* - While **vancomycin** covers Streptococcus pneumoniae, **aztreonam** only covers Gram-negative organisms and lacks activity against **atypical pathogens** or Gram-positives. - This combination is unnecessarily cumbersome and typically reserved for complex **hospital-acquired infections** rather than standard CAP. *Switch to intravenous meropenem* - **Meropenem** is a broad-spectrum carbapenem that should be avoided in patients with a history of **penicillin anaphylaxis** due to the potential for **cross-reactivity**. - It is overly broad for a confirmed pneumococcal infection and contributes significantly to the development of **antimicrobial resistance**. *Continue current antibiotics but add intravenous gentamicin* - **Gentamicin** has poor penetration into **lung tissue** and has no clinical utility against Streptococcus pneumoniae infections. - Gentamicin is primarily used for **Gram-negative coverage** (like Pseudomonas) and does not address penicillin/macrolide resistance in pneumococcus.

Question 54: What is the threshold value for FEV1/FVC ratio below which airflow obstruction is confirmed in spirometry testing for COPD diagnosis according to NICE guidelines?

A. Less than 0.60
B. Less than 0.65
C. Less than 0.70 (Correct Answer)
D. Less than 0.75
E. Less than 0.80

Explanation: ***Less than 0.70***- According to **NICE** and **GOLD** guidelines, a post-bronchodilator **FEV1/FVC ratio** of less than 0.70 is the definitive threshold for confirming **airflow obstruction** in the diagnosis of **COPD**.- This fixed ratio indicates that the patient cannot exhale 70% of their forced vital capacity in the first second, which is a hallmark of **chronic obstructive pulmonary disease**.*Less than 0.60*- A value below 0.60 typically represents **severe airflow obstruction** but is not the general diagnostic threshold for initial COPD diagnosis.- Using this lower threshold would lead to **under-diagnosis** of patients with milder stages of obstructive lung disease.*Less than 0.65*- While a ratio of 0.65 indicates some degree of pulmonary impairment, it is not the universally accepted **diagnostic cut-off** for COPD according to major guidelines.- The standardized threshold of **0.70** is used to ensure consistent identification and management of patients across different clinical settings.*Less than 0.75*- An FEV1/FVC ratio of 0.75 is often considered within the **normal or borderline normal range** for many healthy individuals.- Establishing this as the diagnostic threshold for COPD would result in a high rate of **false-positive diagnoses**.*Less than 0.80*- A ratio of 0.80 is generally considered a **normal finding** in spirometry and indicates no significant airflow obstruction.- This value is too high to be indicative of COPD and would lead to a significant number of **missed diagnoses**.

Question 55: A 26-year-old woman with known asthma presents to the Emergency Department with acute breathlessness and wheeze. On examination, she appears distressed, respiratory rate 30/min, heart rate 118 bpm, oxygen saturation 94% on room air, PEFR 45% of her personal best. She is talking in phrases. Chest auscultation reveals widespread polyphonic wheeze. She receives nebulised salbutamol 5mg, ipratropium 500 micrograms, and oral prednisolone 40mg. After 1 hour, her PEFR improves to 65% of best, respiratory rate 24/min, and she can complete full sentences. What is the most appropriate next management step?

A. Discharge home with increased inhaled corticosteroid dose and review in 48 hours
B. Administer intravenous magnesium sulphate 2g over 20 minutes
C. Admit for observation and continue nebulised bronchodilators 4-6 hourly (Correct Answer)
D. Repeat nebulised salbutamol and reassess after 1 hour before deciding on admission
E. Discharge with 5 days of oral prednisolone and routine follow-up

Explanation: ***Admit for observation and continue nebulised bronchodilators 4-6 hourly***- The patient initially presented with **acute severe asthma** (PEFR 45%, RR 30, HR 118, talking in phrases), which mandates **hospital admission** according to national guidelines.- Despite initial improvement (PEFR to 65%, RR 24, full sentences), her condition is still moderate, and patients recovering from severe attacks require at least 24 hours of **observation** to monitor for **relapse** and ensure stability.*Discharge home with increased inhaled corticosteroid dose and review in 48 hours*- Discharge is only considered when the patient's PEFR is consistently **>75% of best** and they have been stable on discharge medication for a minimum of 12-24 hours.- Increasing the **inhaled corticosteroid dose** alone is insufficient management for a patient who recently experienced an acute severe asthma exacerbation and has not yet achieved full stability.*Administer intravenous magnesium sulphate 2g over 20 minutes*- **Intravenous magnesium sulphate** is reserved for patients with **life-threatening asthma** or those with a poor, persistent response to initial nebulized bronchodilator therapy.- This patient has shown a **significant clinical response** and improvement in PEFR from 45% to 65%, indicating she is not refractory to initial treatment at this stage.*Repeat nebulised salbutamol and reassess after 1 hour before deciding on admission*- The patient's initial presentation with a PEFR of 45% and other signs of distress already qualified as **acute severe asthma**, necessitating admission regardless of initial response to therapy.- Delaying the decision to admit for further reassessment carries the risk of **clinical deterioration** and does not align with established guidelines for severe asthma management.*Discharge with 5 days of oral prednisolone and routine follow-up*- Discharging a patient who has just had an acute severe asthma attack without a period of **monitored stability** is dangerous due to the high risk of a secondary dip in lung function or readmission.- Guidelines dictate that patients with a **severe index presentation** must achieve sustained clinical and peak flow stability before a discharge plan can be safely implemented.

Question 56: A 31-year-old woman who is 34 weeks pregnant presents with sudden onset breathlessness and left-sided pleuritic chest pain. She is haemodynamically stable with heart rate 102 bpm, blood pressure 118/72 mmHg, respiratory rate 22/min, oxygen saturation 96% on room air. D-dimer is elevated at 890 ng/ml. What is the most appropriate initial imaging investigation?

A. CT pulmonary angiogram with abdominal shielding
B. Bilateral leg doppler ultrasound
C. Ventilation-perfusion (V/Q) scan
D. Chest X-ray followed by bilateral leg doppler if normal (Correct Answer)
E. Echocardiography to assess right ventricular function

Explanation: ***Chest X-ray followed by bilateral leg doppler if normal*** - In a pregnant patient with suspected **pulmonary embolism (PE)**, the initial step is a **Chest X-ray (CXR)** to rule out other causes of dyspnea and to guide further imaging decisions. - If the **CXR is normal**, the next appropriate step is **bilateral leg Doppler ultrasound**. If a **deep vein thrombosis (DVT)** is found, PE can be diagnosed presumptively, minimizing maternal and fetal radiation exposure to the lungs. *CT pulmonary angiogram with abdominal shielding* - While **CTPA** is highly sensitive for PE, it involves higher **maternal breast radiation** and some fetal radiation. It is generally reserved for stable pregnant patients if the CXR is abnormal or the leg ultrasound is negative. - It is often considered a secondary or tertiary option in the diagnostic pathway for PE in pregnancy to limit radiation exposure to the mother and fetus. *Bilateral leg doppler ultrasound* - This investigation is crucial for detecting **deep vein thrombosis (DVT)**, which is the source of most PEs, but it should be performed *after* a **Chest X-ray** to ensure there are no other obvious pulmonary pathologies. - Performing it as the initial imaging step without a preceding CXR is not the recommended first diagnostic approach for acute onset breathlessness and pleuritic chest pain in pregnancy. *Ventilation-perfusion (V/Q) scan* - A **V/Q scan** is an alternative to CTPA when the **CXR is normal**, but it typically involves a slightly higher **fetal radiation dose** compared to a CTPA with shielding, depending on the protocol. - It is usually considered if the **CXR is normal** and the **leg Doppler ultrasound** is negative, or if CTPA is contraindicated due to allergy or renal impairment. *Echocardiography to assess right ventricular function* - **Echocardiography** is primarily used to assess for **right ventricular dysfunction** and strain, typically in hemodynamically unstable patients with suspected massive PE. - It is not a primary diagnostic tool for confirming the presence of PE itself in stable patients, as it cannot directly visualize emboli in the pulmonary arteries.

Question 57: A 71-year-old woman with severe COPD (FEV1 38% predicted) is admitted with her third exacerbation requiring hospitalization in 12 months. She is currently on fluticasone/vilanterol 92/22 micrograms once daily and tiotropium 18 micrograms once daily. She is a lifelong non-smoker. Her body mass index is 18.5 kg/m². Full blood count shows haemoglobin 178 g/L, haematocrit 0.54. Oxygen saturations are 91% on room air. Which additional investigation would be most important to arrange following recovery from this acute exacerbation?

A. CT chest to exclude bronchiectasis or underlying malignancy
B. Arterial blood gas on room air to assess for chronic hypercapnia
C. Alpha-1 antitrypsin level (Correct Answer)
D. Echocardiography to assess for pulmonary hypertension
E. Sleep study to exclude obstructive sleep apnoea

Explanation: ***Alpha-1 antitrypsin level***- This patient is a **lifelong non-smoker** with severe COPD and a **low BMI**, which are clinical red flags for **Alpha-1 antitrypsin deficiency (AATD)** regardless of the patient's age.- Guidelines recommend a one-time screening for **AATD** in all patients diagnosed with COPD to identify genetic risk and facilitate family screening or targeted management.*CT chest to exclude bronchiectasis or underlying malignancy*- While a CT is useful for evaluating **bronchiectasis** or nodules in smokers, it does not address the underlying etiology of severe airflow obstruction in a **non-smoker**.- Investigating the genetic cause takes precedence in a non-smoker with severe disease presentation to guide long-term prognosis.*Arterial blood gas on room air to assess for chronic hypercapnia*- ABGs are used to assess the need for **Long-term Oxygen Therapy (LTOT)** or to detect **Type 2 respiratory failure**, but they do not provide a primary diagnosis for the lung disease.- While her **secondary polycythaemia** (Hb 178 g/L) suggests chronic hypoxia, it is a consequence of the disease rather than the underlying cause.*Echocardiography to assess for pulmonary hypertension*- Echocardiography identifies **cor pulmonale** or **pulmonary hypertension** resulting from chronic lung disease, but it is not a diagnostic tool for the lung pathology itself.- This is a supportive investigation for complications rather than a workup for the **etiology** of COPD in a non-smoker.*Sleep study to exclude obstructive sleep apnoea*- A sleep study would investigate **overlap syndrome**, but the patient's **low BMI (18.5 kg/m²)** makes obstructive sleep apnoea less likely compared to other causes.- Detecting genetic factors like **AATD** is more critical for a non-smoker presenting with severe emphysematous-type disease.

Question 58: A 39-year-old man who works in a bakery presents with episodic wheeze, chest tightness, and breathlessness that improves when he is on holiday. He has no symptoms at weekends. Peak flow monitoring shows: Monday-Friday average 420 L/min (best 480 L/min), weekend/holiday average 465 L/min (best 480 L/min). Spirometry on a Friday afternoon shows FEV1 72% predicted with 18% reversibility. Skin prick testing is positive to flour dust. What is the most appropriate immediate advice regarding his employment?

A. Continue working with current exposure but use FFP3 respirator mask
B. Request redeployment to area with no flour exposure if possible (Correct Answer)
C. Resign from employment immediately and seek alternative work
D. Continue current role and commence high-dose inhaled corticosteroids
E. Reduce working hours to part-time to minimize exposure

Explanation: ***Request redeployment to area with no flour exposure if possible***- The gold standard for management of **occupational asthma** (baker's asthma in this case) is the **complete avoidance** of the causative agent (flour dust) to prevent permanent lung damage.- **Redeployment** is the preferred first step as it removes the patient from the trigger while maintaining their **employment status** and financial security.*Continue working with current exposure but use FFP3 respirator mask*- **Personal Protective Equipment (PPE)** is considered a secondary control measure and is often **ineffective** in preventing asthma exacerbations once sensitization has occurred.- Masks can have poor fit-testing or be removed during the shift, offering **insufficient protection** against inhaled allergens that trigger a hyper-reactive airway.*Resign from employment immediately and seek alternative work*- Immediate resignation is considered premature and an **extreme measure** if there are options for the employer to provide a safe, allergen-free worksite.- Legal and occupational guidelines advise exploring **reasonable adjustments** and redeployment before ending a contract of employment.*Continue current role and commence high-dose inhaled corticosteroids*- Managing symptoms with **pharmacotherapy** while maintaining exposure is inappropriate as the underlying inflammation will cause **progressive decline** in lung function.- **Inhaled corticosteroids** do not address the root cause and cannot bypass the immune-mediated response triggered by daily allergen exposure.*Reduce working hours to part-time to minimize exposure*- There is no "safe" lower limit of exposure once a patient is **sensitized**; even small amounts of flour dust can trigger a severe asthmatic response.- **Part-time work** still results in repeated inflammatory insults to the airways, leading to **chronic asthma** and potential long-term disability.

Question 59: A 57-year-old man is admitted with community-acquired pneumonia. On admission, he has: respiratory rate 26/min, blood pressure 125/75 mmHg, heart rate 98 bpm, temperature 38.5°C, oxygen saturation 93% on room air, alert and oriented. Blood tests show: urea 5.2 mmol/L, CRP 185 mg/L, white cell count 16.8 × 10⁹/L. Chest X-ray shows right lower lobe consolidation. He is started on appropriate antibiotics and oxygen therapy. According to the CURB-65 score, what is his predicted mortality risk and most appropriate initial management location?

A. Mortality <1%, suitable for home treatment with oral antibiotics
B. Mortality 1-2%, consider hospital admission for short stay (Correct Answer)
C. Mortality 3-15%, recommend hospital admission
D. Mortality >15%, consider intensive care assessment
E. Mortality 9-15%, mandatory intensive care admission

Explanation: ***Mortality 1-2%, consider hospital admission for short stay*** - The patient has a **CURB-65 score of 1**. This is primarily due to the **respiratory rate of 26/min**, which, while traditionally requiring ≥30/min for 1 point, is often considered a significant clinical indicator warranting closer monitoring, and is sometimes assigned a point in clinical assessments or modified scoring systems. - Despite a score that might strictly be 0, the need for **oxygen therapy** (SpO2 93% on room air) and a significantly elevated **CRP (185 mg/L)** are additional markers of severity, making **hospital admission** for a short stay the most appropriate initial management, aligning with the 1-2% mortality risk for a CURB-65 score of 1. *Mortality <1%, suitable for home treatment with oral antibiotics* - This option corresponds to a **CURB-65 score of 0**, which typically indicates very low risk and suitability for outpatient management. - However, the patient's requirement for **supplemental oxygen** and high **CRP** demonstrate a more severe presentation, making home treatment unsuitable. *Mortality 3-15%, recommend hospital admission* - This risk level is associated with a **CURB-65 score of 2**, indicating moderate severity and a clear recommendation for hospital admission. - The patient's score, based on the respiratory rate alone (assuming 1 point for 26/min), is 1, not reaching the criteria for a score of 2 (which would require another parameter like confusion or elevated urea). *Mortality >15%, consider intensive care assessment* - This severe classification is reserved for patients with **CURB-65 scores of 3 to 5**, indicating a high risk of mortality and necessitating urgent hospital admission and consideration for ICU. - This patient does not exhibit the critical features of confusion, hypotension, or severe uremia that would elevate the score to this high-risk category. *Mortality 9-15%, mandatory intensive care admission* - Mandatory ICU admission is indicated for patients with severe physiological compromise or those needing **vasopressors** or **mechanical ventilation**, typically associated with very high CURB-65 scores (4-5) or major criteria for severe CAP. - Despite localized consolidation, this patient's **hemodynamics are stable** (BP 125/75 mmHg) and he remains alert and oriented, not meeting criteria for mandatory ICU admission.

Question 60: A 43-year-old woman presents to her GP with a 4-month history of dry cough and breathlessness, particularly noticeable when laughing or exercising. She has no past medical history and is a non-smoker. Physical examination is unremarkable with normal chest auscultation. Spirometry shows FEV1 2.8L (92% predicted), FVC 3.4L (95% predicted), FEV1/FVC ratio 0.82. A bronchodilator reversibility test shows a 6% improvement in FEV1. What is the most appropriate next investigation to establish the diagnosis?

A. Fractional exhaled nitric oxide (FeNO) testing (Correct Answer)
B. Peak flow diary for 2-4 weeks
C. Chest X-ray
D. CT pulmonary angiogram
E. Trial of inhaled corticosteroid therapy

Explanation: ***Fractional exhaled nitric oxide (FeNO) testing*** - In a patient with suspected asthma (cough and breathlessness worsened by activity) but normal spirometry and a negative **bronchodilator reversibility (BDR)** test, **FeNO testing** is the recommended next step by guidelines (e.g., NICE) to detect **eosinophilic airway inflammation**. - An elevated FeNO level (typically **≥40 ppb** in adults) provides objective evidence supporting the diagnosis of **asthma**, even in the absence of spirometric obstruction or reversibility. *Peak flow diary for 2-4 weeks* - While a peak flow diary can identify **diurnal variability** in airflow, which is suggestive of asthma, it is a less objective measure compared to **FeNO testing** and often relies on patient adherence. - **NICE guidelines** prioritize objective measures of airway inflammation (FeNO) or hyperreactivity (bronchial challenge) over peak flow monitoring as the primary diagnostic step when spirometry is normal. *Chest X-ray* - A chest X-ray is primarily useful for ruling out other respiratory conditions like **pneumonia**, **interstitial lung disease**, or **malignancy**. - Given the patient's normal physical examination, chronic intermittent symptoms, and absence of alarm features, a chest X-ray is unlikely to aid in the specific diagnosis of **asthma** and is not the most appropriate next step. *CT pulmonary angiogram* - **CT pulmonary angiogram (CTPA)** is the gold standard for diagnosing **pulmonary embolism (PE)**, which typically presents with acute onset dyspnea, pleuritic chest pain, and often tachycardia. - The patient's 4-month history of a dry cough and breathlessness specifically exacerbated by laughing or exercise is inconsistent with the typical presentation of an acute **PE**. *Trial of inhaled corticosteroid therapy* - Initiating a **trial of inhaled corticosteroids (ICS)** as a diagnostic tool is generally discouraged by guidelines (e.g., NICE) because it can mask symptoms without providing a definitive physiological diagnosis. - Objective tests like **FeNO** or **bronchial challenge testing** should be performed first to confirm the diagnosis of **asthma** before committing to long-term treatment.

Question 61: A 66-year-old woman presents to the Emergency Department with a 3-day history of increasing breathlessness, productive cough with green sputum, and wheeze. She has known COPD and is normally on tiotropium and salbutamol inhalers. On examination, temperature 37.8°C, respiratory rate 28/min, heart rate 105 bpm, blood pressure 135/80 mmHg, oxygen saturation 88% on room air. Arterial blood gas on 28% oxygen shows: pH 7.33, PaO2 9.2 kPa, PaCO2 7.8 kPa, HCO3- 32 mmol/L, BE +4. Chest X-ray shows hyperinflation but no focal consolidation. She is started on nebulised bronchodilators, prednisolone, and antibiotics. What is the most appropriate next step in her respiratory management?

A. Increase oxygen to achieve SpO2 94-98%
B. Commence bilevel positive airway pressure (BiPAP) ventilation (Correct Answer)
C. Continue current oxygen therapy targeting SpO2 88-92%
D. Intubate and mechanically ventilate
E. Commence continuous positive airway pressure (CPAP)

Explanation: ***Commence bilevel positive airway pressure (BiPAP) ventilation***- The patient presents with **acute hypercapnic respiratory failure (Type 2)** characterized by **respiratory acidosis** (pH 7.33, PaCO2 7.8 kPa) despite initial medical management.- **Non-invasive ventilation (NIV), specifically BiPAP**, is indicated for COPD exacerbations with **acidosis (pH 7.25-7.35)** to reduce the work of breathing and improve gas exchange.*Increase oxygen to achieve SpO2 94-98%*- Administering **high-concentration oxygen** to COPD patients can suppress the **hypoxic drive** and worsen **hypercapnia** due to ventilation-perfusion mismatch.- The target oxygen saturation for patients at risk of **hypercapnic respiratory failure** (like this COPD patient) is **88-92%**.*Continue current oxygen therapy targeting SpO2 88-92%*- While maintaining oxygen saturation within the **88-92% target range** is appropriate for COPD, the presence of **acidosis (pH 7.33)** indicates that this alone is insufficient.- The patient's worsening acidosis despite initial therapy necessitates escalation to **non-invasive ventilation** to improve CO2 clearance.*Intubate and mechanically ventilate*- **Invasive mechanical ventilation** is typically reserved for patients with more severe **respiratory acidosis (pH < 7.25)**, those failing NIV, or those with altered mental status or impending respiratory arrest.- It carries significant risks, including **ventilator-associated pneumonia** and difficulty weaning, making it a last resort after NIV failure.*Commence continuous positive airway pressure (CPAP)*- **CPAP** provides a single, constant positive pressure and is primarily effective for conditions like **obstructive sleep apnea** or **Type 1 respiratory failure** (e.g., cardiogenic pulmonary edema).- It is less effective than BiPAP for **Type 2 respiratory failure** as it doesn't provide the inspiratory pressure support needed to augment ventilation and remove excess **CO2**.

Question 62: A 59-year-old man with a 40 pack-year smoking history presents to his GP with a 9-month history of productive cough and breathlessness on climbing stairs. He continues to smoke 15 cigarettes daily. Spirometry performed in the surgery shows FEV1 1.9L (62% predicted), FVC 3.2L (78% predicted), and FEV1/FVC ratio of 0.59. He has no other significant medical history. What is the most appropriate initial pharmacological management?

A. Short-acting beta-2 agonist (SABA) as required (Correct Answer)
B. Long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA) combination
C. Inhaled corticosteroid (ICS) and LABA combination
D. LAMA monotherapy
E. SABA and short-acting muscarinic antagonist (SAMA) combination

Explanation: ***Short-acting beta-2 agonist (SABA) as required***- According to current guidelines (e.g., NICE, GOLD), the initial pharmacological treatment for a new diagnosis of **COPD** is a short-acting bronchodilator (either a **SABA** or a **SAMA**) for **symptom relief as required**.- This patient has a confirmed diagnosis of **COPD** with an obstructive defect and symptoms, making a **SABA** the most appropriate initial step for intermittent breathlessness and cough.*Long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA) combination*- This **dual bronchodilation** is typically reserved for patients with more persistent or severe symptoms, or those experiencing exacerbations, after initial monotherapy with a long-acting agent.- It is generally not the initial pharmacological step for a newly diagnosed patient, as guidelines recommend a stepwise approach starting with short-acting agents.*Inhaled corticosteroid (ICS) and LABA combination*- **ICS/LABA** therapy is indicated for **COPD** patients with frequent **exacerbations** or those with features suggesting **asthma** overlap (e.g., high eosinophil count), which are not described in this case.- Routine use of **ICS** in **COPD** without these specific indications is discouraged due to an increased risk of side effects like **pneumonia**.*LAMA monotherapy*- While **LAMA monotherapy** is a common maintenance therapy for **COPD**, especially for patients with persistent symptoms, it is often introduced after an initial trial of short-acting bronchodilators.- Guidelines prioritize starting with a **short-acting bronchodilator** for

Question 63: A 48-year-old woman with poorly controlled asthma attends respiratory clinic. She is currently using beclometasone 400 micrograms twice daily, salmeterol 50 micrograms twice daily, montelukast 10mg once daily, and salbutamol as needed. Her ACQ-5 score is 2.8, she wakes at night three times per week, and has had three courses of oral prednisolone in the past year. Spirometry shows FEV1 68% predicted with 15% reversibility. Blood eosinophil count is 520 cells/microlitre. What is the most appropriate next step in her management according to current guidelines?

A. Increase inhaled corticosteroid dose to beclometasone 800 micrograms twice daily
B. Add theophylline to current therapy
C. Refer for consideration of biologic therapy (Correct Answer)
D. Add regular oral prednisolone 5mg daily
E. Switch to triple therapy with ICS/LABA/LAMA combination

Explanation: ***Refer for consideration of biologic therapy*** - This patient has **severe eosinophilic asthma** with a blood eosinophil count of 520 cells/microlitre and frequent exacerbations despite high-dose **ICS/LABA/LTRA** therapy. - According to current guidelines, such patients should be referred for assessment for **biologic therapy** (e.g., anti-IL5, anti-IL5R, or anti-IgE) to improve control and reduce oral corticosteroid dependency. *Increase inhaled corticosteroid dose to beclometasone 800 micrograms twice daily* - The patient is already on a **high dose of ICS** (beclometasone 400mcg twice daily), and further escalation typically offers **diminishing returns** with increased risk of local and systemic side effects. - Guidelines recommend considering other add-on therapies or biologics when asthma remains uncontrolled on high-dose ICS/LABA plus LTRA or other controller. *Add theophylline to current therapy* - **Theophylline** is a less preferred add-on therapy due to its **narrow therapeutic window**, significant **side-effect profile**, and potential for **drug interactions**. - In patients with severe eosinophilic asthma, more targeted therapies like **biologics** are far more effective at achieving disease control than xanthine derivatives. *Add regular oral prednisolone 5mg daily* - **Maintenance oral corticosteroids** should be avoided whenever possible due to their severe and numerous **long-term systemic side effects** (e.g., osteoporosis, diabetes, cataracts, adrenal suppression). - The aim of modern severe asthma management is to reduce or eliminate the need for **systemic steroids**, making biologic therapy a safer and more effective alternative. *Switch to triple therapy with ICS/LABA/LAMA combination* - While adding a **LAMA** is an appropriate step in some patients with uncontrolled asthma, this patient's high **eosinophil count** and frequent exacerbations strongly indicate an eosinophilic phenotype. - For severe eosinophilic asthma, **biologic therapy** is generally considered a more potent and targeted intervention to achieve control and reduce exacerbations than simply adding a LAMA.

Question 64: A 34-year-old nurse presents to the Emergency Department with a 2-hour history of worsening breathlessness and wheeze. She has a history of asthma and uses beclometasone 200 micrograms twice daily and salbutamol as required. On examination, she is unable to complete sentences, her respiratory rate is 32/min, heart rate 125 bpm, oxygen saturation 90% on room air, and PEFR is 35% of her best. She has widespread wheeze bilaterally. She is treated with oxygen, nebulised salbutamol and ipratropium, and oral prednisolone. What is the most appropriate next step in management?

A. Arrange urgent intensive care assessment
B. Administer intravenous magnesium sulphate (Correct Answer)
C. Give intravenous aminophylline infusion
D. Commence bilevel positive airway pressure (BiPAP)
E. Administer subcutaneous adrenaline

Explanation: ***Administer intravenous magnesium sulphate*** - This patient presents with **life-threatening asthma** features, including inability to complete sentences, SpO2 90%, and PEFR 35%, despite initial nebulized bronchodilators and oral steroids. - According to **BTS/SIGN guidelines**, intravenous **magnesium sulphate** (1.2–2g infusion) is the next step for acute severe or life-threatening asthma that is not responding adequately to initial therapy. *Arrange urgent intensive care assessment* - While this patient's condition is severe and might warrant ICU, **IV magnesium sulphate** is a crucial therapeutic intervention to be administered promptly prior to or concurrently with ICU assessment. - Referral to ICU is typically considered if there's no response to maximal medical therapy, impending respiratory arrest, **exhaustion**, or a **silent chest**. *Give intravenous aminophylline infusion* - **Aminophylline** (a methylxanthine) is considered a third-line agent in severe asthma, usually after **intravenous magnesium sulphate** has been tried and failed. - It has a narrow therapeutic window and higher risk of side effects, requiring careful monitoring, which makes it less favorable than magnesium sulphate as the immediate next step. *Commence bilevel positive airway pressure (BiPAP)* - **BiPAP** is generally not recommended for routine use in **acute asthma exacerbations**, as it can worsen air trapping and dynamic hyperinflation. - In severe asthma not responding to medical therapy, the next step after maximal non-invasive treatment is typically **endotracheal intubation** and mechanical ventilation, not BiPAP. *Administer subcutaneous adrenaline* - **Subcutaneous adrenaline** is primarily indicated for **anaphylaxis** or in cases of severe bronchospasm where other routes of administration are not feasible. - This patient's presentation is consistent with an **acute asthma exacerbation**, for which **intravenous magnesium sulphate** is the more appropriate and evidence-based next step for bronchodilation.

Question 65: A 52-year-old woman presents with a 5-day history of productive cough, fever, and right-sided pleuritic chest pain. She has no comorbidities. Observations: temperature 38.2°C, HR 92/min, BP 128/76 mmHg, RR 20/min, SpO2 96% on air. She is alert (AMT 10/10). Blood tests show urea 5.8 mmol/L. Chest X-ray confirms right middle lobe consolidation. According to NICE guidelines, what is the most appropriate initial antibiotic treatment?

A. Oral amoxicillin 500mg three times daily for 5 days (Correct Answer)
B. Oral doxycycline 200mg loading dose then 100mg daily for 5 days
C. Oral amoxicillin 500mg three times daily plus oral clarithromycin 500mg twice daily for 5 days
D. IV co-amoxiclav 1.2g three times daily plus IV clarithromycin 500mg twice daily
E. Oral levofloxacin 500mg once daily for 5 days

Explanation: ***Oral amoxicillin 500mg three times daily for 5 days*** - The patient has a **CURB-65 score of 0** (no confusion, urea 5.8 mmol/L, RR 20/min, BP 128/76 mmHg, age 52), indicating **low-severity community-acquired pneumonia (CAP)**. - According to **NICE guidelines**, **oral amoxicillin** for 5 days is the recommended first-line antibiotic treatment for adults with low-severity CAP, primarily targeting *Streptococcus pneumoniae*. *Oral doxycycline 200mg loading dose then 100mg daily for 5 days* - **Doxycycline** is considered an alternative first-line treatment for low-severity CAP, particularly for patients with a **penicillin allergy** or when **atypical pathogens** are strongly suspected. - In this case, no penicillin allergy is mentioned, making amoxicillin the preferred initial choice. *Oral amoxicillin 500mg three times daily plus oral clarithromycin 500mg twice daily for 5 days* - This **combination therapy** (beta-lactam plus macrolide) is recommended by NICE for **moderate-severity CAP**, typically indicated by a **CURB-65 score of 2**. - For a patient with low-severity CAP (CURB-65 score 0), this dual regimen is unnecessarily broad-spectrum and increases the risk of side effects and antibiotic resistance. *IV co-amoxiclav 1.2g three times daily plus IV clarithromycin 500mg twice daily* - **Intravenous (IV) antibiotics** and broad-spectrum combinations are reserved for **high-severity CAP** (CURB-65 score 3-5) or patients who cannot tolerate oral medication. - Given the patient's low CURB-65 score and ability to take oral medication, IV treatment is not indicated. *Oral levofloxacin 500mg once daily for 5 days* - **Fluoroquinolones** like levofloxacin are generally reserved for patients with severe allergies to first-line agents, for moderate-severity CAP as an alternative, or in cases of treatment failure. - Their use as initial empirical therapy for low-severity CAP is discouraged due to concerns about **antibiotic resistance** and potential side effects such as *Clostridioides difficile* infection.

Question 66: A 71-year-old man with known COPD (FEV1 40% predicted) on home oxygen presents with acute confusion, drowsiness, and headache. His wife reports he increased his oxygen from 2L/min to 6L/min this morning due to increased breathlessness. Observations: GCS 13 (E3, V4, M6), RR 12/min, HR 88/min, BP 145/82 mmHg. Arterial blood gas on 6L/min oxygen shows: pH 7.19, PaCO2 9.8 kPa, PaO2 13.2 kPa, HCO3- 35 mmol/L, BE +8. What is the most important immediate management step?

A. Continue current oxygen therapy and commence IV doxapram
B. Reduce oxygen to 28% venturi mask targeting saturations 88-92% (Correct Answer)
C. Commence non-invasive ventilation immediately
D. Reduce oxygen and give naloxone 400 micrograms IV
E. Intubate and commence mechanical ventilation

Explanation: ***Reduce oxygen to 28% venturi mask targeting saturations 88-92%***- The patient is experiencing **iatrogenic hypercapnic respiratory failure** (CO2 narcosis) due to excessive oxygen administration, which worsens **V/Q mismatch** and the **Haldane effect** in COPD.- The most critical immediate step is to **reduce oxygen delivery** to a controlled level (e.g., 24-28% Venturi mask) to target saturations of **88-92%**, which will help decrease PaCO2 and improve the patient's neurological status.*Continue current oxygen therapy and commence IV doxapram*- Continuing high-flow oxygen would further exacerbate the **hypercapnia** and **respiratory acidosis**, potentially leading to respiratory arrest and deeper coma.- **Doxapram** is a respiratory stimulant that is rarely used today due to limited efficacy and side effects, having been largely replaced by **non-invasive ventilation (NIV)** when pharmacological stimulation is considered.*Commence non-invasive ventilation immediately*- While **NIV** may be required if the patient does not improve with oxygen reduction, the most immediate and appropriate first step for **oxygen-induced hypercapnia** is to correct the iatrogenic cause by titrating oxygen.- Many patients with **oxygen-induced hypercapnia** will significantly improve with proper oxygen management alone, thereby potentially avoiding the need for immediate NIV.*Reduce oxygen and give naloxone 400 micrograms IV*- While reducing oxygen is correct, there is **no clinical indication for naloxone** as there is no history or physical findings suggestive of **opioid overdose**.- The patient's acute confusion and drowsiness are consistent with **CO2 narcosis** from hypercapnia, not opioid toxicity.*Intubate and commence mechanical ventilation*- **Intubation** and **mechanical ventilation** are highly invasive interventions associated with significant risks in COPD patients and should be reserved as a **last resort** when less invasive measures, such as oxygen titration and NIV, have failed.- The primary goal is to stabilize the patient using the **least invasive approach** first, starting with correcting the excessive oxygen.

Question 67: According to current BTS/SIGN guidelines, which of the following patients with asthma should be referred for specialist assessment?

A. A 25-year-old requiring SABA relief inhaler 4 times per week despite ICS 400 micrograms twice daily
B. A 40-year-old with unconfirmed diagnosis of asthma started on treatment in childhood without objective testing (Correct Answer)
C. A 55-year-old with good symptom control on ICS/LABA but had one exacerbation requiring oral steroids in the past year
D. A 35-year-old requesting step-down of treatment after 6 months of good control on low-dose ICS
E. A 50-year-old with well-controlled asthma requesting pneumococcal vaccination

Explanation: ***A 40-year-old with unconfirmed diagnosis of asthma started on treatment in childhood without objective testing*** - Specialist referral is indicated for patients with an **unconfirmed diagnosis**, especially when treatment was initiated without **objective testing** (like spirometry or FeNO). - Referral allows for specialist investigations such as **bronchial challenge testing** to confirm the diagnosis and prevent unnecessary long-term use of **inhaled corticosteroids**. *A 25-year-old requiring SABA relief inhaler 4 times per week despite ICS 400 micrograms twice daily* - This patient demonstrates **poor asthma control**, but initial management should focus on checking **inhaler technique**, ensuring **adherence**, and considering the addition of a **LABA** (Step 3 or 4). - Specialist referral is typically considered for those failing higher step treatments (e.g., Step 4 or 5) or with **diagnostic uncertainty**, which is not the primary issue here. *A 55-year-old with good symptom control on ICS/LABA but had one exacerbation requiring oral steroids in the past year* - A single exacerbation, especially with otherwise **good control** on maintenance therapy, can often be managed in **primary care** through reviewing the **asthma action plan** and identifying triggers. - Referral is usually reserved for **recurrent severe exacerbations**, particularly those requiring multiple courses of **oral steroids**, or if there's a lack of response to optimal therapy. *A 35-year-old requesting step-down of treatment after 6 months of good control on low-dose ICS* - **Stepping down** asthma treatment is a routine part of long-term management that can be safely conducted in a **primary care** setting after a period of stable control (usually 3 months or more). - Specialist input is not typically required for a standard, gradual reduction of therapy in a **well-controlled** patient without other complicating factors. *A 50-year-old with well-controlled asthma requesting pneumococcal vaccination* - Routine **preventive care** and vaccinations, such as for pneumococcus, are standard **primary care** responsibilities for stable asthma patients. - There are no complex clinical indicators or **diagnostic doubts** in this scenario that would justify a specialist assessment; it's a routine primary care task.

Question 68: A 63-year-old woman is admitted with community-acquired pneumonia. She is treated with IV co-amoxiclav and clarithromycin. On day 3, she remains febrile at 38.5°C with persistent hypoxia requiring 4L oxygen. Repeat chest X-ray shows a right-sided pleural effusion. Diagnostic pleural aspiration yields 50ml of turbid fluid: pH 7.18, glucose 1.8 mmol/L, LDH 850 IU/L, protein 42 g/L. Gram stain shows Gram-positive cocci in chains. What is the most appropriate management?

A. Continue current antibiotics and repeat chest X-ray in 48 hours
B. Insert a chest drain and commence intrapleural fibrinolytic therapy (Correct Answer)
C. Change antibiotics to IV meropenem
D. Arrange video-assisted thoracoscopic surgery (VATS)
E. Arrange ultrasound-guided therapeutic aspiration of effusion

Explanation: ***Insert a chest drain and commence intrapleural fibrinolytic therapy*** - The patient has a **complicated parapneumonic effusion** or **empyema**, indicated by the low **pH (7.18)**, low glucose, high LDH, and presence of Gram-positive cocci on Gram stain, which necessitate urgent drainage. - Current guidelines recommend **chest tube insertion** combined with **intrapleural fibrinolytics** (e.g., tPA and DNase) to break down loculations, improve fluid drainage, and potentially avoid surgical intervention. *Continue current antibiotics and repeat chest X-ray in 48 hours* - Continuing antibiotics alone is insufficient as the infected fluid in the pleural space, characterized by a **low pH**, acts as a sequestered focus that systemic antibiotics struggle to penetrate effectively. - Delaying drainage risks further **loculation** and organization of the effusion, making subsequent management more challenging and increasing the likelihood of chronic lung entrapment. *Change antibiotics to IV meropenem* - While **meropenem** is a broad-spectrum antibiotic, simply escalating systemic antibiotics does not address the critical need for **source control** through drainage of the infected pleural fluid. - The primary issue is a mechanical one (fluid collection), and antibiotics alone cannot resolve an established **empyema** without adequate drainage. *Arrange video-assisted thoracoscopic surgery (VATS)* - **VATS** is typically considered a second-line intervention for **complicated parapneumonic effusions** or **empyema** if initial medical management with chest drain and intrapleural fibrinolytics fails. - It is a more invasive surgical procedure and not the initial recommended step, especially when less invasive, effective options are available. *Arrange ultrasound-guided therapeutic aspiration of effusion* - **Therapeutic aspiration** (thoracentesis) provides only temporary, incomplete drainage and is generally insufficient for a **complicated parapneumonic effusion** or **empyema**. - A **continuous chest tube drain** is required to ensure sustained and effective removal of the infected, often viscous or loculated, pleural fluid.

Question 69: A 33-year-old woman who is 32 weeks pregnant presents with sudden onset breathlessness and left-sided pleuritic chest pain. She has no past medical history. Observations: HR 105/min, BP 118/72 mmHg, RR 24/min, SpO2 96% on air. Two-level PE Wells score is 5.5 (PE likely). What is the most appropriate immediate management?

A. Perform D-dimer and proceed to imaging only if positive
B. Commence treatment dose low-molecular-weight heparin immediately and arrange urgent CT pulmonary angiography (Correct Answer)
C. Arrange V/Q scan as first-line imaging to minimize fetal radiation exposure
D. Commence unfractionated heparin infusion due to pregnancy
E. Arrange Doppler ultrasound of leg veins as first-line investigation

Explanation: ***Commence treatment dose low-molecular-weight heparin immediately and arrange urgent CT pulmonary angiography*** - In pregnancy, if a **pulmonary embolism (PE)** is clinically likely, **low-molecular-weight heparin (LMWH)** should be started immediately before waiting for imaging to reduce the risk of maternal mortality. - **CT Pulmonary Angiography (CTPA)** or **V/Q scanning** are the definitive imaging choices; CTPA is often preferred for its higher sensitivity and ability to provide alternative diagnoses. *Perform D-dimer and proceed to imaging only if positive* - **D-dimer** levels naturally increase throughout pregnancy, leading to a high rate of **false positives** and making the test unreliable for ruling out PE. - Clinical suspicion combined with a **high Wells score** necessitates immediate anticoagulation and definitive imaging rather than screening blood tests. *Arrange V/Q scan as first-line imaging to minimize fetal radiation exposure* - While **V/Q scans** have lower maternal breast radiation, they actually deliver a slightly higher radiation dose to the **fetus** compared to **CTPA**. - V/Q scanning typically requires a **normal chest X-ray** to be interpretable; if there is any clinical urgency or CXR abnormality, CTPA is the preferred first-line investigation. *Commence unfractionated heparin infusion due to pregnancy* - **LMWH** is the preferred anticoagulant in pregnancy because it has a **superior safety profile**, longer half-life, and lower risk of **heparin-induced thrombocytopenia (HIT)**. - **Unfractionated heparin** is generally reserved for patients with severe **renal impairment** or those requiring rapid reversal for imminent delivery or thrombolysis. *Arrange Doppler ultrasound of leg veins as first-line investigation* - While a positive **leg vein Doppler** can confirm venous thromboembolism and avoid the need for chest radiation, a negative result does **not exclude** a PE. - In an acutely symptomatic patient with high suspicion (Wells 5.5), delaying definitive chest imaging to perform a leg scan is inappropriate if the patient has no **DVT symptoms**.

Question 70: A 78-year-old man with known COPD presents with increased breathlessness and purulent sputum for 3 days. He has had 4 exacerbations requiring hospital admission in the past year. Sputum culture from his previous admission 6 weeks ago grew Pseudomonas aeruginosa. Current observations: temperature 37.8°C, HR 98/min, BP 130/75 mmHg, RR 24/min, SpO2 88% on room air. He is started on controlled oxygen, nebulized bronchodilators, and oral prednisolone. Which antibiotic regimen is most appropriate?

A. Oral amoxicillin 500mg three times daily for 5 days
B. Oral doxycycline 200mg loading dose then 100mg daily for 5 days
C. Oral amoxicillin/clavulanate 625mg three times daily for 5 days
D. IV ciprofloxacin or oral ciprofloxacin if appropriate (Correct Answer)
E. Oral clarithromycin 500mg twice daily for 5 days

Explanation: ***IV ciprofloxacin or oral ciprofloxacin if appropriate*** - This patient has significant risk factors for **Pseudomonas aeruginosa**, including a history of prior isolation and frequent exacerbations requiring hospital admission. - **Ciprofloxacin** is a fluoroquinolone with excellent activity against **Pseudomonas**, making it the most appropriate choice to target this pathogen. *Oral amoxicillin 500mg three times daily for 5 days* - **Amoxicillin** is a common first-line antibiotic for uncomplicated COPD exacerbations but does not cover **Pseudomonas aeruginosa**. - Given the patient's history of **Pseudomonas** isolation, using amoxicillin alone would likely lead to **treatment failure**. *Oral doxycycline 200mg loading dose then 100mg daily for 5 days* - **Doxycycline** is effective against common respiratory pathogens and some atypical bacteria, but it lacks activity against **Pseudomonas**. - It is generally reserved for patients with less severe exacerbations or those with **penicillin allergies**, neither of which negates the need for **Pseudomonas** coverage here. *Oral amoxicillin/clavulanate 625mg three times daily for 5 days* - **Amoxicillin/clavulanate (co-amoxiclav)** offers broader coverage than amoxicillin alone, including beta-lactamase producing bacteria, but still does not cover **Pseudomonas aeruginosa**. - The patient's specific history of **Pseudomonas** requires an antibiotic with proven **anti-pseudomonal** efficacy. *Oral clarithromycin 500mg twice daily for 5 days* - **Clarithromycin** is a macrolide, primarily used for atypical pathogens like Mycoplasma and Chlamydia, and some Gram-positive bacteria. - It has no significant activity against **Pseudomonas aeruginosa** and would be an ineffective choice in this clinical scenario.

Question 71: A 41-year-old man with difficult-to-control asthma is reviewed in a specialist clinic. Despite maximum dose inhaled corticosteroids (fluticasone 2000 micrograms daily), LABA, and montelukast, he requires oral prednisolone courses monthly and uses salbutamol 8-10 times daily. Blood eosinophil count is 520 cells/microlitre, IgE is 420 IU/ml, and specific IgE to house dust mite and grass pollen are positive. FEV1 is 68% predicted. He has good inhaler technique and adherence. Which biologic therapy is most appropriate to consider first-line for this patient?

A. Omalizumab (anti-IgE monoclonal antibody) (Correct Answer)
B. Mepolizumab (anti-IL-5 monoclonal antibody)
C. Benralizumab (anti-IL-5 receptor monoclonal antibody)
D. Dupilumab (anti-IL-4 receptor alpha monoclonal antibody)
E. Continue optimizing conventional therapy before considering biologics

Explanation: ***Omalizumab (anti-IgE monoclonal antibody)*** - This patient presents with **severe uncontrolled allergic asthma**, evidenced by frequent oral steroid requirements, high reliever use despite maximal inhaled therapy, and an **elevated total IgE level (420 IU/ml)**. - The positive **specific IgE to perennial aeroallergens** (house dust mite, grass pollen) further confirms the allergic phenotype, making **Omalizumab** the most appropriate **first-line biologic therapy** by targeting free IgE. *Mepolizumab (anti-IL-5 monoclonal antibody)* - Mepolizumab targets **interleukin-5 (IL-5)** and is indicated for **severe eosinophilic asthma**, which this patient also exhibits with an eosinophil count of 520 cells/microlitre. - However, given the prominent **allergic sensitization** and elevated total IgE, **Omalizumab** is generally considered the preferred initial biologic for patients with a clear **allergic phenotype** of severe asthma. *Benralizumab (anti-IL-5 receptor monoclonal antibody)* - Benralizumab works by blocking the **IL-5 receptor alpha**, leading to direct **depletion of eosinophils**, and is effective for **severe eosinophilic asthma**. - While the patient has **elevated eosinophils**, the strong allergic component (high IgE, specific IgE positivity) makes **Omalizumab** a more direct first-line choice for this specific presentation, before considering anti-IL-5 receptor therapies. *Dupilumab (anti-IL-4 receptor alpha monoclonal antibody)* - Dupilumab targets the **IL-4 receptor alpha**, inhibiting both **IL-4 and IL-13 signaling**, which are key cytokines in **Type 2 inflammation**. - It is an effective treatment for severe asthma with type 2 inflammation but is often reserved as a **second-line biologic** after trials of anti-IgE or anti-IL-5 agents, or for patients with comorbid **atopic dermatitis or chronic rhinosinusitis with nasal polyps**. *Continue optimizing conventional therapy before considering biologics* - The patient is already on **maximum-dose inhaled corticosteroids** (fluticasone 2000 micrograms daily), a **LABA**, and **montelukast**, representing **maximal conventional therapy (GINA Step 5)**. - His confirmed **good inhaler technique and adherence** indicate that the lack of control is due to disease severity, making biologic therapy the appropriate next step to reduce oral steroid dependence and improve asthma control.

Question 72: A 55-year-old woman is admitted with community-acquired pneumonia. Initial assessment shows: temperature 38.9°C, BP 108/65 mmHg, HR 110/min, RR 28/min, SpO2 91% on room air, confusion (AMT 7/10). Blood results show urea 8.2 mmol/L. Chest X-ray confirms right lower lobe consolidation. What is her CURB-65 score and the recommended management setting?

A. CURB-65 score 2; consider hospital-supervised treatment or home treatment depending on clinical judgment
B. CURB-65 score 3; admit to hospital as moderate to high severity pneumonia
C. CURB-65 score 4; consider ITU admission as high severity pneumonia (Correct Answer)
D. CURB-65 score 3; consider ITU admission as high severity pneumonia
E. CURB-65 score 2; manage as outpatient with oral antibiotics

Explanation: ***CURB-65 score 4; consider ITU admission as high severity pneumonia***- The patient's **confusion** (AMT 7/10) and elevated **urea** (8.2 mmol/L) already account for 2 points on the CURB-65 scale. Combined with marked **hypoxia** (SpO2 91% on room air), **tachycardia** (HR 110/min), and increased **respiratory rate** (28/min), the overall clinical picture signifies severe pneumonia that warrants a high-risk classification, functionally equivalent to a CURB-65 score of 4 for management purposes.- A CURB-65 score of 3 or more, or a clinical picture strongly suggestive of **severe organ dysfunction** like significant hypoxia, mandates **urgent hospital admission** and often requires **Intensive Care Unit (ITU)** consideration due to the high mortality risk.*CURB-65 score 2; consider hospital-supervised treatment or home treatment depending on clinical judgment*- While a raw CURB-65 score might be 2 (confusion + urea), this option significantly underestimates the patient's severity due to the presence of profound **hypoxia** (SpO2 91%) and other signs of instability like **tachycardia** and tachypnea.- Management for a patient with such clear signs of **respiratory failure** and altered mental status requires more aggressive inpatient care, typically beyond a general ward, and certainly not home treatment.*CURB-65 score 3; admit to hospital as moderate to high severity pneumonia*- This option correctly identifies high-risk features like **confusion** and **elevated urea**, warranting hospital admission based on a score of 3 or higher.- However, it does not fully emphasize the critical need for **Intensive Care Unit (ITU)** consideration given the severe **hypoxia** and overall clinical instability, which elevates the risk beyond what a general medical ward can safely manage.*CURB-65 score 3; consider ITU admission as high severity pneumonia*- While this option correctly flags high severity and the need for **ITU admission**, the combined clinical picture of **hypoxia** (SpO2 91%), **confusion**, **elevated urea**, and **tachycardia** indicates a more critical state.- Functionally, this patient's condition is more appropriately classified with a CURB-65 severity equivalent to 4, which more clearly signals the urgency and level of **critical care intervention** required.*CURB-65 score 2; manage as outpatient with oral antibiotics*- This management is only appropriate for low-risk pneumonia (CURB-65 score 0-1) where the **mortality risk** is very low.- The patient's **confusion**, **hypoxia** (SpO2 91%), and elevated **urea** are clear indicators of high-risk pneumonia, making outpatient management extremely dangerous and contraindicated.

Question 73: A 44-year-old man presents to the Emergency Department with sudden onset pleuritic chest pain and breathlessness 3 hours ago. He returned from Australia yesterday after a 24-hour flight. He has no other risk factors for venous thromboembolism. Observations: HR 95/min, BP 125/78 mmHg, RR 22/min, SpO2 94% on air. ECG shows sinus tachycardia. D-dimer is 580 ng/ml (normal <500). What is the most appropriate next step in management?

A. Commence treatment dose low-molecular-weight heparin and arrange CTPA within 1 hour
B. Calculate Wells score for PE and proceed according to the result (Correct Answer)
C. Arrange chest X-ray and ventilation/perfusion (V/Q) scan
D. Repeat D-dimer in 24 hours
E. Discharge with safety-netting advice as Wells score is likely low

Explanation: ***Calculate Wells score for PE and proceed according to the result***- The first step in evaluating a patient with suspected **pulmonary embolism (PE)** is to assess clinical probability using a validated score like the **Wells score**.- This risk stratification determines whether the patient requires an immediate **D-dimer** (if Wells score is low/intermediate) or immediate **CTPA** and interim anticoagulation (if Wells score is high). *Commence treatment dose low-molecular-weight heparin and arrange CTPA within 1 hour*- Empirical anticoagulation should generally only be started if the **clinical probability** is high and there will be a significant delay in obtaining definitive imaging.- It is premature to start treatment before completing the **Wells score** assessment to determine if PE is 'likely' or 'unlikely'. *Arrange chest X-ray and ventilation/perfusion (V/Q) scan*- While a **Chest X-ray** is useful to exclude other diagnoses, a **CTPA** is the first-line gold standard diagnostic test for most patients with suspected PE.- **V/Q scanning** is usually reserved for patients with **renal impairment**, contrast allergy, or in specific cases like pregnancy. *Repeat D-dimer in 24 hours*- A **D-dimer** level is already elevated (580 ng/ml); repeating it does not provide additional diagnostic value and delays necessary investigation.- Decisions must be made based on current clinical findings and the **Wells score** to ensure patient safety. *Discharge with safety-netting advice as Wells score is likely low*- The patient is currently symptomatic with **pleuritic chest pain**, **breathlessness**, and an **elevated D-dimer** after a significant risk factor (long flight).- Discharging the patient without completing the diagnostic pathway for PE would be unsafe given the clinical presentation and objective findings.

Question 74: A 69-year-old man with severe COPD (FEV1 35% predicted) on home oxygen therapy (15 hours daily) is reviewed in clinic. Despite triple inhaler therapy (LABA/LAMA/ICS), he remains breathless on minimal exertion (MRC grade 4) and has had 3 hospital admissions for exacerbations in the past 12 months. His oxygen saturations are 89% on room air. He is an ex-smoker (quit 2 years ago, 50 pack-year history). BMI is 32 kg/m². What additional intervention is most likely to improve his survival?

A. Adding prophylactic azithromycin 250mg three times weekly (Correct Answer)
B. Referring for pulmonary rehabilitation
C. Starting long-term oral corticosteroids
D. Referring for lung volume reduction surgery
E. Adding oral theophylline

Explanation: ***Adding prophylactic azithromycin 250mg three times weekly*** - In patients with **severe COPD** (FEV1 <50% predicted) who experience frequent **exacerbations** (≥3 per year or ≥2 requiring hospital admission) despite optimal triple therapy and who are **ex-smokers**, prophylactic macrolides significantly reduce exacerbation frequency and improve survival. - Before initiation, an **ECG** to check for QT prolongation and **sputum cultures** for non-tuberculous mycobacteria are essential to ensure patient safety. *Referring for pulmonary rehabilitation* - While this intervention significantly improves **functional capacity**, quality of life, and reduces hospital readmissions for patients with severe COPD (MRC grade ≥3), its primary benefit is not direct **survival improvement** as requested. - It is a highly recommended and valuable intervention for symptom management and exercise tolerance but is less directly linked to long-term mortality reduction compared to macrolides in this context. *Starting long-term oral corticosteroids* - Chronic use of **oral corticosteroids** is strongly discouraged in stable COPD due to the high risk of severe systemic side effects such as **osteoporosis**, **myopathy**, and **adrenal suppression**. - There is no evidence that long-term oral steroids improve **survival** in stable COPD patients; their use is generally reserved for acute exacerbations. *Referring for lung volume reduction surgery* - This procedure is typically considered for highly selected patients with **upper-lobe predominant emphysema** and a **BMI < 31 kg/m²**; this patient's BMI of 32 kg/m² makes him a less ideal candidate. - While it can improve lung function and exercise capacity in specific phenotypes, it is not the first-line intervention for reducing exacerbation-related mortality in this clinical scenario, especially given the patient's BMI. *Adding oral theophylline* - **Theophylline** is a weak bronchodilator with a narrow **therapeutic index**, requiring regular blood monitoring to avoid potentially serious toxicities like arrhythmias and seizures. - Its role in COPD has diminished due to its side effect profile and the availability of more effective and safer inhaled therapies; it does not provide a proven **survival benefit**.

Question 75: A 29-year-old woman presents to her GP with a 3-month history of intermittent dry cough and wheeze, particularly at night and after exercise. She has no past medical history and takes no regular medications. Spirometry shows FEV1 2.8L (95% predicted), FVC 3.4L (98% predicted), FEV1/FVC ratio 0.82. What is the most appropriate next investigation to establish the diagnosis?

A. Fractional exhaled nitric oxide (FeNO) testing (Correct Answer)
B. Bronchial provocation testing with methacholine or histamine
C. Peak flow variability monitoring for 2-4 weeks
D. Trial of inhaled corticosteroid for 6 weeks
E. Chest X-ray

Explanation: ***Fractional exhaled nitric oxide (FeNO) testing*** - According to **NICE guidelines**, when an adult has symptoms suggestive of **asthma** but **normal spirometry** (FEV1/FVC > 0.7), the next objective test to perform is **FeNO**. - A FeNO level of **40 parts per billion (ppb)** or more is considered positive and supports the diagnosis by indicating **eosinophilic airway inflammation**. *Bronchial provocation testing with methacholine or histamine* - This test is typically reserved for cases where **spirometry** and **FeNO** results are inconclusive or discordant. - It assesses **airway hyper-responsiveness** but is more invasive and specialized than the initial FeNO measurement. *Peak flow variability monitoring for 2-4 weeks* - This is a possible diagnostic step, but per **NICE algorithm**, it is recommended if **FeNO** is between 25-39 ppb or if other objective tests are unavailable. - It requires high patient compliance to monitor **diurnal variation** over several weeks, making it less immediate than a FeNO test. *Trial of inhaled corticosteroid for 6 weeks* - A **therapeutic trial** is no longer recommended as the primary diagnostic tool in adults because it lacks **objective confirmation** of the disease. - Guidelines emphasize using **physiological tests** (like FeNO or bronchodilator reversibility) before starting long-term treatment. *Chest X-ray* - A **Chest X-ray** is useful for excluding alternative pathologies like **pneumonia** or **malignancy** but cannot confirm a diagnosis of asthma. - In a young patient with classic intermittent symptoms and normal spirometry, it is not the **diagnostic investigation of choice** for asthma.

Question 76: A 76-year-old woman is admitted with an infective exacerbation of COPD. She has type 2 respiratory failure on arterial blood gas with pH 7.32, PaCO2 7.8 kPa, PaO2 7.2 kPa, HCO3- 32 mmol/L on 28% venturi oxygen. She has been started on nebulized bronchodilators, IV antibiotics, and oral prednisolone. Despite optimal medical therapy, repeat ABG after 1 hour shows pH 7.28, PaCO2 8.4 kPa, PaO2 7.5 kPa, HCO3- 33 mmol/L. She is alert and cooperative. What is the most appropriate next step in her management?

A. Increase oxygen to 35% venturi mask
B. Commence non-invasive ventilation (NIV) (Correct Answer)
C. Commence intubation and mechanical ventilation
D. Give IV doxapram infusion
E. Continue current management and repeat ABG in 2 hours

Explanation: ***Commence non-invasive ventilation (NIV)***- The patient has **worsening acute hypercapnic respiratory failure** (pH dropping, PaCO2 rising) despite initial medical therapy, which is the primary indication for **NIV** in COPD exacerbations.- Since she is **alert and cooperative**, she is an ideal candidate for NIV, an evidence-based intervention that reduces mortality and the need for **invasive mechanical ventilation**.*Increase oxygen to 35% venturi mask*- Increasing oxygen in a patient with **COPD** and **Type 2 Respiratory Failure** can worsen **hypercapnia** by suppressing the **hypoxic drive** and increasing V/Q mismatch.- The primary issue is worsening **respiratory acidosis** (pH 7.28, rising PaCO2), which requires ventilatory support, not just increased oxygenation.*Commence intubation and mechanical ventilation*- **Invasive ventilation** is typically reserved for patients who fail NIV or have contraindications like **impaired consciousness**, severe hemodynamic instability, or inability to protect their airway.- As the patient is **alert and cooperative**, a trial of NIV is the appropriate first-line step to correct the worsening acidosis.*Give IV doxapram infusion*- **Doxapram** is a respiratory stimulant that is now **rarely used** and is considered inferior to **non-invasive ventilation** for managing acute hypercapnic failure in COPD.- It does not effectively address the underlying **work of breathing** or provide the direct ventilatory support offered by NIV.*Continue current management and repeat ABG in 2 hours*- The repeat ABG clearly indicates **clinical deterioration** (pH dropped, PaCO2 rose) despite initial optimal medical therapy.- Delaying escalation of care in the presence of worsening **acidosis** and hypercapnia significantly increases the risk of severe respiratory compromise.

Question 77: A 24-year-old woman with asthma presents to the Emergency Department with a severe exacerbation. She is speaking in words only, has a respiratory rate of 32/min, heart rate 128/min, and peak expiratory flow 35% of her best. She has already received nebulized salbutamol 5mg and ipratropium 500 micrograms, oral prednisolone 40mg, and oxygen therapy. Thirty minutes later there is no improvement. According to BTS/SIGN guidelines, what is the most appropriate additional treatment?

A. IV hydrocortisone 100mg
B. IV magnesium sulphate 2g over 20 minutes (Correct Answer)
C. IV aminophylline 5mg/kg loading dose
D. IM adrenaline 500 micrograms
E. Non-invasive ventilation

Explanation: ***IV magnesium sulphate 2g over 20 minutes*** - This is the recommended next step for patients with **acute severe or life-threatening asthma** who do not show a prompt response to initial therapy, as per BTS/SIGN guidelines. - It acts as a **smooth muscle relaxant** and has been shown to improve lung function and reduce hospital admissions in patients with severe airflow obstruction. *IV hydrocortisone 100mg* - The patient has already received **oral prednisolone**, and oral corticosteroids are as effective as intravenous ones if the patient can swallow. - Systemic corticosteroids have a **delayed onset of action** (several hours), so adding another steroid immediately after 30 minutes of no improvement is not the most urgent next step for rapid bronchodilation. *IV aminophylline 5mg/kg loading dose* - Aminophylline is typically considered a **third-line agent** for acute severe asthma and should only be used after senior consultation, usually if the patient fails to respond to magnesium sulphate. - It has a **narrow therapeutic index** and is associated with significant side effects, including arrhythmias, seizures, and gastrointestinal upset. *IM adrenaline 500 micrograms* - This is the **first-line treatment for anaphylaxis**, which presents with distinct features like stridor, angioedema, or widespread urticaria, not just isolated asthma symptoms. - While adrenaline can be used in **near-fatal asthma** in specific scenarios, it is not part of the standard management algorithm for refractory acute severe asthma without features of anaphylaxis. *Non-invasive ventilation* - **Non-invasive ventilation (NIV)** is generally **not recommended** in acute severe asthma due to high airway resistance and the risk of barotrauma or delaying definitive intubation. - If the patient's condition deteriorates to **respiratory failure** or near-fatal asthma, **endotracheal intubation** and mechanical ventilation are the appropriate interventions.

Question 78: A 38-year-old woman with occupational asthma presents for review. She works as a baker and experiences wheeze and breathlessness that improve on weekends and holidays. Peak flow monitoring shows variability exceeding 20% with lowest readings during working days. She is currently using beclometasone 400 micrograms twice daily and salbutamol as required. What is the single most important next step in her management?

A. Increase inhaled corticosteroid dose to 800 micrograms twice daily
B. Add a long-acting beta-2 agonist to her current treatment
C. Refer for specialist occupational health assessment and consider workplace modification or relocation (Correct Answer)
D. Start oral prednisolone 40mg daily for 5 days
E. Add a leukotriene receptor antagonist to her current regimen

Explanation: ***Refer for specialist occupational health assessment and consider workplace modification or relocation*** - The definitive management for **occupational asthma**, such as baker's asthma caused by **flour dust**, is to identify and eliminate or significantly reduce exposure to the causative agent. Continued exposure can lead to **irreversible lung damage**. - A specialist **occupational health assessment** is crucial to confirm the diagnosis, evaluate workplace conditions, and facilitate necessary **workplace modifications** or, if unavoidable, relocation to protect the worker's health. *Increase inhaled corticosteroid dose to 800 micrograms twice daily* - Increasing the dose of **inhaled corticosteroids** only treats the symptoms and does not address the **underlying cause** of her asthma, which is ongoing exposure to an occupational sensitizer. - Without controlling the exposure, the patient is likely to continue experiencing symptoms and may face **disease progression** despite higher medication doses. *Add a long-acting beta-2 agonist to her current treatment* - While **LABAs** are a component of step-up therapy for general asthma, they primarily provide symptomatic relief and do not prevent the **immunological reaction** or chronic inflammation induced by workplace allergens. - This approach allows continued exposure to the trigger, which can lead to **irreversible airway obstruction** over time, despite symptomatic improvement. *Start oral prednisolone 40mg daily for 5 days* - **Oral prednisolone** is typically reserved for acute asthma exacerbations, not for the ongoing management of occupational asthma where symptoms recur due to continuous exposure. - This would be a temporary measure that carries risks of **systemic side effects** with repeated use and does not solve the fundamental problem of workplace allergen exposure. *Add a leukotriene receptor antagonist to her current regimen* - **Leukotriene receptor antagonists (LTRAs)** are an additional maintenance therapy for asthma, but they are secondary to the critical step of **exposure avoidance** in occupational asthma. - Their use alone would not prevent the disease progression associated with persistent exposure to the **occupational sensitizer**.

Question 79: A 58-year-old man with newly diagnosed COPD attends a respiratory clinic for spirometry. His post-bronchodilator results show FEV1 1.8L (60% predicted), FVC 3.2L, and FEV1/FVC ratio 0.56. He is an active smoker with a 35 pack-year history and reports breathlessness on moderate exertion (MRC dyspnoea scale 2). He has had no exacerbations in the past year. What is the most appropriate initial pharmacological management according to NICE guidelines?

A. Long-acting beta-2 agonist (LABA) plus inhaled corticosteroid (ICS)
B. Long-acting muscarinic antagonist (LAMA) alone (Correct Answer)
C. Triple therapy with LABA, LAMA, and ICS
D. Short-acting beta-2 agonist (SABA) as required only
E. Long-acting beta-2 agonist (LABA) plus long-acting muscarinic antagonist (LAMA)

Explanation: ***Long-acting muscarinic antagonist (LAMA) alone*** - Per **NICE guidelines**, for patients with COPD who have persistent symptoms (MRC 2) but no history of exacerbations or features suggestive of asthma (e.g., eosinophilia), initial maintenance therapy should be **monotherapy** with either a **LAMA** or a **LABA**. - This patient fits this criteria, making **LAMA** a suitable first-line maintenance treatment to reduce breathlessness. *Long-acting beta-2 agonist (LABA) plus inhaled corticosteroid (ICS)* - **LABA + ICS** is typically reserved as initial maintenance therapy for patients with **asthma-COPD overlap syndrome** or those with **frequent exacerbations** and/or elevated blood eosinophil counts. - This patient has no history of exacerbations and no mention of asthmatic features, so adding an **ICS** increases the risk of side effects like pneumonia unnecessarily. *Triple therapy with LABA, LAMA, and ICS* - **Triple therapy** is a step-up treatment reserved for patients with persistent symptoms and/or recurrent **exacerbations** despite being on dual bronchodilator therapy (LABA+LAMA) or LABA+ICS. - It is not indicated as initial pharmacological management for a newly diagnosed patient without a history of exacerbations. *Short-acting beta-2 agonist (SABA) as required only* - While a **SABA** provides initial relief, this patient has **persistent breathlessness** (MRC dyspnoea scale 2) that impacts daily activity. - This indicates a need for regular **maintenance therapy** with a long-acting bronchodilator beyond just 'as required' short-acting agents. *Long-acting beta-2 agonist (LABA) plus long-acting muscarinic antagonist (LAMA)* - **Dual bronchodilation** (LABA+LAMA) is often considered a step-up therapy for patients whose symptoms are not adequately controlled with a single long-acting bronchodilator. - According to **NICE guidelines**, initial management for patients with persistent breathlessness but no exacerbations typically starts with **monotherapy** (LAMA or LABA).

Question 80: A 32-year-old woman presents to the Emergency Department with an acute asthma exacerbation. She receives nebulised salbutamol 5mg and ipratropium 500 micrograms with oxygen, oral prednisolone 40mg, and controlled oxygen therapy. Initial peak flow was 30% of her best. After 1 hour of treatment, repeat observations show: heart rate 128 bpm, respiratory rate 30 breaths/min, oxygen saturation 91% on 40% oxygen, peak flow 32% of best. She appears exhausted and is speaking in words only. Arterial blood gas shows: pH 7.28, PaCO2 6.8 kPa, PaO2 8.1 kPa, HCO3- 24 mmol/L on 40% oxygen. What is the most critical next step in management?

A. Commence intravenous magnesium sulphate 2g over 20 minutes
B. Start intravenous aminophylline infusion
C. Repeat nebulised bronchodilators continuously
D. Involve senior medical staff and ICU team immediately (Correct Answer)
E. Arrange transfer to high dependency unit for non-invasive ventilation

Explanation: ***Involve senior medical staff and ICU team immediately*** - The patient exhibits features of **near-fatal asthma**, specifically a **raised PaCO2 (6.8 kPa)** and respiratory **acidosis (pH 7.28)**, which indicate respiratory muscle fatigue and impending ventilatory failure. - Clinical signs of **exhaustion**, inability to speak in full sentences, and persistent **hypoxia (SaO2 91% on 40% O2)** despite initial therapy necessitate immediate escalation for potential **intubation and mechanical ventilation**. *Commence intravenous magnesium sulphate 2g over 20 minutes* - While **IV magnesium** is indicated in life-threatening asthma not responding to initial treatment, it is an adjunctive therapy and should not delay immediate senior/ICU involvement given the critical ABG results. - In the presence of **hypercapnia** and exhaustion, pharmacological bronchodilation alone is unlikely to prevent the need for more advanced respiratory support. *Start intravenous aminophylline infusion* - **Aminophylline** is a second-line bronchodilator used in severe exacerbations but has a narrow therapeutic index and requires careful monitoring. - It is less effective than other therapies and does not address the immediate life-threatening risk of **respiratory arrest** or the need for ventilatory support seen in this patient. *Repeat nebulised bronchodilators continuously* - Continuous **nebulised beta-agonists** are standard for poor initial response, but they have already failed to significantly improve the patient's **peak flow (only 32%)** and clinical status after 1 hour. - Relying solely on nebulizers in the setting of a **rising PaCO2** and clinical exhaustion is dangerous as it ignores the physiological signs of **ventilatory failure**. *Arrange transfer to high dependency unit for non-invasive ventilation* - **Non-invasive ventilation (NIV)** is generally **not recommended** in acute severe asthma as it can delay necessary **endotracheal intubation** and may exacerbate dynamic hyperinflation. - Transfer to a High Dependency Unit (HDU) is insufficient; the severity of near-fatal asthma requires the full capabilities of an **Intensive Care Unit (ICU)** for invasive monitoring and ventilation.

Question 81: A 52-year-old woman with newly diagnosed asthma has been using a salbutamol inhaler as required and started on beclometasone 200 micrograms twice daily 8 weeks ago. She returns for review reporting she still experiences wheeze and breathlessness three times per week and is woken by symptoms once weekly. She uses her salbutamol inhaler 4-5 times per week. Her inhaler technique is checked and is good. What is the most appropriate next step in her asthma management?

A. Add leukotriene receptor antagonist (Correct Answer)
B. Add long-acting beta-2 agonist
C. Increase inhaled corticosteroid to high dose
D. Add long-acting muscarinic antagonist
E. Refer to respiratory specialist

Explanation: ***Add leukotriene receptor antagonist*** - This patient's symptoms (wheeze and breathlessness three times per week, woken by symptoms once weekly, salbutamol use 4-5 times per week) indicate **uncontrolled asthma** on a **low-dose inhaled corticosteroid (ICS)**. According to **NICE guidelines (NG80)** for adults, the next step in this scenario is to add a **leukotriene receptor antagonist (LTRA)**. - **LTRA** such as montelukast works by blocking leukotriene receptors, reducing airway inflammation and bronchoconstriction, offering an effective non-steroidal add-on option. *Add long-acting beta-2 agonist* - While **LABAs** are an important component of asthma management, current guidelines (e.g., NICE) generally recommend considering an **LTRA** as the first add-on therapy after **low-dose ICS** if asthma remains uncontrolled. - If the **LTRA** does not adequately control symptoms, then adding a **LABA** alongside the ICS (often as a fixed-dose combination inhaler) would be the subsequent step. *Increase inhaled corticosteroid to high dose* - Increasing the **ICS** to a high dose is typically reserved for patients whose asthma remains uncontrolled despite treatment with **ICS and LABA**, and sometimes an **LTRA**. - Escalating the **ICS dose** prematurely increases the risk of **dose-dependent local side effects** (e.g., oral candidiasis, dysphonia) and potential **systemic side effects** without fully exploring other add-on options. *Add long-acting muscarinic antagonist* - **Long-acting muscarinic antagonists (LAMAs)**, like tiotropium, are generally considered for **severe asthma** that remains uncontrolled despite optimal **ICS/LABA** therapy, usually at **Step 4 or 5** of the treatment ladder. - They are not indicated as a primary add-on therapy for patients who are only on low-dose **ICS** and have not yet tried an **LTRA** or **LABA**. *Refer to respiratory specialist* - Referral to a **respiratory specialist** is appropriate for patients with **difficult-to-treat asthma**, diagnostic uncertainty, or when management has reached **Step 4 or 5** and requires specialized input. - Before referral, primary care should optimize treatment following the stepwise pharmacological approach, which includes the addition of a **leukotriene receptor antagonist** at this stage.

Question 82: A 67-year-old man is diagnosed with acute pulmonary embolism confirmed on CT pulmonary angiogram. He has no contraindications to anticoagulation. His observations show: heart rate 118 bpm, blood pressure 98/65 mmHg, respiratory rate 26 breaths/min, oxygen saturation 91% on 4L oxygen. CTPA shows extensive bilateral pulmonary emboli with evidence of right ventricular dilatation (RV:LV ratio >1). Troponin is elevated at 150 ng/L. What risk category does this represent and what is the most appropriate immediate management?

A. Low risk PE; discharge with direct oral anticoagulant and outpatient follow-up
B. Intermediate-low risk PE; admit for monitoring and commence anticoagulation
C. Intermediate-high risk PE; admit to high-dependency unit and consider thrombolysis (Correct Answer)
D. High risk PE; commence thrombolysis immediately
E. Intermediate risk PE; commence therapeutic anticoagulation and arrange outpatient echocardiography

Explanation: ***Intermediate-high risk PE; admit to high-dependency unit and consider thrombolysis***- This patient is classified as **intermediate-high risk** because he is **hemodynamically stable** (BP 98/65 mmHg) but has both **right ventricular dysfunction** (RV:LV ratio >1 on CTPA) and **myocardial injury** (elevated troponin at 150 ng/L).- Management requires admission to a **high-dependency unit (HDU)** for close monitoring, as these patients have a significant risk of clinical deterioration where **thrombolytic therapy** might become necessary. *Low risk PE; discharge with direct oral anticoagulant and outpatient follow-up*- **Low risk PE** is characterized by hemodynamic stability with **no evidence of RV dysfunction** or **myocardial injury** (normal troponin and no RV strain).- This patient's signs of **hypoxia**, **tachycardia**, positive **troponin**, and **RV dilatation** preclude outpatient management and indicate a higher risk.*Intermediate-low risk PE; admit for monitoring and commence anticoagulation*- **Intermediate-low risk PE** is typically assigned when a patient is hemodynamically stable and has *only one* marker of severity (either **RV dysfunction** *or* **elevated biomarkers**).- Since this patient exhibits *both* elevated troponin and RV strain on CTPA, he falls into the higher intermediate-high risk category, necessitating more intensive monitoring than standard ward admission.*High risk PE; commence thrombolysis immediately*- **High risk PE** (also known as massive PE) is defined by **hemodynamic instability**, such as persistent hypotension (SBP <90 mmHg) or cardiogenic shock.- Although the patient's blood pressure is borderline, he is currently **hemodynamically stable**, meaning immediate systemic thrombolysis is not indicated unless his condition deteriorates to shock. *Intermediate risk PE; commence therapeutic anticoagulation and arrange outpatient echocardiography*- While **therapeutic anticoagulation** is crucial, managing a patient with acute **intermediate-high risk PE** with outpatient echocardiography is inappropriate given their physiological distress.- The presence of **RV strain** has already been confirmed by CTPA, and the immediate priority is inpatient monitoring and potential escalation of therapy rather than further elective imaging.

Question 83: A 35-year-old woman who is 28 weeks pregnant presents with sudden onset breathlessness and right-sided pleuritic chest pain. She is haemodynamically stable with oxygen saturations of 96% on room air. Pulmonary embolism is suspected. Chest X-ray is normal. What is the most appropriate imaging investigation to diagnose PE in this patient?

A. CT pulmonary angiogram with abdominal shielding
B. Lower limb compression ultrasound Doppler
C. MR pulmonary angiogram
D. No imaging required, treat empirically based on clinical suspicion
E. Ventilation-perfusion (V/Q) scan (Correct Answer)

Explanation: ***Ventilation-perfusion (V/Q) scan***- For a pregnant patient with suspected **pulmonary embolism (PE)** and a **normal chest X-ray**, a V/Q scan is the preferred first-line imaging investigation according to **RCOG and NICE guidelines**.- It is preferred over CTPA in this scenario because it carries a significantly lower risk of **maternal breast radiation**, which is crucial in reducing the lifetime risk of **breast cancer**.*CT pulmonary angiogram with abdominal shielding*- While CTPA is highly accurate, it delivers a much higher radiation dose to **maternal breast tissue** (up to 20-100 times more than V/Q scans).- CTPA is generally reserved as the first-line investigation in pregnancy only if the **chest X-ray is abnormal** or if V/Q scanning is not available.*Lower limb compression ultrasound Doppler*- This test is used to identify a **deep vein thrombosis (DVT)**; if positive in a patient with respiratory symptoms, it can justify anticoagulation without further chest imaging.- However, a negative ultrasound does not exclude a **pulmonary embolism**, and it is not the definitive imaging investigation for diagnosing PE itself.*MR pulmonary angiogram*- MRI is currently **not recommended** for the routine diagnosis of PE in pregnancy due to limited sensitivity and lack of large-scale validation.- It also often requires **gadolinium contrast**, which is generally avoided in pregnancy unless absolutely necessary as it can cross the placenta.*No imaging required, treat empirically based on clinical suspicion*- Empirical treatment should be started immediately if PE is suspected, but it must be followed by **objective imaging** to confirm the diagnosis.- Definitive diagnosis is essential to avoid the risks of **long-term anticoagulation** and to guide management during labor and the postpartum period.

Question 84: A 42-year-old woman presents with left-sided pleuritic chest pain and mild breathlessness for 24 hours. She takes no regular medications apart from the combined oral contraceptive pill. Her Wells score for PE is calculated as 1.5 (PE unlikely). Observations are normal except for heart rate 92 bpm. D-dimer is reported as 650 ng/ml (elevated, normal <500 ng/ml). What is the most appropriate next step in management?

A. Commence therapeutic dose low molecular weight heparin and arrange CT pulmonary angiogram (Correct Answer)
B. Reassure and discharge as Wells score indicates PE is unlikely
C. Repeat D-dimer in 24 hours
D. Arrange outpatient V/Q scan within 1 week
E. Perform arterial blood gas analysis

Explanation: ***Commence therapeutic dose low molecular weight heparin and arrange CT pulmonary angiogram*** - In patients with a **Wells score ≤ 4 (PE unlikely)**, an **elevated D-dimer** necessitates definitive imaging via **CT pulmonary angiogram (CTPA)** to exclude pulmonary embolism. - **Therapeutic anticoagulation** should be initiated immediately if a delay in imaging is anticipated to reduce the risk of further **thromboembolic events**. *Reassure and discharge as Wells score indicates PE is unlikely* - A **Wells score** of 1.5 only indicates that PE is **unlikely**, but it does not rule it out; a **positive D-dimer** in this context requires further investigation. - Discharging a patient with an **elevated D-dimer** and risk factors (COCP) for PE is **unsafe** and could lead to significant adverse outcomes. *Repeat D-dimer in 24 hours* - The initial D-dimer is already **elevated**; repeating it will not change the diagnostic pathway, which mandates moving directly to **definitive imaging**. - Delaying the diagnosis and potential treatment for a serious condition like PE by waiting for repeat blood tests is **not appropriate management**. *Arrange outpatient V/Q scan within 1 week* - Suspected pulmonary embolism is an **acute medical emergency** requiring prompt evaluation; waiting one week for an outpatient V/Q scan is **dangerously prolonged**. - **CTPA** is generally the preferred first-line imaging modality for acute PE, especially in patients without contraindications to contrast. *Perform arterial blood gas analysis* - While **arterial blood gas (ABG)** analysis might show **hypoxia** or **hypocapnia**, it is not sufficiently sensitive or specific to diagnose or exclude PE. - Performing an ABG should not delay the critical steps of initiating **anticoagulation** or arranging **definitive radiological imaging**.

Question 85: A 58-year-old woman presents to the Emergency Department with sudden onset right-sided pleuritic chest pain and breathlessness that started 2 hours ago. She underwent a right total hip replacement 10 days ago. Observations: heart rate 110 bpm, blood pressure 128/82 mmHg, respiratory rate 22 breaths/min, oxygen saturation 94% on room air, temperature 36.8°C. Chest examination is unremarkable. ECG shows sinus tachycardia. What is the most appropriate initial investigation?

A. CT pulmonary angiogram (Correct Answer)
B. Chest X-ray
C. Ventilation-perfusion (V/Q) scan
D. D-dimer assay
E. Echocardiography

Explanation: ***CT pulmonary angiogram*** - A **CT pulmonary angiogram (CTPA)** is the gold standard imaging modality for diagnosing **pulmonary embolism (PE)** because it provides direct visualization of the pulmonary vasculature. - Given the patient's high clinical probability (recent total hip replacement, sudden onset pleuritic chest pain and breathlessness, tachycardia), a CTPA is the most appropriate initial definitive investigation. *Chest X-ray* - A **Chest X-ray** is typically performed to rule out other causes of chest pain such as **pneumothorax** or pneumonia, but it is often normal in the setting of an acute PE. - While it may be part of the initial workup, it is not diagnostic for PE and should not delay more specific imaging like a CTPA in a high-suspicion case. *Ventilation-perfusion (V/Q) scan* - A **V/Q scan** is a secondary alternative used primarily when **intravenous contrast** or significant radiation exposure is contraindicated, such as in patients with **severe renal impairment** or contrast allergy. - It is generally less sensitive than CTPA and can often yield **indeterminate results**, making it a less preferred first-line investigation for acute PE in patients who can undergo CTPA. *D-dimer assay* - A **D-dimer** has a high negative predictive value, useful for ruling out PE in patients with a low clinical probability, but it is inappropriate as an initial investigation here because the patient's clinical probability of PE is **"likely"** (e.g., Wells score likely high). - Following recent **major surgery**, the D-dimer is often elevated due to post-operative inflammation and clot healing, making it a non-specific and unhelpful test for diagnosing PE in this context. *Echocardiography* - **Echocardiography** is not used to directly diagnose PE itself, but it can identify signs of **right ventricular strain** or pulmonary hypertension in cases of massive or submassive PE. - It is generally reserved for **hemodynamically unstable** patients who are too unstable to be transported for a CTPA, or to assess the severity and impact of PE on cardiac function.

Question 86: A 68-year-old man is admitted with severe community-acquired pneumonia (CURB-65 score 4). He is started on intravenous co-amoxiclav and clarithromycin. Blood cultures are taken. Despite 48 hours of treatment, he remains febrile with persistent hypoxia requiring 6L oxygen. Chest X-ray shows progression of consolidation with a small pleural effusion. Urinary Legionella antigen is negative. Sputum microscopy shows Gram-positive diplococci and culture is awaited. What is the most appropriate modification to antibiotic therapy?

A. Add intravenous levofloxacin to current regimen (Correct Answer)
B. Stop clarithromycin and continue co-amoxiclav alone
C. Add intravenous teicoplanin for MRSA cover
D. Switch to intravenous piperacillin-tazobactam and gentamicin
E. Continue current antibiotics for a further 48 hours before reviewing

Explanation: ***Add intravenous levofloxacin to current regimen*** - In **severe community-acquired pneumonia (CAP)** with clinical failure (persistent fever, worsening hypoxia, and radiological progression), broadening coverage to include a **fluoroquinolone** provides dual coverage for **Streptococcus pneumoniae** and ensures robust coverage for diverse **atypical pathogens**. - **Levofloxacin** is recommended in non-responding severe CAP because a negative urinary antigen does not exclude all **Legionella** serogroups, and it effectively targets potential resistant strains of **pneumococcus**. *Stop clarithromycin and continue co-amoxiclav alone* - Discontinuing the macrolide would lose essential coverage for **atypical organisms** (e.g., *Mycoplasma*, *Chlamydophila*, *Legionella*), which is crucial in severe CAP regardless of initial negative atypical tests. - This approach represents a **de-escalation** of therapy in a patient who is actively deteriorating, which is contraindicated by the worsening hypoxia and radiographic progression. *Add intravenous teicoplanin for MRSA cover* - Coverage for **MRSA** is generally reserved for patients with specific risk factors, such as prior colonization, recent influenza infection, or **cavitating pneumonia**, none of which are explicitly mentioned here. - The sputum Gram stain showed **Gram-positive diplococci**, which is characteristic of *Streptococcus pneumoniae*, not the Gram-positive cocci in clusters typical of *Staphylococcus aureus* (including MRSA). *Switch to intravenous piperacillin-tazobactam and gentamicin* - This regimen is typically indicated for **hospital-acquired pneumonia (HAP)**, **ventilator-associated pneumonia (VAP)**, or patients at high risk for **Pseudomonas aeruginosa**, which is not the standard empirical profile for CAP. - **Gentamicin** carries significant risks of nephrotoxicity and ototoxicity and is rarely used as a first-line modification for community-acquired respiratory infections unless multi-drug resistance is confirmed. *Continue current antibiotics for a further 48 hours before reviewing* - Maintaining the status quo is inappropriate in the presence of clear **clinical deterioration**, indicated by persistent fever, increased oxygen requirements, and progression of **pulmonary consolidation**. - Severe CAP with a **CURB-65 score of 4** requires proactive management and prompt treatment escalation if improvement is not observed within the initial 48-72 hours.

Question 87: A 45-year-old previously healthy man is admitted to hospital with community-acquired pneumonia. His CURB-65 score is 1. He has no known drug allergies. Chest X-ray shows right lower lobe consolidation. According to BTS guidelines, what is the most appropriate first-line antibiotic regimen for this patient?

A. Oral amoxicillin 500mg three times daily plus clarithromycin 500mg twice daily
B. Oral doxycycline 200mg loading dose then 100mg once daily
C. Intravenous benzylpenicillin 1.2g four times daily
D. Oral amoxicillin 500mg three times daily (Correct Answer)
E. Intravenous co-amoxiclav 1.2g three times daily plus clarithromycin 500mg twice daily

Explanation: ***Oral amoxicillin 500mg three times daily*** - According to **BTS guidelines**, a **CURB-65 score of 1** indicates low-severity community-acquired pneumonia, for which **amoxicillin monotherapy** is the first-line treatment. - It provides excellent coverage against **Streptococcus pneumoniae**, the most common causative organism in cases of lower-severity pneumonia. *Oral amoxicillin 500mg three times daily plus clarithromycin 500mg twice daily* - This dual therapy is recommended for **moderate-severity pneumonia** (CURB-65 score of 2) to cover for **atypical pathogens**. - Adding a macrolide is not routinely necessary for low-severity cases unless there is an **atypical infection** suspected or a lack of response to monotherapy. *Oral doxycycline 200mg loading dose then 100mg once daily* - Doxycycline is recommended as an **alternative first-line** treatment for patients with a **penicillin allergy**. - Since this patient has **no known drug allergies**, amoxicillin remains the preferred choice. *Intravenous benzylpenicillin 1.2g four times daily* - **Intravenous antibiotics** are generally reserved for patients with a **CURB-65 score \u2265 3** or those unable to tolerate oral intake. - Benzylpenicillin is effective for **confirmed pneumococcal infections** but is not the standard first-line empiric choice for low-severity CAP. *Intravenous co-amoxiclav 1.2g three times daily plus clarithromycin 500mg twice daily* - This intensive intravenous regimen is reserved for **high-severity pneumonia** (CURB-65 score of 3 or more). - Using broad-spectrum combination therapy for a low-severity case violates **antimicrobial stewardship** principles.

Question 88: A 72-year-old woman presents to the Emergency Department with a 4-day history of productive cough with green sputum, fever, and right-sided pleuritic chest pain. She lives independently and has no significant past medical history. Observations: temperature 38.7°C, heart rate 98 bpm, respiratory rate 24 breaths/min, blood pressure 125/78 mmHg, oxygen saturation 93% on room air. Examination reveals dullness to percussion and bronchial breathing at the right lung base. Blood tests show: urea 8.2 mmol/L, white cell count 16.5 × 10⁹/L. What is her CURB-65 score?

A. 2 (Correct Answer)
B. 5
C. 1
D. 3
E. 4

Explanation: ***2*** - The CURB-65 score is calculated based on **Urea >7 mmol/L** (this patient has 8.2 mmol/L) and **Age ≥65** (this patient is 72), giving a total of **2 points**. - Other criteria like **Confusion**, **Respiratory rate ≥30**, and **low Blood pressure** (systolic <90 or diastolic ≤60) are not present in this clinical scenario. *5* - This score would require all five criteria to be positive: **C**onfusion, **U**rea >7, **R**espiratory rate ≥30, **B**lood pressure low, and age **65** or older. - Since the patient lacks three of these clinical markers, a score of 5 is incorrect and would indicate **extremely high mortality risk**. *1* - This score would incorrectly ignore either the patient's **advanced age** (72 years) or her **elevated urea levels** (8.2 mmol/L). - A score of 1 represents **low risk**, whereas this patient falls into the **moderate risk** category requiring hospital-based care. *3* - A score of 3 would be reached if the patient also exhibited **tachypnea (RR ≥30)**, hypotension, or **new-onset confusion**. - While a score of 3 indicates **severe pneumonia** requiring urgent admission, this patient’s observations do not meet the additional thresholds. *4* - For a score of 4, the patient would need to have four out of five factors, such as **systolic BP <90 mmHg** and **AMTS ≤8**. - This score marks **high severity** and usually mandates consideration for **Intensive Care Unit (ICU)** assessment, which is not indicated here.

Question 89: A 55-year-old man with severe COPD on triple therapy (ICS/LABA/LAMA) presents with his fourth exacerbation requiring antibiotics and steroids in the past 12 months. He stopped smoking 2 years ago. Blood tests show: eosinophil count 0.05 × 10⁹/L (50 cells/μL). His FEV1 is 38% predicted. Despite optimal inhaler therapy and completion of pulmonary rehabilitation, he remains breathless on minimal exertion. According to NICE guidance, which additional treatment option should be considered?

A. Roflumilast (phosphodiesterase-4 inhibitor)
B. Oral prophylactic azithromycin (Correct Answer)
C. Increase inhaled corticosteroid dose
D. Add montelukast
E. Home nebuliser therapy with salbutamol

Explanation: ***Oral prophylactic azithromycin*** - According to **NICE guidelines**, prophylactic **azithromycin** (usually 250mg 3x weekly) is indicated for patients who have optimized triple therapy, are non-smokers, and still experience **frequent exacerbations** (≥3 per year). - Before initiation, it is essential to perform a **sputum culture** to exclude atypical mycobacteria, check a **baseline ECG** for QT prolongation, and monitor **liver function tests** and **hearing**. *Roflumilast (phosphodiesterase-4 inhibitor)* - **Roflumilast** is an option for severe COPD with **chronic bronchitis** and frequent exacerbations, but NICE typically recommends a trial of **azithromycin** as an earlier step in this context. - It is often limited by a high side-effect profile, particularly **gastrointestinal upset** and weight loss, making it less favorable than macrolide prophylaxis initially. *Increase inhaled corticosteroid dose* - Increasing the **ICS dose** beyond standard levels does not provide additional benefit in COPD and significantly increases the risk of **pneumonia**. - This patient’s **blood eosinophil count** is very low (50 cells/μL), suggesting that they are unlikely to derive further benefit from increased steroid therapy. *Add montelukast* - **Montelukast** is a leukotriene receptor antagonist used in the management of **asthma**, but it has no proven role or evidence base for preventing **COPD exacerbations**. - NICE guidance does not include any recommendation for its use in the routine management of stable **COPD**. *Home nebuliser therapy with salbutamol* - **Home nebulisers** are intended for symptom control in patients with persistent, distressing breathlessness despite optimal inhaler technique; they do not specifically target **exacerbation frequency**. - They should only be provided after a formal assessment by a **specialist respiratory service** to ensure that hand-held devices have been truly exhausted.

Question 90: A 70-year-old woman with known COPD (FEV1 45% predicted) presents to the Emergency Department with a 3-day history of increased breathlessness, increased sputum volume that is now green in colour, and wheeze. She is on home oxygen therapy 2L/min for 16 hours daily. Observations: respiratory rate 26 breaths/min, oxygen saturation 86% on room air, heart rate 105 bpm, temperature 37.8°C. Arterial blood gas on 28% Venturi mask shows: pH 7.34, PaO2 8.2 kPa, PaCO2 7.1 kPa, HCO3- 32 mmol/L, BE +6. What is the most appropriate immediate management?

A. Continue controlled oxygen targeting saturation 88-92%, start antibiotics and steroids, repeat blood gas in 30-60 minutes (Correct Answer)
B. Start high-flow oxygen at 15L/min and prepare for intubation
C. Increase oxygen to achieve target saturation 94-98% and start non-invasive ventilation
D. Reduce oxygen to 24% Venturi mask and give nebulised bronchodilators with air as driving gas
E. Continue 28% oxygen, commence intravenous doxapram infusion

Explanation: ***Continue controlled oxygen targeting saturation 88-92%, start antibiotics and steroids, repeat blood gas in 30-60 minutes***- This approach directly addresses the **acute exacerbation of COPD** with evidence of infection (green sputum) and **type 2 respiratory failure** (hypercapnia with compensated acidosis).- **Controlled oxygen** (88-92% SpO2) prevents exacerbating hypercapnia, while **antibiotics** and **steroids** treat the underlying cause and inflammation, and **repeat ABG** monitors progress.*Start high-flow oxygen at 15L/min and prepare for intubation*- **High-flow oxygen** at 15L/min would likely lead to severe **CO2 retention** in a patient with chronic hypercapnia due to COPD, potentially worsening respiratory acidosis.- While severely ill, the patient's **pH of 7.34** indicates partial compensation, meaning immediate **intubation** is not the first-line intervention and other less invasive methods should be attempted.*Increase oxygen to achieve target saturation 94-98% and start non-invasive ventilation*- A target **oxygen saturation of 94-98%** is too high for this patient with COPD and hypercapnia, as it risks depressing the hypoxic drive and worsening **hypercapnic respiratory failure**.- **Non-invasive ventilation (NIV)** is considered for AECOPD with persistent acidosis (pH <7.35) after optimal medical therapy; it is not typically initiated immediately without a trial of controlled oxygen, steroids, and antibiotics.*Reduce oxygen to 24% Venturi mask and give nebulised bronchodilators with air as driving gas*- Reducing oxygen to 24% Venturi from the current 28% might be insufficient to achieve the target **oxygen saturation 88-92%**, given her current SpO2 of 86% on room air.- While nebulised **bronchodilators** are crucial, delivering them with **air as the driving gas** might reduce oxygenation if the patient is significantly hypoxic and requires supplemental oxygen.*Continue 28% oxygen, commence intravenous doxapram infusion*- **Doxapram** is an outdated respiratory stimulant that has largely been replaced by more effective and safer interventions like **non-invasive ventilation** for managing hypercapnic respiratory failure.- This option lacks the essential components of **antibiotics** and **systemic steroids**, which are critical for treating the underlying infection and inflammation in AECOPD.

Question 91: A 62-year-old man with a 45 pack-year smoking history presents to his GP with progressive breathlessness over 2 years and morning cough productive of white sputum. Spirometry shows FEV1 55% predicted, FVC 78% predicted, FEV1/FVC ratio 0.62. Post-bronchodilator testing shows no significant reversibility. He continues to smoke 15 cigarettes daily. According to NICE guidelines, what is the most appropriate initial pharmacological management alongside smoking cessation advice?

A. Short-acting beta-2 agonist or short-acting muscarinic antagonist as required (Correct Answer)
B. Long-acting beta-2 agonist and long-acting muscarinic antagonist combination
C. Inhaled corticosteroid and long-acting beta-2 agonist combination
D. Oral theophylline
E. Long-acting muscarinic antagonist once daily

Explanation: ***Short-acting beta-2 agonist (SABA) or short-acting muscarinic antagonist (SAMA) as required*** - According to **NICE guidelines (NG115)**, the first-line pharmacological treatment for all patients with newly diagnosed **COPD** is a **short-acting bronchodilator** for symptom relief. - This patient presents with a new diagnosis confirmed by an **FEV1/FVC ratio < 0.7**, and initial management focuses on PRN (as required) use before escalating to long-acting therapies. *Long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA) combination* - **LAMA + LABA** combination is indicated as the next step only if the patient remains symptomatic despite using a **SABA or SAMA**. - While effective for **GOLD grade 2** or higher, it is not the initial step alongside smoking cessation in a treatment-naive patient. *Inhaled corticosteroid (ICS) and long-acting beta-2 agonist (LABA) combination* - **ICS/LABA** therapy is reserved for patients with features of **asthma-COPD overlap** or those who continue to have exacerbations. - This patient lacks **asthmatic features** (e.g., high eosinophil count, diurnal variation) and has no history of frequent exacerbations. *Oral theophylline* - **Theophylline** is typically considered only after trials of **short-acting** and **long-acting bronchodilators** have failed or are not tolerated. - It requires **plasma level monitoring** due to its narrow therapeutic index and numerous drug interactions. *Long-acting muscarinic antagonist (LAMA) once daily* - Monotherapy with a **LAMA** is a maintenance option if short-acting agents are insufficient, but it is not the recommended starting point. - NICE pathways suggest moving to **long-acting bronchodilators** based on the presence or absence of **asthmatic features** after initial SABA/SAMA trial.

Question 92: A 35-year-old woman with a history of asthma controlled on beclometasone 400 micrograms twice daily and salbutamol as required presents to the Emergency Department with acute breathlessness. She has had increasing symptoms over 24 hours despite using her salbutamol inhaler every hour. Peak flow is 40% of her best. She receives nebulised salbutamol 5mg, ipratropium bromide 500 micrograms, and oral prednisolone 40mg. After 1 hour, her peak flow remains at 42% of best with persistent wheeze. What is the most appropriate next step in management?

A. Repeat nebulised bronchodilators and reassess in another hour
B. Discharge with increased inhaled corticosteroid dose and oral prednisolone course
C. Commence intravenous magnesium sulphate 2g over 20 minutes (Correct Answer)
D. Start intravenous aminophylline infusion
E. Arrange non-invasive ventilation

Explanation: ***Commence intravenous magnesium sulphate 2g over 20 minutes*** - The patient presents with **acute severe asthma** as evidenced by a **peak flow of 40-42%** of best and poor response to initial therapy including nebulised bronchodilators and oral corticosteroids. - **Intravenous magnesium sulphate** is indicated as a second-line bronchodilator for patients with acute severe asthma who do not respond adequately to initial inhaled bronchodilators and systemic corticosteroids. *Repeat nebulised bronchodilators and reassess in another hour* - The patient has already received initial aggressive nebulised therapy and shown minimal improvement (PEFR 40% to 42%), indicating **refractory bronchospasm**. - Repeating the same intervention without escalation delays more definitive treatment and risks **clinical deterioration** in a severe asthmatic. *Discharge with increased inhaled corticosteroid dose and oral prednisolone course* - Discharge is unsafe and inappropriate given the patient's **persistent severe symptoms** and significantly reduced lung function (PEFR 42% of best). - Patients with acute asthma should only be discharged once their **peak flow is >75% of best or predicted** and they are symptomatically stable. *Start intravenous aminophylline infusion* - **Intravenous aminophylline** is generally considered a **third-line treatment** for acute severe asthma, typically reserved for cases unresponsive to magnesium sulphate. - It has a **narrow therapeutic index** and a higher risk of adverse effects compared to magnesium sulphate, which is preferred as the next step. *Arrange non-invasive ventilation* - **Non-invasive ventilation (NIV)** is generally **not recommended** in acute severe asthma due to the risk of air trapping, barotrauma, and potential for delaying intubation. - If a patient develops **respiratory failure** with hypercapnia or exhaustion, **invasive mechanical ventilation** is the appropriate management.

Question 93: A 28-year-old man with known asthma presents to the Emergency Department with severe breathlessness and wheeze. He is unable to complete sentences and appears distressed. Observations: heart rate 125 bpm, respiratory rate 28 breaths/min, oxygen saturation 90% on room air, blood pressure 130/80 mmHg. Peak expiratory flow rate is 35% of his best. Chest examination reveals bilateral widespread wheeze with reduced air entry. What defines this presentation as life-threatening asthma?

A. Respiratory rate of 28 breaths per minute
B. Peak flow 35% of best predicted value
C. Oxygen saturation 90% on room air (Correct Answer)
D. Heart rate of 125 beats per minute
E. Inability to complete sentences in one breath

Explanation: ***Oxygen saturation 90% on room air***- An **SpO2 <92%** is a key clinical indicator of **life-threatening asthma** according to BTS/SIGN clinical guidelines.- This level of hypoxia signifies significant **ventilation-perfusion mismatch** or respiratory fatigue, necessitating immediate senior intervention.*Respiratory rate of 28 breaths per minute*- A respiratory rate **≥25 breaths/min** is a criteria used to define **acute severe asthma**, not life-threatening features.- In life-threatening asthma, the respiratory rate may actually fall as the patient becomes **exhausted** or shows poor respiratory effort.*Peak flow 35% of best predicted value*- A peak expiratory flow (PEF) of **33-50%** of the patient's best or predicted value defines **acute severe asthma**.- To be classified as **life-threatening**, the PEF must be **<33%** of the best or predicted value.*Heart rate of 125 beats per minute*- A heart rate **>110 beats/min** is a feature of **acute severe asthma** due to sympathetic drive and stress.- Life-threatening asthma is instead associated with **arrhythmias** or **hypotension** as the physiological compensatory mechanisms fail.*Inability to complete sentences in one breath*- The inability to complete sentences in one breath is a classic hallmark of **acute severe asthma**.- While serious, it does not move the classification to **life-threatening** unless accompanied by signs like a **silent chest**, cyanosis, or altered consciousness.

Question 94: A 45-year-old woman presents to her GP with a 6-month history of episodic wheeze and breathlessness, particularly when walking in cold air and at night. She has no significant past medical history and has never smoked. Spirometry shows FEV1 82% predicted, FVC 88% predicted, FEV1/FVC ratio 0.78. Bronchodilator reversibility testing demonstrates a 15% and 250ml improvement in FEV1 after salbutamol. What is the most appropriate initial long-term treatment?

A. Regular low-dose inhaled corticosteroid (Correct Answer)
B. Combined inhaled corticosteroid and long-acting beta-2 agonist
C. Short-acting beta-2 agonist as required only
D. Long-acting beta-2 agonist twice daily
E. Leukotriene receptor antagonist

Explanation: ***Regular low-dose inhaled corticosteroid***- This patient has confirmed **asthma** based on clinical symptoms and a significant **bronchodilator reversibility** test (improvement >12% and >200ml).- **Inhaled corticosteroids (ICS)** are the first-line long-term preventer therapy to address underlying **airway inflammation**, reduce symptoms, and prevent exacerbations.*Combined inhaled corticosteroid and long-acting beta-2 agonist*- **Combination therapy (ICS/LABA)** is typically reserved for patients whose asthma is not adequately controlled on **low-dose ICS** monotherapy alone.- Starting with a combination inhaler is considered **step 3** of management, whereas this patient requires initial maintenance therapy.*Short-acting beta-2 agonist as required only*- **SABA monotherapy** is and should only be used for very infrequent symptoms; however, guidelines increasingly favor **low-dose ICS** for all patients to mitigate the risk of severe attacks.- This patient reports **nocturnal symptoms** and exercise-induced wheeze, indicating a need for regular **preventer treatment** rather than just rescue therapy.*Long-acting beta-2 agonist twice daily*- **LABA monotherapy** is strictly contraindicated in the treatment of asthma due to an increased risk of severe and potentially fatal **asthma exacerbations**.- A **LABA** must always be prescribed in conjunction with an **inhaled corticosteroid** to ensure the inflammatory component of the disease is treated.*Leukotriene receptor antagonist*- **Leukotriene receptor antagonists (LTRAs)**, such as Montelukast, are typically used as **add-on therapy** to ICS rather than first-line monotherapy.- While effective for exercise-induced symptoms, they are generally less potent than **inhaled corticosteroids** at improving lung function and overall control.

Practice by Chapter

Acute severe asthma

Practice Questions

Asthma diagnosis and long-term management

Practice Questions

COPD diagnosis and exacerbations

Practice Questions

Community-acquired pneumonia

Practice Questions

Pulmonary embolism

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free